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ABSTRACT
Extracellular nucleotides, acting via P2 receptors, modulate bone remodelling by 
inhibiting osteoblast and stimulating osteoclast activity. The aim of this thesis was to 
investigate further the effects of extracellular nucleotides on bone cell function under 
both normal and stress situations. Nucleotide agonists were shown to evoke 
intracellular Ca2+ responses in rat osteoblasts from >0.2 |nM. The approximate order of 
potency was ATP > UTP = ATPyS > ADP > UDP > 2-MeSATP = BzATP > aP- 
meATP, consistent with the expression of functional P2 X2 , P2 X5 , P2 X7 , P2Yi, P2 Y2 , 
P2 Y4  and P2Y6 receptors. A dramatic increase in intracellular Ca responses to ATP 
or UTP was observed in osteoblasts cultured for 8-10 days compared to 4 days, 
indicating that osteoblast responsiveness to nucleotides increases with cell 
differentiation. P2 receptor mRNA and protein expression in osteoblasts was shown to 
be differentiation dependent and was characterised by a shift from P2X to P2Y 
expression, with mature osteoblasts strongly expressing P2 Y2 , P2 Y4  and P2Y6  
receptors. Closer investigation revealed ATP and UTP decrease alkaline phosphatase 
expression and activity, indicating that extracellular nucleotides primarily inhibit 
mineralisation rather than organic matrix synthesis. Taken together these data suggest 
the P2 Y2 receptor, and possibly the P2 Y4  receptor could function as “off-switches” for 
mineralised bone formation. Constitutive ATP release from primary rat osteoblasts 
was found to occur via vesicular exocytosis in a differentiation dependent manner. 
Moreover, transient exposure to hypoxia (2 % O2) or hyperthermia (40°C) induced a 
rapid, significant increase in ATP release. In contrast, continuous culture at 2% O2, 
34°C or 40°C caused marked impairment of osteoblast function and ATP release. 
Given the negative effects of extracellular nucleotides on bone cell function, locally 
increased concentrations following stress situations may contribute to the bone loss 
associated with hypoxia or inflammation in vivo. A bone densitometer was used to 
screen mice deficient in selected P2 receptors. Bone mineral content and density were 
increased up to 18% in P2 X2 ' '  mice, decreased up to 10% in P2Yf ' and P2 X2/3 ^ //' 
mice but unaffected in P2 X3"  animals. In summary, the work described here provides 
further evidence for the role of extracellular nucleotides and their receptors in the 
regulation of bone cell function in health and disease.
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PREFACE
The primary aim of this research was to investigate the effects of extracellular 
nucleotides on bone cell function during normal and stress situations. Previous work 
has demonstrated the important role of extracellular nucleotides and their receptors in 
the modulation of bone remodelling and the work carried out here builds on this pre­
existing knowledge. Chapter 1, the general introduction, provides an overview of (1) 
the differentiation and function of bone cells; (2 ) extracellular nucleotides and 
purinergic signalling, and (3) purinergic signalling and bone cell function
Bone cells express a number of P2 receptors, activation of which causes increased 
intracellular calcium (Ca2+). In Chapter 2, several techniques allowed the detailed 
study of P2 receptors expression in osteoblasts as they differentiate with time in 
culture. Using the high-throughput fluorescence imaging plate reader (or FLIPR), it is 
possible to measure intracellular responses to agonist stimulation; this system utilises a 
96-well format and allows the simultaneous addition of test compounds to cell layers. 
Using osteoblasts derived from primary rat calvaria, the FLIPR was employed to 
screen multiple purine agonists, including ATP, UTP and ADP, for activity. In 
agreement with expression of functional P2 receptors, nucleotides stimulated increased 
intracellular Ca2+ in osteoblasts with the following order of potency ATP > UTP = 
ATPyS > ADP > UDP > 2-MeSATP = Bz-ATP > ap-meATP. Using the FLIPR, 
responses to nucleotide agonists were tested in osteoblasts cultured for 4, 8  and 10 
days; the amplitude of response increased dramatically with time in culture whilst cell 
number only doubled. These data indicated osteoblast responses to ATP and UTP 
increased with differentiation and time in culture. Semi-quantitative reverse 
transcriptase PCR (RT-PCR) and immunofluorescence were employed to investigate 
mRNA and protein levels, respectively. RT-PCR demonstrated P2X2 and P2 X5 
receptor expression to be highest in proliferating osteoblasts and less prominent in 
mature cells. P2 X7  and P2Yi receptor expression remained relatively constant, whilst 
P2Y2 receptor expression increased dramatically with differentiation. P2 Y4  and P2Y6 
receptor levels appeared highest at intermediate periods. Immunofluorescence 
confirmed these trends. Study of the inhibitors suramin and reactive blue 2  suggested 
that nucleotides exhibit their inhibitory effects on bone formation via the P2Y2
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receptor subtype, although the involvement of the P2 Y4  receptor subtype cannot be 
discounted. Furthermore, correlating with the increased P2 Y2 receptor expression, 
bone nodule formation assays demonstrated that addition of ATP or UTP to mature 
osteoblasts can effectively “switch off’ bone formation.
In Chapter 3, the nucleotide-mediated inhibition of bone nodule formation was 
studied in more detail. Using light microscopy it became apparent that deposition of 
organic matrix is generally unaffected in nucleotide treated cultures. As alkaline 
phosphatase (ALP) is important in mineralisation the effect of nucleotides on enzyme 
activity were quantified; both ATP and UTP but not ADP and UDP, significantly 
inhibited ALP activity in vitro. RT-PCR analysis demonstrated a marked down 
regulation of ALP and osteocalcin mRNA in nucleotide treated cultures, whilst 
expression of other bone matrix proteins was unaffected. These findings suggest ATP 
and UTP can act via the P2Y2 receptor and possibly the P2 Y4  receptor to down 
regulate ALP expression, and by primarily inhibiting mineralisation disrupt bone 
formation.
Chapter 4 investigates ATP release from osteoblasts under normal and stress 
situations. Using our established primary cell culture system, basal ATP release was 
measured from bone forming rat osteoblasts via the luciferin-luciferase assay. Levels 
of ATP release increased with differentiation with more mature osteoblasts releasing 
up to 7-fold more ATP. The mechanism of ATP release from osteoblasts was 
investigated using specific inhibitors of vesicular exocytosis, and mechanosensitive ion 
channels; data produced suggested that basal ATP release is mediated, at least in part 
via vesicular mechanisms.
Many pathological situations causing bone loss are characterised by a localised 
decrease in oxygen tension (hypoxia) and inflammation (increased temperature). As 
extracellular nucleotides have striking negative effects on bone remodelling, the effect 
of hypoxia (2 % O2 ), hyperthermia (40°C) and hypothermia (34°C) on osteoblast 
function and ATP release were investigated. Low oxygen significantly inhibited 
osteoblast proliferation and function as well reducing cell viability as determined by 
MTT, bone nodule formation and LDH cytotoxicity assays, respectively. A transient 
exposure to hypoxia causes a rapid, significant 2-3-fold increase in ATP release from
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osteoblasts, an affect not caused by increased cell lysis. In contrast, the level of ATP 
release from cells continually cultured at 2 % O2 appeared slightly decreased.
Prolonged culture at 34°C or 40°C also significantly impaired mineralised bone 
nodule formation and cell proliferation. Transient hypothermia did not influence ATP 
release, however, transient hyperthermia increased ATP release 2-fold. Unlike 
hypoxia-induced release, hyperthermia-induced ATP release appeared more sustained 
and lasted hours as opposed to minutes. Long-term culture at hypothermic or 
hyperthermic temperatures also significantly impairs ATP release. These data suggest 
long-term culture under stressful conditions will markedly affect osteoblast function, 
whilst transient exposures stimulate ATP release increasing the extracellular 
concentration and potentially initiating local purinergic signalling.
Knockout animals have yielded a lot of information regarding the physiological 
roles of many gene products, including the P2 receptors. Chapter 5 investigates the 
effect of P2 X2 , P2 X3 , P2 X2 /3 and P2 Yi receptor removal on bone phenotype, using a 
PIXImus bone densitometer. The single P2X receptor knockouts were scanned aged 2, 
4, 6  and 9 months, and the P2 X2 -null animals displayed a significantly increased bone 
mineral content, bone mineral density and weight, however the effects appeared age 
related. Conversely, P2 X3 -receptor deficient animals exhibited no differences in bone 
phenotype. P2 X2 /3  double knockouts were scanned aged 6  and 8  months; they 
displayed a decreased bone mineral density but not content. The P2Yi receptor 
knockouts were scanned at 2  months only and found to exhibit small but significant 
decreases in bone mass.
Chapter 6 is a general discussion in which these results are summarised and 
discussed in a broader context. Potential future experiments to further knowledge 
about extracellular nucleotides and bone cell function are also suggested.
Appendix I contains a list of all the abbreviations used and Appendix II provides 
details of all the publications and abstracts arising from this research, together with one 
paper containing work performed but not included in this thesis “Hypoxia is a major 
stimulator of osteoclast formation and activity” by Arnett et al, 2003.
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CHAPTER 1
GENERAL INTRODUCTION
OVERVIEW OF BONE STRUCTURE AND FUNCTION
The skeletal system is a dynamic living tissue comprised of bone and cartilage. Bone 
is a specialised connective tissue with three main functions: firstly, by providing 
support and site for muscle attachment the skeleton has a mechanical role. Secondly, it 
protects the vital organs and bone marrow from damage and thirdly, as bone comprises 
of approximately 65% inorganic mineral, it functions as a large reservoir of ions to 
help maintain calcium (Ca2+) and phosphate (PO43' or Pi) homeostasis (Baron, 2003). 
The extracellular matrix of bone comprises of inorganic mineral salts deposited within 
an organic collagen matrix and three main cell types: osteoblasts, osteoclasts and 
osteocytes, all of which are distinct in their function, activity and appearance. The 
combined action of these cells ensures constant skeletal remodelling and enables 
growth, adaptation and repair.
Individual bones are often characterised according to their shape. Long bones 
such as the femur are longer than they are wide and usually found in the limbs. Short 
bones, including those in the wrists and ankles, are generally equal in breadth and 
length. Flattened bones are relatively thin and often curved and include the bones 
found in the skull (such as the calvariae) and the mandible (Recker, 1992).
Anatomically, each bone is subdivided into distinct regions, best illustrated by the 
long bones. The central cavity, termed the medullary canal, is filled with red and 
yellow marrow; red marrow being the site of blood cell formation whereas yellow 
marrow is mainly adipose tissue. Encompassing the medullary canal is the shaft or 
diaphysis; a region primarily composed of cortical bone. The metaphysis is the cone 
shaped region separating the diaphysis from the bone ends or epiphysis. Primarily 
formed of trabecular bone, the epiphysis is delineated from the metaphysis by the
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epiphyseal line; this region is a remnant of the broad cartilaginous growth plate (the 
epiphyseal plate) that became ossified upon cessation of bone growth. Encasing the 
entire skeleton is a layer of connective tissue termed the periosteum. The outer 
periosteal layer is a sheath of fibrous connective tissue containing blood vessels and 
nerves, which surrounds an inner cell layer (cambrian layer) chiefly containing 
undifferentiated progenitor cells (Baron, 2003).
Each bone shares the same basic architecture comprising of an outer, protective 
layer of cortical (or compact) bone surrounding the inner trabecular (or cancellous) 
bone and the bone marrow. Cortical and trabecular bone contain the same cell types 
and matrix elements but display structural and functional differences. By volume, 
cortical bone is 80-90% calcified bone tissue, whereas trabecular bone is only 15-25% 
bone (the remainder being occupied by bone marrow, blood vessels and connective 
tissue) (Baron, 2003). The lower volume of calcification in trabecular bone means it is 
less dense than cortical bone. Structurally, cortical bone consists of thin sheets (3-7 
pm) called lamellae arranged in concentric layers around a central Haversian canal, 
each canal being lined with a layer of endosteum and housing a blood vessel. These 
cylindrical structures are referred to as osteons or Haversian systems and located in- 
between them are interstitial lamellae; layers of bone that are remnants of previously 
remodelled osteons. Surrounding these central Haversian systems are the outer and 
inner circumferential lamellae, the latter giving way to the inner cavities containing the 
trabeculae and marrow. In combination, these structural properties give cortical bone a 
mainly mechanical and protective function (Recker, 1992; Baron 2003).
Trabecular bone is found at the ends of long bones, the inner parts of flat bones and 
in the vertebrae. The microstructure of cancellous bone appears “honeycombed”, 
consisting of thin (50-400 pm) interconnecting rods called trabeculae, each trabecular 
element comprises of several lamellae embedded with osteocytes. Covering the bone 
surface is a single cell layer of osteoblasts and some osteoclasts and this interface 
between the marrow and trabecular bone, often termed the endosteal or trabecular 
envelope, is a key site of bone metabolism. Since remodelling only occurs at exposed 
locations, the large surface area of trabecular bone means it fulfils a mainly metabolic 
function (Baron, 2003; Recker, 1992).
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Microscopically, bone can also be classified into two types: woven or lamellar. 
Woven bone contains collagen fibres arranged in randomly orientated bundles and 
irregularly distributed large osteocytes. It is produced when osteoblasts synthesize 
osteoid rapidly, such as in embryonic life and childhood, but also in adults with 
pathological conditions characterized by rapid new bone formation for example in 
Paget’s disease and fracture repair (Baron, 2003). In comparison, lamellar bone 
comprises of regular parallel bands of collagen fibres arranged in sheets. Remodelling 
of the skeleton gradually replaces the immature woven bone with mature lamellar bone 
and therefore, virtually all bone in a healthy adult is lamellar.
OSTEOBLASTS
Origin & phenotype
Bone formation or osteogenesis is performed by osteoblasts, mononuclear cells 
derived from mesenchymal stem cells, a lineage that also gives rise to adipocytes, 
chondrocytes, myoblasts and fibroblasts (Grigoriadis et al, 1988). Once committed to 
the osteoblastic lineage, these stem cells are referred to as osteoprogenitor cells. 
Morphologically, osteoblasts are most akin to fibroblasts but can be distinguished by 
the presence of mineralised extracellular matrix (ECM). Active osteoid secreting 
osteoblasts are large, polarised and cuboidal in shape, with a prominent rough 
endoplasmic reticulum, whereas quiescent osteoblasts, often referred to as “bone lining 
cells”, have a flat morphology.
The differentiation and activity of osteoblasts can be spilt into three distinct phases: 
(1) proliferation of osteoprogenitors, (2) ECM development and maturation, 
characterised by the upregulation of genes associated with the mature osteoblast 
phenotype (type I collagen, osteocalcin (OCN) and alkaline phosphatase (ALP)), and 
(3) mineralisation of the organic matrix. The progression of osteoblast differentiation 
is associated with a gradual decrease in cellular proliferation.
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Osteoblast differentiation
The use of multipotent mesenchymal progenitors in vitro has provided abundant 
information regarding osteoblast differentiation and although knowledge has increased 
over recent years, many questions remain unanswered especially relating to the 
interactions between different signalling pathways. Osteoblast differentiation or 
osteoblastogenesis is a complex process and requires the sequential activation and 
suppression of phenotype specific genes (Figure 1.1). This section discusses the main 
transcription factors and local regulators involved in differentiation, most being 
involved in both skeletogenesis and post-natal osteoblast development.
Decreasing proliferation/ Increasing differentiation
Factors contributing tow ards phenotype
Runx2, Osx, 
Ihh, BMPs, 
FGFs
Runx2, c-fos, 
BMPs, FGFs, 
PTH/PTHrP, 
W nts
Runx2, Msx2, 
FGFs, Wnts, 
PTH/PTHrP, 
Glucocorticoids
Fra-1, PGE2, 
PTH/PTHrP, 
Glucocorticoids, 
1 ,2 5  (0H )2D3,
Self 
renewing Proliferation Proliferation Proliferation
Post
Proliferation
Mesenchymal I Osteoprogenitor Pre 
stem cell I (determined) osteoblast
(committed)
Osteoblast Os\
Adipocytes
Myoblasts
Fibroblasts
n h n n d rn rv tp s
Figure 1.1. A schematic diagram illustrating the transcription factors, cytokines and 
hormones important in osteoblast differentiation
This diagram shows the principal phases of osteoblast differentiation and the major factors 
(local and systemic) implicated at each stage (see text for description).
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Transcription factors
Osteoblast differentiation is mediated by a number of transcription factors, the earliest 
and most specific being runt related transcription factor 2 (Runx2j, also called core 
binding factor al (Cbfal). The heterodimeric Runx2 belongs to the Runx family of 
transcription factors. In mammals, the Runx family has three members (Runxl, -2, - 
3); each contains a characteristic runt domain responsible for DNA binding and 
regulates a distinct developmental pathway (haematopoiesis, osteogenesis and 
neurogenesis, respectively). All mesenchymal condensations during early embryonic 
development express Runx2, making it a common factor in both chondrocyte and 
osteoblast differentiation. Runx2 activates transcription by binding to osteoblast- 
specific cis-acting elements (OSE) located in the promoter regions of specific genes, 
for example two OSEs, OSE1 and OSE2, are located upstream of the OCN gene (Ducy 
et al, 1996). Work using transgenic mouse models demonstrated the fundamental role 
of Runx2 in osteoblast differentiation; for example, overexpression of Runx2 in vitro 
leads to osteoblast-specific gene expression in fibroblasts and myoblasts and in vivo 
causes ectopic endochondral bone formation (Ducy et al, 1997). Homozygous Runx2- 
deficient mice lack osteoblasts and osteoclasts and have skeletons exclusively made of 
cartilage (Komori et al, 1997), whereas heterozygous Runx2 knockouts exhibit 
delayed ossification in certain cranial bones (Otto et al, 1997). In mature osteoblasts, 
Runx2 influences osteogenesis by controlling the expression of numerous genes 
required for bone formation including ALP (Ducy et al, 1996), osteopontin (Sato et 
al, 1998), OCN (Ducy et al, 1996) and bone sialoprotein (Benson et al, 1999).
Other osteogenic transcription factors include Osterix (Osx), Muscle segment 
homologue 2 (Msx2), homeobox containing transcription factor Distal-less gene 5 
(Dlx5), HLH proteins (Id, Twist, Dermo) and transcription factors of the activating 
protein-1 (AP-1) complex. Osx is a zinc finger transcription factor believed to 
function downstream of Runx2, an idea supported by the lack of Osx expression in 
Runx2 knockout mice and the complete lack of bone formation in Osx-deficient mice 
(Nakashima et al, 2002). Both Msx2 and Dlx5 are important during development and 
appear antagonistic; Msx2 acts to prevent terminal osteoblastic differentiation, whereas 
Dlx5 expression coincides with the expression of bone marker genes and seems to 
exert positive regulatory effects (Bendall et al, 2000). Removal of either factor 
produces animals with multiple defects including abnormal osteogenesis (Acampora et
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al, 1999 ; Satokata et al, 2000). Members of the AP-1 family of transcription factors 
are important regulators of bone cell proliferation and differentiation. Suggestive of a 
role stimulating osteogenesis, overexpression of AFosb, a fosB  splice variant, leads to 
increased bone formation and impaired adipogenesis (McCabe et al, 1996; Sabatakos 
et al, 2000). Moreover, enhanced expression of Fra-J, another member of the AP-1 
family, also causes increased bone mass. Fra-l is abundant in mature osteoblasts and 
by increasing the expression of bone specific genes it can stimulate bone formation 
(Jochum et al, 2000). The early response gene c-fos, which mediates cell growth and 
development, is expressed in osteoprogenitor cells but not mature osteoblasts 
indicating a role for this transcription factor in osteoblast differentiation (Machwate et 
al, 1995). By repressing genes of the mature osteoblast phenotype, HLH proteins 
negatively regulate differentiation and allow osteoprogenitor expansion; these proteins 
have to be downregulated to allow differentiation to proceed (Ogata et al, 1991).
Regulators o f osteoblast differentiation
By controlling the expression and/or activity of these and other transcription factors, 
many local signalling factors act to regulate osteoblast differentiation and osteogenesis.
The hedgehog family of signalling molecules contains Indian, Sonic and Desert 
{Ihh, Shh and Dhh, respectively), all of which are essential in different developmental 
pathways. Although primarily expressed in chondrocytes, Ihh appears to be a key 
regulator of the developing endochondral skeleton: as illustrated by Ihh-deficient mice, 
which display reduced chondrocyte proliferation and lack osteoblasts in endochondral 
bone (St Jacques et al, 1999). Exactly how Ihh signals to promote osteoblast 
differentiation and osteogenesis remains unclear but two important components in 
mediating its effects are the cell surface receptor Patched and the transmembrane 
protein, Smo. Activation of Patched induces ALP activity and mineralisation in vitro 
(Nakamura et al, 1997), conversely osteoprogenitors devoid of Smo fail to respond to 
Ihh, inhibiting osteoblast differentiation (Long et al, 2004).
The bone morphogenetic proteins (BMPs) are potent regulators of both osteoblast 
differentiation and bone formation. With the exception of BMP-1, all belong to the 
transforming growth factor J3 (TGF-|3) superfamily, members of which regulate 
proliferation, differentiation and cell death in many tissues (Massague et al, 2 0 0 0 ;
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Wrana, 2000). In osteoprogenitors, BMP-induced signalling induces the expression 
and/or activity of Runx2, Osx and Msx-2 and of the > 15 BMPs implicated in 
osteoblast differentiation, BMP-2, -4, -5, - 6  and -7 are thought to be particularly 
important. For example, BMP-2 stimulates precursors into the osteogenic lineage and 
enhances ALP activity, parathyroid hormone (PTH) responsiveness and OCN 
production in vitro (Yamaguchi et al, 2000). Moreover, reports suggest that BMPs 
regulate osteoblast cell survival during the induction of differentiation (Chen, 2001). 
Knockout animals have provided limited information regarding the involvement of 
these factors in skeletal development as BMP-2, BMP-4 and BMP-7 null mice all die 
shortly before or after birth (Yamaguchi et al, 2000).
The FGFs are a large family of polypeptides that function to control proliferation 
and differentiation in many cell types. Initiation of FGF signalling in osteoprogenitors, 
via binding to specific FGF receptors (FGFR), stimulates proliferation and 
differentiation: a role emphasized by transgenic mouse models such as FGF-18 null 
mice, which display delayed ossification and reduced expression of osteogenic markers 
(Liu et al, 2002). Moreover, conditional inactivation of FGFR2 produces animals with 
skeletal dwarfism, decreased bone density and impaired osteoprogenitor proliferation 
and mature osteoblast function (Yu et al, 2003). FGFs function by enhancing the 
activity of osteogenic transcription factors; for example, FGF-2 facilitates the binding 
of Runx2 to its OSE consensus sequence thereby providing a mechanism enabling 
FGF signalling to directly stimulate the expression of Runx2-dependent osteoblast 
genes (Debiais et al, 2004). FGFs also influence bone remodelling by regulating the 
expression of other growth factors that affect bone cell function including TGF-P 
(Noda & Vogel, 1989) and prostaglandins (Kawaguchi et al, 1995).
Wnts are secreted, lipid-modified glycoproteins that regulate cellular activities 
including proliferation, migration and gene expression (Moon et al, 2002). By 
signalling through the Frizzled family of receptors, Wnts activate at least three 
intracellular pathways including the Wnt/(3-catenin or canonical pathway. Activation 
of this pathway stabilises p-catenin, allowing it to interact with a number of different 
transcriptional regulators and control the expression of target genes. The involvement 
of Wnt/p-catenin signalling in osteoblast differentiation is an area of active research 
and recently WntlOb was reported to induce Runx2, Dlx5 and Osx expression but
19
suppress the adipogenic transcription factors, PPARy and C/EBPa. Additionally, 
WntlOb knockout mice display decreased trabecular bone (Bennett et al, 2005). The 
recent observation that P-catenin localisation does not occur in Ihh-null mice suggested 
Wnt signalling occurs downstream of Ihh during osteogenesis; this indicates cross talk 
exists between these pathways, however, at present the exact nature of this interaction 
remains unclear (Hu et al, 2005).
Cellular Interactions
Cell-to-cell and cell-to-matrix interactions also play an important role in osteoblast 
differentiation and function and if lost can lead to apoptosis (Jilka et al, 1998). 
Cadherins, which are Ca2+ dependent transmembrane glycoproteins, mediate cell-to- 
cell interactions. In osteoblasts, expression of N-cadherin (Marie, 2002) and cadherin- 
11 (Kii et al, 2004) appears to influence differentiation as partial disruption of their 
activity indirectly favours progenitor cell commitment to the adipogenic lineage 
(Castro et al, 2004). Furthermore, although N-cadherin null mutations are lethal 
(Radice et al, 1997), cadherin-11 deficient mice exhibit a reduced bone density in the 
calvaria and long bone metaphysis (Kawaguchi et al, 2001).
Integrins mediate cell-to-matrix interactions by coupling proteins of the 
extracellular matrix to structural proteins of the cytoskeleton. These interactions 
enable propagation of modulatory signals that influence cell differentiation, adhesion, 
and cytoskeletal organisation. Important in osteoblast differentiation and bone 
development are the pi integrins (a ip i ,  a ip2 , a3 p i, a2pi); for example interactions 
between type I collagen and a ip i/a 2 p i integrins accelerate osteoblast differentiation 
by activating the mitogen activated protein kinase (MAPK) signalling pathway and 
increasing Runx2 activity (Xiao et al, 1997; Xiao et al, 1998).
BONE FORMATION
Bone is formed by the action of mature osteoblasts in a two-step process, with the first 
stage being synthesis and deposition of the organic matrix. Osteoblasts synthesize 
type I collagen and many non-collagenous bone matrix proteins (NCPs), which are 
packaged into vesicles and then released via exocytosis. In the extracellular 
environment, thin layers of these non-mineralised proteins become embedded in the
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ground substance to form a matrix known as osteoid; subsequent mineralisation of 
which produces the calcified bone tissue. The ground substance is primarily composed 
of proteoglycans and glycoproteins. Also synthesised by osteoblasts, proteoglycans 
are macromolecules consisting of a central core protein with covalently attached acidic 
glycosaminoglycan side chains; important proteoglycans in bone include decorin, 
biglycan and fibromodulin.
Collagen
The collagens are important structural extracellular matrix proteins accounting for 
around 25% of total body protein. To date some 27 types of collagen have been 
identified, with the main forms found in connective tissue being type I, II, III, V and 
XI. Type I collagen accounts for approximately 90% of the total protein in bone and 
plays a fundamental role in the development and proper function of the skeleton. It is 
a heterotrimeric molecule comprising of two identical a l  (I) chains and one a2 (I) 
chain, which combine to form a triple helix structure. Collagen biosynthesis is a multi- 
step process involving a number of post-translational modifications. Initially the a  
chains are synthesized with a short N-terminal signal sequence plus propeptides at both 
N- and C-terminals, and following translation are injected into the endoplasmic 
reticulum (ER) lumen. All a-chains are characterised by a repeating Gly-X-Y motif, 
where X is usually proline and Y is hydroxyproline. Within the ER, individual a- 
chains undergo a series of reactions that facilitate triple helix formation, including the 
hydroxylation of proline by prolyl-4-hydroxylase to produce 4-hydroxyproline, a 
reaction that enables the formation of stabilising intrastrand hydrogen bonds. Prolyl-4- 
hydroxylase is oxygen-dependent and, following catalysis requires ascorbate (vitamin 
C) for regeneration; in its absence, the inhibition of proline hydroxylation produces 
collagen that denatures (or “melts”) at a lower temperature. A select number of lysine 
residue are also hydroxylated, a modification necessary for the glycosylation and 
cross-linking of the collagen molecule. These reactions are catalysed by one of three 
lysyl hydroxylases (LH), each encoded by an individual gene termed PLOD-1, -2 or -3 
(Valtavaara et al, 1997; Valtavaara et al, 1998). Differential expression of the PLOD 
genes causes the formation of tissue specific cross-links and may explain why the type 
I collagen in skin exhibits a different bonding pattern to the type I collagen in bone. 
PLOD-1 expression is widespread, thus LH1 produces cross-links which are relatively
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ubiquitous between tissues (Valtavaara et al, 1997). In contrast, expressions of PLOD- 
2 and -3 are more tissue specific and the observed upregulation of PLOD-2 in 
differentiated osteoblasts means the LH2 isoform is likely to confer a bone specificity 
to type I collagen (Uzawa et al, 1999).
Once formed, the stable triple helix is secreted into the extracellular matrix via 
exocytosis, where proteolytic cleavage converts procollagen into collagen via removal 
of the propeptides. Individual collagen triple helices then combine to form fibrils, 
ranging in diameter from 10-300 nm and up to hundreds of micrometers in length. 
These fibrils are stabilised by the oxidative deamination of e-amino groups of specific 
lysine and hydroxylysine residues, a reaction catalysed by lysyl oxidase. This forms 
highly reactive aldehyde moieties that rapidly form the covalent cross-links necessary 
for the development of functional mature collagen. Inhibition of this reaction 
drastically reduces collagens tensile strength, leading to defective bone and cartilage 
formation. Finally, collagen fibrils condense to form structures known as collagen 
fibres.
Bone matrix proteins
NCPs constitute the remaining 10-15% of the organic matrix, and are either 
exogenously derived (~ 25%) or synthesised by osteoblasts (~ 75%), however their 
roles in the bone microenvironment are by no means fully characterised. Exogenous 
NCPs include the serum-derived proteins, albumin and a 2HS-glycoprotein. Many of 
the NCPs synthesised by osteoblasts undergo post-translational modifications such as 
phosphorylation and/or glycosylation. Important NCPs involved in bone formation 
including OCN, osteonectin, osteopontin, bone sialoprotein (BSP) and matrix gla 
protein (MGP). OCN is a widely used marker of osteoblast differentiation, primarily 
because of its restricted expression profile (mineralising osteoblasts and hypertrophic 
chondrocytes). It is the most abundant NCP in bone and is post-translationally 
modified by vitamin K dependent y-carboxylases to produce residues with a high 
affinity for Ca2 . OCN-deficient mice exhibit increased bone mineral density but show 
no defects in resorption indicating a role in the regulation of mineralisation (Ducy et 
al, 1996). MGP is expressed in vascular smooth muscle cells, chondrocytes and 
osteoblasts where it acts to inhibit mineralisation; a role illustrated by MGP-knockout 
mice, which develop calcification in extraskeletal sites including the arteries and
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growth plate (Luo et a/,1997). The glycoprotein osteonectin is transiently expressed in 
tissues undergoing rapid proliferation, remodelling or changes in architecture. The 
functions of osteonectin in bone remain unclear although osteonectin-null mice display 
decreased bone remodelling because of reduced osteoblast and osteoclast number. As 
the defect in bone formation is greater, knockouts animals exhibit a progressive age- 
related reduction in bone mass (Delany et al, 2000). Osteonectin may also play a role 
in cell attachment (Young et al, 1992).
Some NCPs belong to a family called the SIBLINGS (Small Integrin Binding 
Ligand N-linked Glycoproteins) members of which contain the integrin-binding 
consensus sequence RGD (Arg-Gly-Asp). Both osteopontin and BSP belong to this 
family and are important in mediating cell-to-cell and cell-to-matrix interactions, 
anchorage of osteoclasts to bone and can bind Ca2+ with high affinity (Reinholt et al, 
1990; Asou et al, 2001). BSP, a virtually bone specific attachment protein, is a potent 
nucleator of hydroxyapatite crystals, an effect dependent on the poly (glutamic) acid 
sequences present in the protein. Conversely osteopontin, which is structurally similar 
to BSP but lacks the glutamic acid structural motif, potently inhibits hydroxyapatite 
crystal deposition and propagation (Boskey et al, 1993; Hunter & Goldberg, 1993). 
Further illustrating this inhibitory role, osteopontin knockout mice display a small 
increase in mineralisation (Boskey et al, 2 0 0 2 ). Osteoblasts synthesize many other cell 
attachment proteins, each containing the RGD sequence, including, fibronectin, 
vitronectin and osteoadherin.
Following osteoid secretion, there is a lag period prior to calcification termed the 
osteoid maturation period, which, in humans, lasts about 10 days. Subsequent 
mineralisation involves the deposition of inorganic ions into the osteoid matrix and 
produces mature bone. The mineralisation process, which is regulated by the activities 
of phosphatases, NCPs and cell-to-cell/matrix interactions, will be discussed in detail 
in Chapter 4.
23
BONE GROWTH AND DEVELOPMENT
During embryonic development, osteoblast differentiation and bone formation occur 
via two distinct pathways: endochondral ossification or intramembranous ossification. 
Intramembranous ossification occurs in the clavicle and some cranial bones. In these 
regions, mesenchymal stem cells under the influence of local growth factors 
proliferate and differentiate into pre-osteoblasts and then osteoblasts. At ossification 
centres, osteoblasts form immature woven bone that is later remodelled into the mature 
lamellar bone characteristic of the adult skeleton.
Endochondral ossification is associated with foetal bone development and day-to- 
day bone growth. This process involves the formation of a cartilage template that is 
later replaced by bone. The initial site of ossification is in the bone diaphysis and is 
termed the primary ossification centre. It is here where the activity of local growth 
factors (BMPs, FGF, parathyroid hormone-related peptide (PTHrP), Ihh) and specific 
transcription factors (Sox9, Sox5 & Sox6 ) cause mesenchymal stem cells to condense, 
differentiate into chondrocytes and secrete cartilaginous matrix. At any one time there 
are four distinct subpopulations of chondrocytes in growth plates: resting, 
proliferating, prehypertrophic and hypertrophic; each is arranged into distinct zones 
and surrounded by undifferentiated mesenchymal cells forming the perichondrium. 
Hypertrophic chondrocytes are responsible for mineralising the previously deposited 
cartilaginous matrix and display a dramatic increase in expression of ALP, type X 
collagen and matrix metalloproteinase 9 (MMP-9). The gradual development of a 
calcified extracellular matrix around the hypertrophic chondrocytes causes them to 
secrete vascular endothelial growth factor (VEGF), a factor that along with MMP-9 
facilitates the invasion of blood vessels from the perichondrium. Vascular invasion 
promotes resorption of the calcified cartilage, and osteoblast differentiation from 
perichondrial mesenchymal cells; the osteoblasts then replace the cartilage template 
with bone. Later osteoclast activity breaks down this bone to form the medullary 
cavity. Subsequently, chondrocytes become localised to the epiphysis of the growing 
bone, where the process continues away from the primary ossification centre to 
facilitate longitudinal growth. The interface between the midshaft and the epiphysis is 
termed the growth or epiphyseal plate and lengthening of the bone diaphyses pushes 
the two growth plates apart. Longitudinal growth continues until maturity, when
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hormonal changes inhibit further cartilage production and calcify the epiphyseal 
cartilage in a process termed secondary ossification.
The various steps of chondrogenesis and endochondral ossification are tightly 
controlled to prevent abnormal growth or ossification. Important regulatory factors 
include Runx2, Sox9, Ihh, PTHrP, TGF-J3 and FGFs. Runx2 is highly expressed in 
non-hypertrophic chondrocytes and in a role distinct from that in osteoblastogenesis, 
acts to promote differentiation to the prehypertrophic stage; a role identified using 
knockout animals which display defects in this process (Inada et al, 1999). Sox9 is a 
transcription factor fundamental in the conversion of condensed mesenchymal cells to 
chondrocytes and its expression is necessary for induction of the other Sox members 
(Sox5, -6 ) involved in differentiation (Akiyama et al, 2002). Hypertrophic 
chondrocytes are characterised by the expression of Ihh and the PTHrP receptor, which 
work in combination to regulate chondrocytic differentiation. Following secretion, Ihh 
binds to cells in the perichondrium to influence PTHrP production and osteoblast 
differentiation. PTHrP and Ihh are thought to interact in a negative feedback, where 
PTHrP induced by Ihh binds to its receptor on prehypertrophic chondrocytes and 
suppresses differentiation (Vortkamp et al, 1996). FGFs exert an inhibitory effect on 
Ihh production to ensure a balance exists between the stimulation and inhibition of 
chondrocyte differentiation (Wagner & Karsenty, 2001).
OSTEOCYTES
Actively mineralising osteoblasts can become trapped within the bone matrix, where 
they may undergo a terminal differentiation step to form an osteocyte. These cells are 
characterised by an extensive network of cytoplasmic processes that permeate through 
the canaliculi and contact adjacent cells; interactions that are essential for cell 
maturation, activity and survival as they enable osteocytes to communicate with and 
obtain nutrients from surface osteoblasts. Gap junctions, formed by the membrane 
protein connexin 43, facilitate intercellular communication (Civitelli et al, 1993). 
Mice lacking connexin 43 display skeletal malformations, delayed mineralisation and 
osteoblast dysfunction (Furlan et al, 2001). Their widespread distribution and ability 
to respond to strain with biochemical signals makes osteocytes the most likely 
candidates for sensing mechanical load and influencing the appropriate bone
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remodelling in vivo (Lanyon, 1993). Although not fully elucidated, signalling 
pathways mediating these effects are thought to involve prostaglandin E2 (PGE2 ) and 
nitric oxide, both of which are important in mechanically induced bone formation. 
Osteocyte apoptosis, a process influenced by mechanical loading, may also influence 
cell signalling and thus bone remodelling (Noble et al, 1997; Noble et al, 2003)
OSTEOCLASTS
Phenotype
Osteoclasts are large, multinucleate cells responsible for bone resorption. Actively 
resorbing osteoclasts are highly polarised with four distinct membrane domains: ( 1 ) 
the sealing or clear zone, (2) the ruffled boarder, (3) the functional secretory domain 
and (4) the basolateral upper domain. Morphologically, osteoclasts resemble 
macrophages and bone resorption employs some of the same cellular machinery as 
phagocytosis.
Osteoclast differentiation
Osteoclast formation (or osteoclastogenesis) requires the fusion of mononuclear 
precursors derived from haematopoietic stem cells of the monocyte/macrophage 
lineage; promyeloid precursors that give rise to many cell types including macrophages 
and dendritic cells. Naturally occurring mutations and targeted knockout mutations 
have resulted in the identification of at least 24 genes that positively or negatively 
regulate osteoclastogenesis. Two cytokines are essential for osteoclast formation: 
macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor 
kappa B ligand (RANKL); together they induce the expression of genes that typify the 
osteoclast lineage including cathepsin K and tartrate-resistant acid phosphatase 
(TRACP). This section discusses the principal factors involved in osteoclastogenesis; 
for a more comprehensive review, the reader is referred to Quinn et al, 2005 and Blair 
et al, 2005. Figure 1 . 2  shows a schematic diagram of the osteoclast differentiation 
pathway and the principal factors involved.
In vivo osteoclastogenesis is tightly regulated, however, the inhibition of osteoclast 
production and/or function leads to defective bone resorption and increased levels of
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mineralised tissue. For example, osteopetrosis, a rare hereditary condition 
characterised by the failure of osteoclast-mediated resorption, leads to trabecular and 
cortical thickening, loss of the bone marrow cavity and dense but fragile bones. 
Conversely uncontrolled osteoclast formation and/or activity will result in excessive 
bone resorption, a decrease in bone mass and an increased fracture risk, commonly 
termed osteoporosis.
Important factors involved in osteoclast differentiation and activity
M-CSF
Haematopoietic
precursor
M-CSF
RANKL/RANK 
TRAF 6, NFkB, 
c-fos, mi/Mitf, IL-1, 
TNFa, TGF-p
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Figure 1.2. A schematic diagram illustrating the transcription factors, cytokines and 
hormones important in osteoclast differentiation
This diagram shows the different stages of osteoclast differentiation and the main transcription 
factors, cytokines and hormones involved (see text for description).
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Important regulators o f osteoclastogenesis
The myeloid and B-cell-specific transcription factor PU. 1 regulates the initial 
differentiation from haematopoietic stem cell and is currently the earliest known 
marker of osteoclast differentiation. Disruption of the PU.l gene produces an 
osteopetrotic phenotype characterised by arrested osteoclast and macrophage 
development (Tondravi et al, 1997).
The homozygous osteopetrotic (op/op) mouse first demonstrated the important role 
of M-CSF in osteoclastogenesis; these animals possess a mutated M-CSF gene, lack 
osteoclasts and macrophages and their stromal cells fail to release active M-CSF 
(Yoshida et al, 1990). However, exogenous application of M-CSF partially restores 
the impaired bone resorption (Takahashi et al, 1991). Both osteoblasts and T- 
lymphocytes secrete M-CSF, which binds to the c-fms receptor on osteoclast 
precursors. Levels of c-fms depend on PU.l expression, and receptor activation 
enhances the proliferation, differentiation and survival of both haematopoietic 
precursors and mature osteoclasts (Lagasse & Weissman, 1997).
RANKL, the fundamental osteoclast differentiation factor, was initially identified 
as being important in T-lymphocyte and dendritic cell function, however, its crucial 
role in osteoclastogenesis was revealed during investigations into the osteoclast 
inhibitory factor, osteoprotegerin (OPG) (Yasuda et al, 1998a; Yasuda et al, 1998b). 
This cytokine, also known as TNF-related activation induced cytokine (TRANCE), 
osteoclast differentiation factor (ODF), and OPGL, belongs to the tumour necrosis 
factor (TNF) superfamily. Both osteoblasts and activated T-lymphocytes secrete 
RANKL and by upregulating osteoblastic expression, many factors indirectly stimulate 
osteoclastogenesis. RANKL exists in two forms, surface bound and soluble, with 
proteolytic cleavage of the former directly producing the latter. The essential role in 
osteoclast production is further illustrated by RANKL-deficient mice, which although 
possessing osteoclast progenitors, lack mature osteoclasts and exhibit severe 
osteopetrosis (Kong et al, 1999). Additionally, RANKL can act on pre-existing 
mature cells to increase bone resorption (Burgess et al, 1999).
RANKL binds to a member of the TNF receptor (TNFR) superfamily termed 
RANK, a transmembranous receptor widely expressed on cells of the 
monocyte/macrophage lineage including pre- and mature osteoclasts. RANK-deficient
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mice also lack osteoclasts and exhibit a severe osteopetrosis, although this phenotype 
can be rescued by transplantation of normal bone cells (Dougall et al, 1999).
OPG is a secreted TNFR-related protein that functions to regulate bone mass; this 
soluble decoy receptor, produced by osteoblasts, acts to inhibit osteoclastogenesis by 
preventing the binding of RANKL to RANK on osteoclast precursors (Lacey, 1998). 
OPG-deficient mice display severe osteoporosis accompanied by calcification of the 
aorta and renal arteries, whilst OPG overexpression blocks osteoclastogenesis leading 
to osteopetrosis (Bucay et al, 1998). Levels of OPG and RANKL are therefore 
coordinated to regulate bone resorption and any modification to this equilibrium will 
directly influence bone remodelling.
Intracellular signalling pathways in osteoclast formation and activity
Binding of M-CSF, RANKL and other osteoclastogenic cytokines to their appropriate 
receptors activates numerous intracellular signalling cascades, which result in the 
expression of specific genes involved in osteoclast differentiation, activation and 
survival. Activation of c-fms by M-CSF controls the expression of intermediate early 
transcription factors such as c-fos, an important regulator of osteoclast differentiation. 
Homozygous c^/av-deficient mice are osteopetrotic, have deficits in bone remodelling 
and tooth eruption and display high levels of macrophages because differentiation 
follows this pathway (Wang et al, 1992).
RANK activation by RANKL induces at least five distinct signalling pathways: 
inhibitor of NFkB (IKK), c-Jun N-terminal kinase (JNK), p38, extracellular signal 
regulated kinase (ERK) and src pathways (Boyle et al, 2003). The cytoplasmic 
domain of RANK contains specific motifs that enable the binding of TNFR-associated 
factors or TRAFs (including TRAF1, -2, -3, -5 and -6 ) (Wong et al, 1998; Kim et al, 
1999). TRAF6  is one of the key adaptor proteins involved in osteoclastogenesis as it 
can signal via several pathways to activate nuclear factoncB (NFkB). Following 
activation, NFkB translocates to the nucleus where it acts to enhance the transcription 
of genes associated with the osteoclast phenotype. Mice deficient in TRAF6  (Lomaga 
et al, 1999) or both p50 and p52 subunits of NFkB (Franzoso et al, 1997) exhibit 
severe osteopetrosis due to a complete inhibition of osteoclast formation. Stimulation 
of other TNFR family members can also influence NFkB activity, therefore allowing
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other cytokines to replace, augment or prevent RANKL-mediated signalling. For 
example, interferon-y (IFN-y) causes the rapid degradation of TRAF6  and strongly 
inhibits activation of the JNK pathway and NF-kB. RANKL-mediated signalling also 
stimulates nuclear factor of activated T cells 1 (NFATcl), and accumulating evidence 
now suggests this transcription factor also plays an important role in 
osteoclastogenesis (Ikeda et al, 2004; Matsuo et al, 2004). In contrast to the IKK 1/2 
and JNK pathways, activation of the ERK cascade is thought to negatively regulate 
osteoclastogenesis (Boyle et al, 2003).
The c-src and p38 pathways are more important in mature osteoclasts. The 
signalling induced by c-src acts to induce cell survival, cytoskeletal rearrangement and 
osteoclast cell motility (Wong et al, 1999). Mice deficient in c-src display an 
osteopetrotic phenotype because the osteoclasts present are incapable of resorption 
(Boyce et al, 1992). Activation of the p38 pathway induces the transcriptional 
activator mi/Mitf, which controls the expression of genes characterising the mature 
osteoclast phenotype such as TRACP and cathepsin K.
BONE RESORPTION
The sequence of cellular events required for bone resorption involves 5 main steps: (1) 
formation and migration of the osteoclast to the resorption site, (2 ) attachment of the 
osteoclast to bone, (3) polarisation, (4) resorption and (5) osteoclast apoptosis or return 
to the non-resorbing stage. F igu re  1.3 shows an actively resorbing osteoclast and the 
principal components involved.
The initial step of resorption is osteoclast recruitment, a process probably mediated 
by cytokines including M-CSF, RANKL and VEGF. Once in position, to enable them 
to function, osteoclasts must attach to the bone surface. Interactions between the 
osteoclast and bone matrix occur at the clear or sealing zone, a region that contains no 
organelles and is rich in filamentous actin (f-actin). These microfilaments are 
organised into a ring (actin ring) separating the basolateral membrane from the ruffled 
boarder (a highly fenestrated region of membrane orientated towards the bone matrix). 
This structure isolates the resorption pit (Howship’s lacunae) and prevents leakage of 
bone degradation products. Matrix recognition at the site of attachment is thought to 
involve integrins, and osteoclasts express at least four types: avp3, av(35, a2(3l and
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avpi (Nesbitt et al, 1993). These integrins are thought to facilitate attachment via 
interactions with bone matrix proteins containing the RGD consensus sequence, such 
as osteopontin (Miyauchi et al, 1991).
Following attachment, osteoclasts secrete protons (FT), Cl' and proteolytic 
enzymes (including TRACP, cathepsin K, aryl sulphatases) across the ruffled boarder 
into the resorption pit. Within the osteoclast cytoplasm, a vacuolar-type V-ATPase 
proton pump packages FT into acidic vesicles, which following diffusion to the ruffled 
border, are released via exocytosis. This action decreases the pH of the resorption pit 
to ~ pH 4.0 and enables the dissolution of the strongly basic hydroxyapatite. 
Following the removal of the inorganic components, proteases can degrade the now 
exposed organic matrix. One of the most important enzymes involved in bone 
resorption is cathepsin K, which cleaves collagen at multiple sites within the triple 
helix facilitating its breakdown (Gamero et al, 2003). Transcytotic vesicles remove 
the organic and inorganic degradation products from the lacunae, diffuse across the 
cell and release their contents via the functional secretory domain into the extracellular 
environment (Salo et aly 1997). On completion of bone resorption, osteoclasts either 
return to a quiescent non-resorbing stage or die by apoptosis.
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BONE REMODELLING
The adult skeleton is in a dynamic state being continually broken down and replaced 
by the coordinated action of osteoblasts and osteoclasts in a process termed bone 
remodelling. These tightly coupled processes allow bone growth, repair and shape 
changes, Ca2+ regulation and the adaptation of bone to mechanical loading. Bone 
remodelling proceeds in one direction and takes place at discrete sites throughout the 
skeleton; these regions, first described by Frost in the 1960’s, are termed bone 
multicellular units (BMUs) (Frost, 1962).
At a new BMU site, remodelling begins with recruitment of osteoclasts, which 
over the period of approximately 1 0  days degrade the bone matrix; resorption proceeds 
until the lacunae is ~ 1 0 0  pm in diameter and 50 pm deep. Subsequent recruitment of 
osteoblasts to the BMU permits the deposition of osteoid, beginning at the bottom of 
the lacunae. After ~ 80 days this process is complete and the osteoid is mineralised 
with hydroxyapatite giving the BMU its tensile strength. Finally, the remodelled area 
enters a quiescent phase to complete the - 1 2 0  day process. At any one time, 5-20% of 
the skeleton is being remodelled by ~ 2 million BMUs (Mundy, 1999).
There is a net increase in bone mass until the 3rd-4th decade of life, followed by a 
period where the bone mass stays relatively constant, thereafter, at the level of the 
BMU a gradual net decrease in bone mass occurs. In men, this decrease is osteoblast- 
mediated, as the cells do not entirely fill the lacunae, resulting in a small deficit at each 
BMU. Women generally experience a rapid decrease in bone density during the 
postmenopausal years, this occurs for several reasons; firstly, in addition to the 
osteoblast-mediated bone loss observed in men, the lacunae produced by osteoclasts 
are deeper than the standard 50 pm causing a greater deficit at each BMU. Secondly, 
oestrogen deficiency after the menopause further enhances bone loss by causing an 
increased number of BMUs (Mundy, 1999).
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CONTROL OF BONE REMODELLING
Bone remodelling is tightly controlled to avoid excessive bone formation or resorption; 
many hormones, growth factors and cytokines act, both locally and systemically, to 
control bone cell function via direct or indirect mechanisms. This section discusses 
some of the important regulators of bone remodelling including systemic hormones, 
prostaglandins, nitric oxide, insulin growth factors (IGFs), protons, mechanical stimuli, 
hypoxia and temperature.
Non-steroid hormones
There are two broad groups of hormones important in bone cell function, steroid and 
non-steroid hormones.
Parathyroid hormone (PTH), the major systemic regulator of Ca2  homeostasis, is 
synthesised by the chief cells of the parathyroid gland. It is secreted during periods of 
relative Ca2+ deficiency, and acts to maintain the extracellular concentration. The 
skeletal effects of PTH are complex, dosage and cellular differentiation dependent, 
involve osteoblasts and osteoclasts and are both catabolic and anabolic. During 
skeletogenesis, PTH in conjunction with Ihh is essential in controlling differentiation 
into the chondrogenic or osteogenic lineages. Intermittent dosing of PTH appears to 
stimulate the proliferation/differentiation of osteoprogenitor cells and increase bone 
formation, whereas continuous application appears to enhance early development but 
suppress the later stages of osteogenic development (Hollnagel et al, 1997). PTH also 
stimulates osteoclastic bone resorption, an effect initially thought to be mediated 
indirectly via osteoblasts; however, recent findings have provided evidence for a direct 
stimulatory action of PTH on human osteoclasts (Dempster et al, 2005).
PTHrP, despite being encoded by a different gene, binds to PTH receptors and has 
similar actions. It is expressed on both osteoblasts and chondrocytes and acts locally 
to regulate cell proliferation and differentiation (Suda et al, 1996; Karaplis & 
Goltzman, 2000). The role of PTHrP in skeletal development is highlighted by 
knockout mice, which exhibit widespread abnormalities in endochondral bone 
formation (Karaplis et al, 1994).
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Calcitonin is synthesised by the thyroid glands and functions to lower circulating
9 4 -Ca and Pi by acting on the kidneys and bone. Since committed osteoclast precursors 
express calcitonin receptors they are often used as an osteoclastic marker (Hattersley & 
Chambers, 1989; Lee et al, 1995). Calcitonin is a powerful inhibitor of osteoclast 
activity in vitro (Chambers et al, 1982; Arnett & Dempster, 1987) and in vivo can 
prevent bone loss and reduce risk of fracture in postmenopausal women (Rico et al, 
1995). Although calcitonin can inhibit osteoblast and osteocyte apoptosis, the exact 
actions on these cells requires further investigation (Plotkin et al, 1999).
Thyroid hormones act systemically to increase the basal rate of oxygen 
consumption, metabolism and heat production. Moreover, by stimulating bone 
resorption, regulating osteoblastic gene expression and controlling the production of 
several growth factors (IGF-1) and cytokines (interleukin 6  (IL-6 )), thyroid hormone 
can also regulate bone remodelling (Mosekilde et al, 1990). Both excess and reduced 
levels of thyroid hormone have profound consequences on body homeostasis including 
marked skeletal effects. In overt hyperthyroidism (Graves’ disease), metabolic rate 
and heat production are strikingly increased, as is osteoclast activity and bone 
turnover; thus, prolonged exposure to excess thyroid hormone leads to reduced bone 
mass, increased fracture risk and osteoporosis. In contrast, hypothyroidism is 
characterised by a lower metabolic rate and body temperature as well as reduced bone 
turnover (Lakatos, 2003).
Recent work has identified the peptide hormone leptin as an important mediator of 
bone mass, although its effects remain unclear. Osteoblasts express both leptin and its 
receptor and in vitro leptin promotes osteoblast proliferation, differentiation and 
survival, collagen synthesis and mineralisation (Gordeladze et al, 2002). Conversely, 
both leptin and leptin-receptor deficient mice are obese with an increased bone mass, 
suggesting this hormone inhibits bone formation possibly indirectly via the 
sympathetic nervous system (Ducy et al, 2000; Takeda et al, 2002).
Steroid hormones
All steroid hormones function in a similar manner; following ligand binding the 
hormone-receptor complex translocates to the nucleus, where acting as a transcription 
factor it can activate or repress expression by binding, as homo- or heterodimer, to
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hormone response elements (HREs) in the promoter region of target genes 
(Mangelsdorf et al, 1995).
Glucocorticoids, such as cortisol, are derived from cholesterol and secreted by the 
adrenal cortex. They have wide-ranging, albeit species dependent, effects on 
osteoblast differentiation and bone remodelling. In rats, glucocorticoids increase the 
number of osteoprogenitors, stimulate osteoblast differentiation and enhance 
expression of osteoblast markers including ALP (Bellows et al, 1998; Bland, 2000). In 
humans, the effects are less clear as in vitro data suggest glucocorticoids are required 
for osteoblast differentiation however, in vivo administration decreases bone 
formation, increases bone resorption and leads to a decrease in bone mass. These in 
vivo effects are probably mediated indirectly because glucocorticoids inhibit Ca2+ 
uptake from the gut, thus stimulating PTH release and increasing bone resorption.
Given the dramatic bone loss that occurs in postmenopausal women, the sex 
steroids, particularly oestrogens, are fundamental in the control of bone remodelling. 
There are many naturally occurring oestrogens, including 17(3-oestradiol, and they act 
via two distinct intracellular receptors, ERa and ERJ3, to reduce bone resorption by 
inhibiting either osteoclastogenesis or osteoclast function (Robinson et al, 1997). 
Additionally, oestrogens act on osteoblasts to stimulate proliferation (Robinson et al,
1997) and the expression of several osteoblastic marker genes including type I 
collagen, OCN and ALP (Gray et al, 1987; Qu et al, 1998). Oestrogens can also 
influence bone remodelling indirectly by modulating the production of cytokines and 
growth factors from bone cells (Jilka, 1998).
The actions of androgens (including testosterone) on bone cell function are less 
well-investigated, nevertheless earlier work demonstrated expression of androgen 
receptors on osteoblasts and osteoclasts (Bellido et al, 1995; Pederson et al, 1999). 
These hormones influence bone metabolism by stimulating osteoblast proliferation, 
decreasing bone resorption and regulating IL- 6  and TGF-(3 expression and secretion 
(Bellido et al, 1995; Kasperk et al, 1997).
Vitamin D3 (l,25(OH)2D3) is a steroid-related hormone important in Ca2+ 
homeostasis. The action of UV light forms inactive vitamin D3 (cholecalciferol) in the 
skin; subsequent hydroxylations in the liver and kidneys produce the active form, 1,25-
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dihydroxyvitamin D3. The major biological function of vitamin D3 is to maintain 
normal blood levels of Ca2 and Pi: when the plasma concentration of Ca2 decreases, 
PTH stimulates the production of vitamin D3, which acts to restore Ca2+ levels to 
normal by increasing transport in the intestines, bone and kidney. Vitamin D3 
deficiency profoundly impairs bone and cartilage mineralisation, leading to 
osteomalacia in adults and rickets in children, conditions characterised by the 
formation of soft bones with an increased tendency to fracture. Vitamin D3 regulates 
osteoblast differentiation by activating or repressing the transcription of genes such as 
ALP, type I collagen and OCN (van Leeuwen et al, 2001). However, like PTH, the 
effects appear complex, with marked differences between species. In human and some 
rat osteoblasts, vitamin D3 regulates the early stages of osteoblast differentiation and 
favours the osteogenic over the adipogenic pathway (Beresford et al, 1992; Beresford 
et al, 1994). In contrast, in primary rat calvarial cells vitamin D3 promotes 
differentiation into adipocytes (Bellows et al, 1994). Furthermore, there are 
conflicting reports regarding the effect of vitamin D3 on Runx2 activity, with some 
saying its is stimulated and others saying it is inhibited (Drissi et al, 2002; Viereck et 
al, 2 0 0 2 ).
Local regulators
Tumour necrosis factor-a (TNFa), a major inflammatory mediator active in diseases 
such as rheumatoid arthritis, is synthesised by activated macrophages and T- 
lymphocytes. This cytokine can potently enhance osteoclastogenesis indirectly via 
actions on osteoblasts or directly by stimulating NFkB activity. Recent evidence 
suggests TNFa can function either independently or synergistically with RANKL, 
however, in combination these cytokines have a greater effect on osteoclast formation 
(Kudo et al, 2002). The effects of TNFa on osteoclast activity are less clear but are 
probably mediated via interactions with osteoblasts, as TNFa failed to stimulate 
resorption in isolated osteoclast cultures (Thomson et al, 1987; Azuma et al, 2000). 
The pro-resorptive effects of TNFa are compounded by its ability to suppress 
osteoblast differentiation and function.
The pleiotrophic cytokine interleukin-1 (IL-1 ) has two isoforms with identical 
activities (IL-la, IL-1 p) and is produced by stromal and haematopoietic cells. In
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mouse and human marrow cultures as well as stromal-cell free cultures, IL-1 in the 
presence of RANKL and M-CSF, acts to stimulate osteoclastogenesis (Lader & 
Flanagan, 1998; Ma et al, 2004). IL-1 promotes mature osteoclast survival and can 
stimulate resorption either directly or indirectly by enhancing RANKL expression in 
osteoblasts (Jimi et al, 1998; Xing et al, 2003). Furthermore, IL-1 can promote the 
secretion of other proinflammatory cytokines including EL- 6  and TNFa. IL-1 acts to 
inhibit bone formation by decreasing osteoblastic expression of ALP and type I 
collagen (Tanabe et al, 2004). These catabolic effects mean EL-1 has been implicated 
in the bone loss associated with inflammatory disease (Kwan et al, 2004).
Many cell types, including osteoblasts, synthesise IL-6 , which is a member of the 
gpl30 cytokine family. Although osteoclastogenic, IL- 6  mediates most of its effects 
indirectly; it stimulates osteoblasts to produce downstream effectors including 
RANKL, which can either act on osteoclasts directly or in a paracrine manner to 
further stimulate their manufacture by osteoblasts (Kotake et al, 1996).
The potent multifunctional cytokine TGFp has three isoforms (TGFpi, -2, -3) with 
TGF(31 being the most abundant in the bone matrix. Once synthesised by osteoblasts 
TGFP is stored in a latent form within the bone matrix, until release and activation 
following bone resorption. TGFP is a potent mitogen for osteoprogenitor cells and 
therefore can increase the number of cells expressing the osteoblast phenotype. In 
vitro TGFP exerts different effects depending on culture conditions; in co-cultures of 
osteoblasts and haematopoietic cells TGFP suppresses osteoclastogenesis by 
increasing OPG secretion and/or decreasing RANKL expression (Takai et al, 1998; 
Quinn et al, 2001). Conversely, in mouse marrow cultures, TGFp suppresses 
apoptosis and enhances osteoclast formation in cells stimulated with RANKL and M- 
CSF, an effect abolished by soluble TGFP receptor II (Fuller et al, 1998; Sells Galvin 
eta l, 1999).
Prostaglandins such as PGE2 are synthesized from membrane phospholipids by the 
actions of phospholipase A2 and cyclooxygenases; they are potent multifunctional 
regulators of bone formation and resorption that function by mediating the actions of 
other growth factors, cytokines and mechanical stimulation. PGE2 has anabolic 
actions and promotes the recruitment of osteoblast precursors and stimulates
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proliferation, collagen synthesis and ALP activity (Hakeda et al, 1985; Raisz et al,
1999). In some cases the actions of prostaglandins and extracellular nucleotides are 
interrelated, for example, osteoblasts stimulated by fluid flow release enhanced levels 
of ATP, which then acts in a paracrine way to stimulate PGE2 production and release 
(Genetos et al, 2005). The effects of prostaglandins on osteoclast function appear to 
be species dependant as they stimulate resorption in whole organ cultures (Hoebertz et 
al, 2001) and isolated human osteoclasts (Lader & Flanagan, 1998) but inhibit 
resorption in isolated chick osteoclasts (Arnett & Dempster, 1987).
Nitric oxide (NO) mediates many physiological processes including vascular 
relaxation, neurotransmission and mechanically induced bone formation. This highly 
reactive free radical is generated by nitric oxide synthase (NOS), an enzyme with three 
differentially expressed isoforms: neuronal (nNOS), endothelial (eNOS) and inducible 
(iNOS). NO has been implicated in the local regulation of bone metabolism and exerts 
potent biphasic effects on bone cell function. Osteoblasts constitutively produce NO at 
a low level and once released it may act in an autocrine manner to stimulate 
proliferation and cytokine production (van't Hof & Ralston, 2001). The eNOS isoform 
appears to be particularly important in this process as eNOS knockouts display 
defective bone formation and reduced osteoblast number (Aguirre et al, 2001). Low 
concentrations of NO may also be necessary for osteoclast motility and activity. High 
NO concentrations, which commonly occur after stimulation with proinflammatory 
cytokines, are associated with osteoblast cell death (Damoulis & Hauschka, 1997) and 
impaired osteoclast formation and activity (van't Hof & Ralston, 1997).
Both insulin-like growth factors (IGF-1, IGF-2) are present in the systemic 
circulation, synthesized in numerous tissues including bone and are potent modulators 
of growth in vivo. In bone, many systemic hormones regulate synthesis of IGF; for 
example, glucocorticoids inhibit IGF-1 expression in osteoblasts, an event thought to 
contribute towards the decreased bone formation observed following glucocorticoid 
treatment (Delany & Canalis, 1995). IGFs are weakly mitogenic for osteoblasts, 
enhance mature cell function and prevent apoptosis (Hill et al, 1997). They promote 
bone formation by increasing levels of type I collagen and decreasing the expression of 
collagen degrading enzymes, matrix metalloproteinase (MMP)-13 and collagenase 3 
(Canalis et al, 1995). These effects appear to be important for maintenance of bone
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mass as IGF-1 null mice display decreased bone formation (Bikle et al, 2002). 
Addition of IGF-2 to murine mouse marrow cultures enhanced osteoclast formation in 
a dose dependent manner, suggesting IGFs may also influence osteoclastogenesis in 
vivo (Fukuoka et al, 2005).
Acidosis
Acid is a by-product of metabolism and given the negative effects of systemic acidosis, 
it is necessary for multicellular organisms to maintain the acid-base balance within 
narrow limits. The large inorganic component of the skeleton provides a massive 
reservoir of base to buffer excess protons (H+) if the kidneys and lungs alone cannot 
maintain the acid-base balance. Initially, the negative skeletal effects of acidosis were 
thought to result from simple physico-chemical dissolution of bone mineral to buffer a 
decreased pH, however, this is now known to be untrue (Green & Kleeman, 1991). 
Acidosis directly stimulates bone resorption, with osteoclasts exhibiting a clear acid 
activation curve; around pH 7.1-7.2 small decreases of only a few hundredths of a unit 
will cause a doubling of resorption pit formation by rat osteoclasts in vitro (Arnett & 
Dempster, 1986; Arnett & Dempster, 1987; Arnett & Spowage, 1996). Acidification is 
a key requirement for resorption, and once activated, osteoclasts can be further 
stimulated by many agents including vitamin D3 (Meghji et al, 2001), ATP, ADP 
(Morrison et al, 1998), RANK and RANKL (Arnett, 2003). Contrastingly, acidosis 
inhibits the production of many matrix components (Kaysinger & Ramp, 1998; Frick 
& Bushinsky, 1999) and progressively blocks the formation of mineralised bone 
nodules by rat osteoblasts in vitro (Brandao-Burch et al, 2005). The solubility of Ca2+ 
and Pi is increased 2-fold and 4-fold, respectively when the pH is reduced and thus the 
primary action of low pH is to block mineralisation (Larsen & Jensen, 1989).
Mechanical stimulation
Mechanical loading (resulting in strain) is necessary for the maintenance of bone mass 
and adaptation of the skeleton. Periods of unloading such as during cast 
immobilisation are characterised by significant bone loss (Duncan & Turner, 1995; 
Ehrlich & Lanyon, 2002). The effects of mechanical loading on bone remodelling 
depend on several factors including the frequency, duration and magnitude of the strain 
but in general, short periods of intermittent loading are most effective at inducing an
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adaptive response (Turner, 1998). The osteogenic effects of bone loading also depend 
on the extent to which the strain is different from normal and appear to decrease with 
ageing. Mechanotransduction is the process by which cells, most likely osteocytes and 
osteoblasts, perceive physical stimuli and respond with biochemical signals. Although 
the exact mechanisms involved remain unclear, it is thought that physiological levels 
of strain distort the bone tissue and cause movement of extracellular fluid through the 
canaliculi. Fluid flow can stimulate cells via direct membrane deformation or by 
inducing an increase in intracellular Ca2+ (Pavalko et al, 1998); the subsequent 
signalling events cause cells to increase expression of Runx2 (Ziros et al, 2002) and 
release anabolic growth factors particularly PGE2 and NO (Jiang et al, 2001). 
Following release, these chemical mediators can act to regulate bone remodelling by 
inhibiting resorption and stimulating bone formation in vivo.
Hypoxia
Bone is highly vascular receiving a blood flow of 200-400 ml/min, approximately 8 % 
of the total cardiac output in a resting adult human. Long bones are fed by multiple 
arterial supplies that diverge into arterioles and control the blood supply into the 
cortical capillaries and bone marrow (De Mameffe, 1951). Disruption of this blood 
supply causes profound ischemia followed by vascular congestion, osteocyte death and 
finally osteoporosis, illustrating the importance of microvasculature in bone 
remodelling and repair.
Oxygen tension (PO2 ) in arterial blood is about 95 mmHg (~ 12%) and in venous 
and capillary blood is about 40 mmHg (~ 5%), approximately a quarter of that in 
atmospheric air. In normal tissues the interstitial p0 2  is usually between 5-12% and 
has been measured in the bone marrow of healthy volunteers at ~ 6.5% (Harrison et al, 
2002) and in the synovial fluid of normal joints at 6-7% (Lund-Olesen, 1970). 
Localised hypoxia occurs when blood supply to a tissue is reduced or disrupted, for 
example following fracture or tissue damage. It can also arise because of natural 
processes including aging and the menopause, which influence the delivery of O2  to 
the tissues. Following vascular disruption, the ensuing hypoxic gradient will lead to a 
very low pC>2 in the centre of the affected area; in diseased tissues such as 
osteoarthritic joints the pC>2 has been reported to fall to < 1 % (Lewis et al, 1999).
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In order to function cells must be able to sense and respond to changes in oxygen 
tension. Acute exposure to hypoxia activates both fast and delayed cellular responses; 
fast responses include a rapid increase in intracellular Ca2  and a switch from aerobic 
mitochondrial-based metabolism to anaerobic glycolysis-based metabolism. The 
delayed responses involve altered gene expression primarily caused by the 
upregulation/stabilisation of specific transcription factors, the most important being 
hypoxia-inducible factor (HIF). Under normal conditions, cells constitutively produce 
the heterodimeric HIF, which consists of two subunits (HIF-a and HIF-P) each 
containing an amino-terminal basic-helix-loop-helix-PAS domain required for 
dimerisation and DNA binding (Wang et al, 1995). The HIF-P subunit or 
arylhydrocarbon nuclear translocator (ARNT) is a constitutive nuclear protein. In 
contrast, oxygen tightly regulates HIF-a expression and levels increase exponentially 
as oxygen concentrations decrease. There are three closely related forms of the HIFa 
subunit (HIF-la, -2a, -3a), each encoded by a distinct gene locus. In terms of 
structure and regulation, HIF-la and -2a are analogous, however less closely related is 
the HIF-3a subunit, which lacks DNA binding activity. Expression of H IF-la is 
universal, whereas HIF-2a expression is restricted to certain cell types including 
osteoblasts (Akeno et al, 2001). HIF-3a is a negative regulator of the other HIFa 
subunits and by binding HIF-p functions to inhibit hypoxia induced, HIF-mediated 
gene expression (Hara et al, 2001).
Normally, oxygen and iron sensitive enzymes hydroxylate a proline residue 
(pro564) on HIF-la, targeting it for intracellular destruction via the ubiquitin- 
proteosome pathway (Pugh & Ratcliffe, 2003). These enzymes, belonging to the 
prolyl hydroxylase family, have an absolute requirement for molecular oxygen and 
therefore provide a direct link between oxygen availability and the regulation of HIF 
(Bruick & McKnight, 2001). During hypoxia, suppression of enzyme catalysis enables 
H IF-la to accumulate, translocate to the nucleus and dimerise with HIF-p. The active 
HIF complex acts to enhance transcription by binding to the hypoxia response element 
(HRE), via the consensus sequence 5’-RCGTG-3’, situated in the promoter region of 
target genes (Semenza, 1996). There are three broad groups of hypoxia-inducible 
genes: (1) factors related to oxygen delivery such as erythropoietin and VEGF, (2) 
enzymes involved with glucose metabolism especially those of the glycolytic pathway,
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and (3) factors involved in cell proliferation and survival including IGF-2 (Wenger et 
al, 2002). Conserved across most mammalian cells, this oxygen sensing system allows 
employment of the appropriate cellular responses to hypoxia.
Despite the high level of skeletal vasculature, both chondrocytes and osteocytes 
occupy avascular matrix bound sites and receive nutrients by passive diffusion. In 
vivo, H IF-la mRNA has been detected in articular cartilage (Stokes et al, 2002), and a 
critical role in developing bone was illustrated when H IF-la deletion caused the death 
of chondrocytes in the cartilaginous growth plate (Aigner et al, 2001; Schipani et al,
2001). Hypoxia may also represent a novel mechanotransduction pathway as 
mechanical unloading (24 hours) leads to rapid increase in hypoxic and HIF-la 
expressing osteocytes; however, this effect is transient and a subsequent short period 
of loading restores oxygen homeostasis (Dodd et al, 1999; Gross et al, 2001).
Earlier work on cultured osteoblasts demonstrated diverse responses to hypoxia 
including the induction of many genes involved in fracture repair such as VEGF 
(Steinbrech et al, 1999; Steinbrech et al, 2000), IGF2 (Akeno et al, 2001), TGF-P and 
type I and III collagen (Warren et al, 2001). In contrast, expression of the fundamental 
osteoblast differentiation factor Runx2 is decreased (Park et al, 2002). The effect of 
hypoxia on osteoblast function will be discussed further in Chapter 4. It is well 
documented that low oxygen stimulates the formation and activation of cells derived 
from marrow precursors, including those of the monocyte/macrophage lineage 
(Bradley et al, 1978; Broxmeyer et al, 1990; Lewis et al, 1999). Pathological bone 
loss commonly occurs during ischemia, fractures, tumours, inflammation and/or 
infection where the pC>2 is reduced and these conditions have striking effects on other 
cells of the monocyte/macrophage lineage. During the course of this research, low 
oxygen (2 %) was shown to dramatically increase osteoclast formation and activity 
(please see paper by Arnett et al, 2003 in Appendix II).
Temperature
Homeothermic animals regulate their body temperature and possess mechanisms to 
detect changes in both internal and external temperatures and compensate accordingly. 
When the temperature decreases, the body adjusts by reducing heat loss and increasing 
heat production. Conversely, when the temperature rises, the body increases its heat
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loss and reduces heat production. These regulatory responses involve a number of 
autonomic, somatic and endocrine responses and are necessary because even small 
deviations from the 37°C norm markedly affects cellular metabolism. Extreme 
changes in temperature can lead to organ failure and even death. Changes in body 
temperature can occur locally or systemically for example; the increased temperature 
seen during inflammation or infection is part of the body’s innate defence mechanisms 
and is caused by the activities of proinflammatory cytokines such as IL-1 and IL- 6  
(Netea et al, 2000). Some pathological conditions are also associated with changes in 
core body temperature such as in hyperthyroidism or hypothyroidism.
All cells must be able to sense and respond to changes in ambient temperature. At 
present the mechanisms involved remain unclear, however, considerably more 
information exists regarding cellular responses to heat shock as opposed to cold shock. 
The heat shock response is ubiquitous, highly conserved and essentially acts as a 
defence mechanism to protect cells from a range of harmful conditions including heat 
stress, hypoxia and inflammation (Feder & Hofmann, 1999). This response involves 
the induction of proteases and heat shock proteins (Hsps); Hsps were initially 
identified following heat shock and are a diverse family of molecular chaperones that 
play an essential role in protein folding and translocation (Ellis et al, 1991). Hsps are 
classified, according to size, into six major families (HsplOO, Hsp90, Hsp70, Hsp60, 
Hsp40 and the small heat shock proteins). Within each Hsp family, there are members 
that are either constitutively expressed or inducible. It is now accepted that certain 
Hsps function under normal conditions to aid in protein folding, however, heat stress 
acts to further increase protein levels. Induction of Hsp expression requires a heat 
shock element (HSE) in the promoter region; these HSEs are bound by heat shock 
factors (HSFs), of which there are three in human cells (Morimoto et al, 1998). The 
ubiquitously expressed HSF-1 has a principal role in stress-induced expression of Hsp 
genes. Normally, Hsps particularly Hsp70, bind and inactivate HSF-1; however, 
increased temperature causes Hsp70 to assume its chaperoning function freeing HSF-1 
to bind, as a trimer, to the HSE in target genes and enhancing transcription (Zhong et 
al, 1998). Prokaryotic cells express cold shock proteins (Csps), which act as RNA 
chaperones to prevent the formation of inappropriate secondary structures. To date 
Csps have not been identified in eukaryotic cells and are not thought to be involved in 
their cold shock response (Graumann & Marahiel, 1998).
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The mechanisms via which cells sense changes in external temperature remain 
undefined but may involve members of the transient receptor potential (TRP) 
superfamily. Individual TRP channel subunits contain six transmembranous domains 
and assemble as tetramers to form cation-permeable (such as Ca2+, Na+) pores. 
Subdivided into seven subfamilies, including TRPC, TRPV, TRPM and TRP A, the 
TRP channels are important in sensory physiology with roles in vision, taste, smell, 
mechanosensation and thermosensation. Of these, the TRPV channels are thought to 
be most important in temperature sensing. TRPVI, TRPV2 and TRPV3 are activated 
by temperatures of 43°C, 52°C and 39°C, respectively and therefore could function as 
heat sensors (Xu et al, 2002; Patapoutian et al, 2003; Bender et al, 2005). Whereas 
TRPV4, TRPM8  and TRPAl channels are stimulated by 27°C, 23-28°C and 17°C 
respectively thus making them cold sensors (Peier et al, 2002; Story et al, 2003). Cells 
expressing these receptors possess the ability to respond to a wide range of 
temperatures from noxious heat (> 43°C) to uncomfortable cold (> 17°C). At 
present, an involvement of TRP channels in the responses of bone cells to temperature 
and other noxious stimuli remains unproven. Nevertheless, as osteoblasts express the 
non-thermosensitive TRPV6  channel, expression of other thermosensitive TRP 
channels on bone cells is possible (Weber et al, 2001). The effects of temperature on 
osteoblast function are discussed further in Chapter 4.
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EXTRACELLULAR NUCLEOTIDES AND PURINERGIC 
SIGNALLING
Overview
All cells require energy in order to carry out the biochemical reactions necessary for 
survival; the free energy donor in most processes is adenosine triphosphate (ATP). 
ATP belongs to a large family of molecules essential in cellular function called the 
nucleotides, all of which are synthesised de novo from simple organic building blocks 
(amino acids and sugars). Each nucleotide consists of a purine (adenine or guanine) or 
pyrimidine (thymine, uracil or cytosine) base, a sugar (ribose or deoxyribose) and a 
phosphate (mono-, di- or tri-) group joined to the sugar by an ester linkage. 
Nucleotide biosynthesis is a complex process involving multiple enzymatic reactions 
and feedback inhibition to prevent overproduction. Once formed nucleotides are 
readily interconvertible for example, removal of one, two or three phosphate ions from 
ATP generates adenosine diphosphate (ADP), adenosine monophosphate (AMP) and 
adenosine, respectively. Nucleotides are ubiquitous across all cell types, are involved 
in numerous intracellular biochemical processes and metabolic pathways and are the 
substrates for a wide range of enzymes.
In 1929, following the observation that adenosine and AMP could elicit biological 
effects on the mammalian heart, Drury and Szent-Gyorygi first proposed a role for 
purines as extracellular signalling molecules; however, it was 1972 before the concept 
of purinergic neurotransmission was proposed. In his hypothesis, Bumstock suggested 
ATP was a neurotransmitter involved in non-adrenergic and non-cholinergic responses 
of smooth muscle in the gastrointestinal tract and bladder (Bumstock et al, 1970; 
Bumstock, 1972). This concept took time to gain acceptance since ATP was first 
recognised for its role in intracellular biochemical processes and because such a 
ubiquitous and simple molecule seemed an unlikely extracellular messenger. In 1976, 
the finding that ATP was a co-transmitter released during nerve transmission 
(Bumstock, 1976a) had a significant influence on the purinergic field and led to the 
first report of purinergic receptors (Bumstock, 1976b). This was followed, two years 
later, by the proposal that there were specific purinoreceptors for nucleosides (PI 
receptors) and nucleotides (P2 receptors) (Bumstock, 1978). The P2 receptors are
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further subdivided into the ionotrophic P2X and the metabotrophic P2Y (first proposed 
by Bumstock & Kennedy, 1985), on the basis of their structure, pharmacological 
profile and tissue distribution (Abbracchio & Bumstock, 1994). Currently, seven P2X 
receptors and eight P2Y receptors have been characterised (Ralevic & Bumstock, 
1998; Bumstock 2004). The most potent agonists at purinergic receptors are the 
adenine and uridine-containing nucleotides; adenosine potently activates PI receptors, 
whilst P2 receptors respond to ATP, ADP, uridine triphosphate (UTP) and uridine 
diphosphate (UDP).
PI receptors
The endogenous purine nucleoside adenosine, is formed either by the sequential 
breakdown of ATP to ADP, AMP and finally adenosine or by the hydrolysis of S- 
adenosyl-L-homocysteine. It potently activates four different PI receptor subtypes: 
Ai, A2 A, A2B and A3 (Ralevic & Bumstock, 1998; Fredholm et al, 2001). Each PI 
receptor is G-protein linked and activation modulates adenylate cyclase (AC) activity. 
Ai and A3 receptors are Gi coupled and decrease cAMP (3-5'cyclic adenosine 
monophosphate) production by inhibiting AC, whereas A 2a  and A2B receptors are Gs 
coupled and stimulate AC leading to increased cAMP production. Individual PI 
receptors display distinct pharmacological profiles and tissue distributions, being 
expressed in amongst others the brain, heart, lungs, liver, bladder, large intestine and 
spinal cord (Ralevic & Bumstock, 1998). Adenosine signalling through the PI 
receptors mediates diverse biological effects including vasodilatation in the heart and 
neuroprotection during hypoxia. There are selective agonists and antagonists for each 
PI receptor facilitating mechanistic investigation and potentially providing therapeutic 
targets. Although PI receptor-mediated signalling is important in chondrocytes and 
cartilage, bone cells do not express PI receptors and therefore they were not the focus 
of this research.
P2X receptors
All seven members of the P2X receptor family (P2 X1.7 ) are ligand gated ion channels. 
Each receptor subunit has two transmembranous domains (TM1 and TM2), separated 
by an extensively N-glycosylated extracellular loop that constitutes a large portion of 
the protein and always contains 10 cysteine residues (North, 2002). These conserved
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cysteines are thought to contribute towards the protein tertiary structure by disulphide 
bond formation. TM1 is involved in channel gating, TM2 lines the ion pore, and a 
hydrophobic H5 region close to the pore vestibule is the ATP binding site. Each P2X 
subunit possesses a short intracellular N-terminus and C-terminus, the only exception 
being the P2 X7  receptor. The P2X subunits share a 35-48% sequence identity and vary 
in size from 379 to 595 amino acids. The stoichiometry of P2X receptors involves at 
least three subunits combining to form homo or heteromultimers. Currently there are 
four known heteromultimers: P2 X2/3 , P2Xi/s, P2 X2 /6  and P2 X4 /6 , although how 
individual P2X subunits influence receptor phenotype remains unclear. ATP is the 
main natural ligand at P2X receptors, although many synthetic ATP analogues also 
activate specific P2X receptor subtypes. Conversely, all uridine-containing 
nucleotides are inactive. All P2X receptors mediate fast signalling and activation 
induces a rapid, non-selective cation current permeable to Na+, K+ and Ca2+ ions.
The P2Xi receptor
Homomeric P2Xi receptors are potently activated by ATP and its synthetic analogue 
a,P-methylene ATP (a,P-meATP), but can be inhibited by cyclic pyridoxine-a4,5- 
monophosphate-6-azophenyl-2',5'-disulphonate (MRS2220) or 2’,3’-0-(2,4,6- 
trinitrophenyl)-ATP (TNP-ATP) (North, 2002). Agonist stimulation causes rapid 
receptor desensitisation (decline in the current elicited during the continued presence 
of ATP) with a slow recovery. P2Xi receptors are permeable to Ca2+ and Na+ ions, 
with expression detected in smooth muscle, platelets and the cerebellum (Ralevic & 
Bumstock, 1998). P2Xi receptor-deficient mice demonstrated an important role for 
this receptor in the vasoconstriction of renal vasculature (Inscho et al, 2004).
The P2X2 receptor
At present, there are no selective agonists or antagonists for P2 X2 receptors; however, 
one unique property of this receptor subtype is its sensitivity to protons and low 
concentrations of zinc and copper ions. A pH of ~ 7.0 causes a significant potentiation 
in ATP-evoked currents, a response considerably effected by removal of a specific 
amino acid residue (His-319) (Nakazawa et al, 2003). Following agonist stimulation, 
the homomeric P2 X2 receptors become particularly permeable to Ca2+ but unlike other 
P2X receptors exhibit little or no desensitisation. Expression of the P2 X2  receptor is
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widespread and includes nervous tissue, the bladder and intestine. P2 X2 knockout 
mice display reduced ventilatory responses to hypoxia (Rong et al, 2003) plus deficits 
in pain related behaviours and normal sensory processes suggesting this receptor 
mediates some of the sensory effects of ATP (Cockayne et al, 2005).
The P2 X 3  receptor
The synthetic analogue 2-methylthio-ATP (2-MeSATP) and to lesser extent a,p- 
meATP potently activate homomeric P2 X3 receptors, which like P2Xi receptors, 
experience rapid desensitisation following ligand binding. These receptors are 
predominantly expressed in sensory nerves but are also present on endothelial and 
epithelial cells. Involvement of this receptor in mediating peripheral pain responses 
and urinary bladder volume reflexes was demonstrated in vivo using receptor knockout 
mice (Cockayne et al, 2000; Zhong et al, 2001).
The P2 X 2 /3  receptor
The heteromeric P2 X2 /3  receptor is expressed in certain sensory neurons and shares 
some of the properties of both homomeric P2 X2 and P2 X3 receptors including 
potentiation by low pH, slow desensitisation and activation by a,P-meATP (North, 
2002). Moreover, P2X2/3-null mice display the same deficits as both single P2 X2 and 
P2 X3 knockouts such as impaired ventilatory responses to hypoxia (Rong et al, 2003) 
and urinary bladder reflexes (Cockayne et al, 2005).
The P2 X 4  receptor
Homomeric P2X* receptors are potently activated by ATP, however they have no 
selective antagonists and are relatively insensitive to the more general inhibitors, 
suramin and pridoxal-5-phosphate-6-azophenyl-2’,4’-disulphonic acid (PPADS). 
Upon activation, P2 X4  receptors become particularly permeable to Ca2+ and 
desensitisation is intermediate between that observed at P2Xi and P2 X2 receptors 
(North, 2002). Receptor expression is widespread being especially prominent on cells 
from the CNS.
48
The P2Xs receptor
Compared to other P2X receptors, homomeric P2X5 receptors elicit only small currents 
in response to agonist (ATP) stimulation (North, 2002). This receptor is inhibited by 
suramin and PPADS and, following activation, experiences slow desensitisation. P2X5 
receptors are widely expressed in proliferating cells of the skin (Greig et al, 2003), gut, 
bladder (Groschel-Stewart et al, 1999), thymus (Glass et al, 2000), skeletal muscle 
(Meyer et al, 1999; Ryten et al, 2002) and spinal cord, where receptor activation acts 
to stimulate cell division. It is also prominent in several cell types during embryonic 
development (Ryten et al, 2001).
The P2Xi/s receptor
Cells expressing heteromeric P2 X1/5 receptors provide responses to ATP that have 
several distinct features; firstly, they are more sensitive to ATP than their homomeric 
counterparts and, secondly, a,(3-meATP evokes a sustained current which is not seen 
in either P2Xi or P2Xs homomultimers (North, 2002). Expression of P2 Xi/5 receptors 
has been reported in some blood vessels (Bumstock & Knight, 2004).
The P2Xe receptor
Unlike the other members of the P2X receptor family, P2X6 subunits do not form 
functional homomultimers (Ralevic & Bumstock, 1998). P2X6 subunit expression is 
widely distributed throughout the CNS where it forms heteromultimers with P2 X4  or 
P2 X2 receptors.
The P2X2/6 and P2X&6 receptor
Expression of the P2 X2 /6  and P2 X4 /6  receptors has been reported in the brain stem and 
central nervous system neurons, respectively (Bumstock & Knight, 2004). However, 
for both heteromeric channels information regarding receptor pharmacology is still 
limited (North, 2002).
The P2X 7 receptor
The P2X7 (formerly P2Z) receptor is distinct from other family members in several 
ways; firstly, it has a significantly longer C-terminus and secondly, it is the only P2X 
subunit not to form functional heteromultimers. This receptor has a relatively low
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sensitivity for ATP (> 100 |xM) and preferentially binds to 2’,3’-0-(benzoyl-4- 
benzoyl)-ATP (Bz-ATP). P2 X7  receptors can be inhibited by several different 
antagonists including Brilliant Blue G and the large organic cation, KN-62 (North,
2002). Prolonged or repeated exposure to high agonist concentrations, mediates the 
formation of cytolytic pores (Murgia et al, 1992), whereas, transient receptor 
stimulation causes the formation of nonselective membrane pores permeable to 
molecules up to 900 Kda in size (Di Virgilio, 1995). The P2 X7  receptor is 
predominantly expressed on immune cells including macrophages, microglia and 
certain lymphocytes. This receptor has been implicated in the inflammatory response 
as leukocytes derived from P2 X7  knockout mice failed to release IL-1(3 in response to 
ATP (Labasi et al, 2002). Moreover, these animals were less susceptible to 
monoclonal antibody induced arthritis.
P2Y receptors
In keeping with other G-protein coupled receptors (GPCRs), all P2Y receptors possess 
the characteristic seven transmembrane domain structure; an extracellular N-terminus 
and an intracellular C-terminus that gives rise to the structural diversity between 
subtypes and contains protein kinase binding motifs. The P2Y receptors display a 19- 
55% sequence homology and there are eight family members: P2Yi, P2 Y2, P2Y4, 
P2Y6, P2Yn, P2 Y i2, P2Y n and P2Ym (Ralevic & Bumstock, 1998; Bumstock, 2004). 
The missing numbers in the series represent receptors cloned from non-mammalian 
vertebrates or receptors currently undergoing functional characterisation.
Each P2Y receptor couples to a heterotrimeric G protein and can be further 
subdivided according to pharmacology, structure and downstream signalling. The 
P2Yi, P2Y2, P2Y4 and P2Y6 receptors couple to Gq/11, thus receptor stimulation 
activates phospholipase C, which hydrolyses phosphatidyl inositol 4,5-bisphosphate 
(PIP2) to inositol triphosphate (IP3) and diacylglycerol (DAG) and results in Ca2+ 
release from internal stores. In contrast the P2Yn, P2Y n and P2Yi4 receptors couple 
to Gi, inhibit AC and alter cAMP levels. The P2Y n receptor subtype is distinct and 
couples to both Gq/11 and Gs(King & Bumstock, 2002; Bumstock, 2004).
Classification in terms of pharmacology splits the P2Y receptors into the adenosine 
nucleotide-preferring receptors (P2Yi, P2Yi2, P2Yn (human and rodent) and human
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P2Y n), the uridine nucleotide-preferring receptors (human P2Y4 and P2Y6) and finally 
the receptors of mixed selectivity (human and rodent P2 Y2 and rodent P2Y4) 
Structurally P2Y receptors can be subdivided into two groups, the first of which 
contains P2Yi, P2 Y2, P2Y4, P2Y6 and P2Yn and the second P2Yi2, P2Y n and P2Yi4. 
For the first subgroup, a Y-Q/K-X-X-R motif in TM7 participates in ligand binding; 
this is additional to the fundamental H-X-X-R/K motif in TM6 that all P2Y receptors 
possess. In the second group, the additional ligand-binding motif is K-E-X-X-L, this 
alternative sequence suggesting a different mode of agonist binding (Abbracchio et al,
2003).
The P2Yi receptor
The P2Yi receptor is activated by adenine containing nucleotides, particularly ADP 
and, to a lesser extent, ATP; conversely, UTP and UDP are inactive. This is the only 
P2Y receptor subtype with specific, high-affinity, synthetic agonists (2- 
MethylthioADP (2-meSADP)) and antagonists (A6-methyl-2'-deoxyadenosine-3', 5'- 
bisphosphate (MRS2179) and 2-chloro-A6-methyl-(Ar)-methanocarba-2'-deoxy- 
adenosine-3',5'-bisphosphate (MRS2279)). The P2Yi receptor has a widespread 
distribution with expression reported in tissues such as brain, heart, muscle, intestine, 
platelets and astrocytes (Bumstock & Knight, 2004). P2Yi-deficient mice exhibit 
decreased platelet aggregation and increased bleeding indicating an important role for 
this receptor in induction of platelet aggregation (Fabre et al, 1999; Leon et al, 2001).
The P2 Y2  receptor
The P2 Y2 receptor (formerly P2U) displays a mixed selectivity being potently 
activated by both ATP and UTP but insensitive to nucleotide diphosphates. Receptor 
expression is widespread and has been identified in amongst others the heart, blood 
vessels, lung, kidney, astrocytes and skeletal muscle (Bumstock & Knight, 2004). 
Currently assigned roles for the P2Y2 receptor include astrogliosis, transmitter release, 
mucus escalation and airway hydration. Knockout studies revealed a critical role for 
P2 Y2  receptors in the regulation of ion transport in airway epithelial cells (Cressman et 
al, 1999; Homolya et al, 1999).
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The P2 Y4 receptor
Both ATP and UTP activate the P2Y4 receptor and in many species, UTP is the more 
potent with the exception of rat where these agonists are equipotent. Compared to 
other family members, P2Y4 receptor expression is less widespread although is found 
in brain, epithelial cells, macrophages, monocytes, and smooth muscle. Knockout 
mice have no overt phenotype but lack UTP- and ATP-induced chloride secretory 
responses in jejunum epithelial cells, indicating a role for P2Y4 receptors in this 
process (Robaye et al, 2003).
The P2Y6 receptor
The P2Y6 receptor is selective for uridine-containing nucleotides, particularly UDP. 
This receptor displays widespread expression being present in tissues as diverse as 
kidney, lung, spleen, thymus, smooth muscle, heart and epithelium. The P2Y6 receptor 
has a proposed role in lymphocytic maturation (King & Bumstock, 2002); however, as 
no knockout model is available, further functions remain undefined.
The P2Yn receptor
ATP, ADP and the synthetic nucleotides 2-MeSATP and Bz-ATP all activate this 
receptor, whilst it is weakly antagonized by suramin and reactive blue 2. Expression is 
relatively widespread having been detected in the spleen, brain, placenta, intestine and 
granulocytes. At present no P2Yn knockout model is available therefore functional 
effects of receptor activation remain undefined, although this receptor has been 
implicated in the differentiation of granulocytes into neutrophils (Communi et al,
2000).
The P2Yj2 receptor
The P2Yn receptor is another member of the P2Y family primarily activated by ADP 
and is structurally related to the UDP-glucose receptor (49% identity). Expression is 
more restricted having only been identified in the brain and on platelets, where the 
receptor plays a role in haemostasis. A truncated form of the P2 Y 12 receptor is non­
functional and in one patient was associated with a bleeding disorder (Hollopeter et al, 
2001)
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The P2 Yj3 receptor
The recently identified P2Yn receptor is activated by ADP and has a high sequence 
homology with the P2Yi2 receptor (Marteau et al, 2003). Expression of this receptor 
has been reported in the spleen, liver, brain and erythrocytes (Fumagalli et al, 2004). 
Recently, P2Yo receptors were implicated in a negative feedback that leads to the 
inhibition of ATP release from erythrocytes (Wang et al, 2005).
The P2Yu receptor
There is some debate over whether this is a true P2Y receptor or not because it 
specifically responds to UDP-glucose and UDP-galactose but not UTP or UDP. The 
P2Yh receptor, also known as the UDP-glucose receptor, has no defined physiological 
role although transcripts are widely expressed throughout the neuroaxis (Abbracchio et 
al, 2003).
Sources andfates o f extracellular nucleotides
The mechanisms of ATP release and breakdown are discussed in more detail in 
Chapters 4 and 6.
Physiological roles o f purinergic signalling
It is now widely recognised that purinergic signalling is involved in both neuronal and 
non-neuronal tissues, where extracellular nucleotides can mediate short-term, fast 
actions or long-term, slower, trophic actions. Evidence now implicates extracellular 
purines and pyrimidines in biological processes as diverse as smooth muscle 
contraction and relaxation, inflammation, platelet aggregation and endocrine and 
exocrine secretions [see review by Bumstock & Knight, 2004].
ATP mediates short-term signalling by acting as a cotransmitter in both the central 
and peripheral nervous system. For example, sympathetic co-transmission of 
noradrenaline and ATP has been demonstrated in the smooth muscle of blood vessels, 
whereas ATP and acetylcholine are co-transmitters from peripheral or central nerve 
terminals including the parasympathetic nerves supplying the urinary bladder. Other 
short-term actions include the regulation of ion transport in epithelial cells and the
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stimulation of insulin from the (3 cells of the pancreas (Abbracchio & Bumstock, 
1998).
Long-term purinergic signalling plays a role in the regulation of embryonic 
development, cell proliferation, differentiation and apoptosis, however the exact 
consequences are dependent on many factors including concentration, target cell and 
receptor expression. For example, low micromolar concentrations of nucleotides can 
stimulate DNA synthesis and proliferation in a number of cell types including 
fibroblasts, haematopoietic cells and keratinocytes; however, millimolar concentrations 
of ATP can induce apoptosis, probably via the P2X7 receptor (Abbracchio & 
Bumstock, 1998).
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PURINERGIC SIGNALLING AND BONE
There is now growing evidence that extracellular nucleotides, signalling through P2 
receptors play an important role in the regulation of bone remodelling. This section 
will provide a brief overview of current knowledge regarding purinergic signalling and 
bone cell function.
Extracellular nucleotides and osteoblasts
Osteoblasts express at least seven P2 receptor subtypes (see Table 1), however, only 
four have been assigned functional effects based on in vitro data. In many cell types, 
the P2 X5 receptor plays a role in stimulating proliferation (Bumstock & Knight, 2004); 
following the observation that 10-100 pM ATP stimulates DNA synthesis in human 
osteoblast-like cells via activation of the mitogen activated protein (MAP) kinase 
pathway (Nakamura et al, 2000) a similar role was proposed in osteoblasts. The role 
of the P2 X7  receptor in osteoblast function is less clear, however, it has been 
implicated in osteoblast apoptosis (Gartland et al, 2001).
In vitro evidence suggests that purinergic signalling via the P2Yi receptor, can act 
to modulate osteoblast responses to systemic factors. In rat UMR-106 osteoblast-like 
cells, compared to treatment with PTH alone, co-stimulation with ADP and PTH 
caused increased CREB phosphorylation and, by binding to the Ca/CRE region in the 
promoter region, they synergistically increased expression of the transcription factor c- 
fos  (Buckley et al, 2001). Similar effects were also observed in human osteoblast-like 
SaOS-2 cells, albeit through a different pathway; in these cells activation of both the 
serum response element (SRE) and the Ca/CRE in the promoter region were required 
for increased c-fos expression (Bowler et al, 1999). Consequently, locally released 
extracellular nucleotides may cooperate with systemic factors to activate signalling in 
osteoblasts above a key threshold, which alone neither stimulus could achieve; 
allowing the integration of local and systemic factors in the control of bone 
remodelling (Bowler et al, 2001).
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Receptor Receptoragonists
Species and cell 
type Evidence Reference
Osteoblasts
P2XZ
ATP (H+ 
sensitive
Rat (primary)
Immunocytochemistry, in 
situ hybridisation
Hoebertz et al, 2000
P2XS ATP
Rat (primary) 
Human (MG-63)
Immunocytochemistry
RT-PCR
Hoebertz et al, 2000 
Nakamura et ai, 2000
P2X7
BzATP > 
ATP > 2- 
MeSATP
Human (MG-63) 
Human (primary, SaOS-2) 
Mouse (primary)
RT-PCR
Immunocytochemistry
RT-PCR
Nakamura et al, 2000 
Gartland et al, 2001 
Ke et al, 2003
P2Yi
2-MeSADP
>ADP>ATP
Rat (primary) 
Human (MG-63)
In situ hybridisation 
RT-PCR
Hoebertz et al, 2000 
Maier etal, 1997
P2Y2 UTP > ATP
Rat (primary) 
Human (MG-63) 
Human (primary, SaOS-2)
In situ hybridisation 
RT-PCR 
RT-PCR, Southern blotting
Hoebertz et al, 2000 
Maier et al, 1997 
Bowler etal, 1995
P2Y4 UTP = ATP Human (MG-63) RT-PCR Maier etal, 1997
P2Y« UDP > UTP Human (MG-63) RT-PCR Maier etal, 1997
Osteoclasts
P2Xi
a0meATP = 
ATP
Human (primary) RT-PCR Buckley et al, 2002
P2X2 As above Rat (primary)
Immunocytochemistry, in 
situ hybridisation
Hoebertz et al, 2000
P2Xi ATP
Rat (primary)
Rabbit (primary) 
Human (primary)
Immunocytochemistry, in 
situ hybridisation 
RT-PCR 
RT-PCR
Hoebertz et al, 2000
Naemsch et al, 1999 
Buckley et al, 2002
P2X7 As above
Rat (primary) 
Human (primary)
Immunocytochemistry
RT-PCR,
immunocytochemistry
Hoebertz et al, 2000 
Buckley et al, 2002 & 
Gartland et al, 2003
P2Y, As above
Rat (primary) 
Human (primary)
In situ hybridisation 
RT-PCR
Hoebertz et al, 2000 
Buckley et al, 2002
P2Y2 As above
Rat (primary) 
Human (ostoclastoma) 
Human (primary)
In situ hybridisation 
RT-PCR 
RT-PCR
Hoebertz et al, 2000 
Bowler ef al, 1995 
Buckley et al, 2002
P2Y4 As above Human (primary) RT-PCR Buckley et al, 2002
P2Y« As above
Rabbit (primary) 
Human (primary)
RT-PCR
RT-PCR
Korcok et al, 2005 
Buckley et al, 2002
P2Y,i
BzATP > 
ATP > ADP
Human (primary) RT-PCR Buckley et al, 2002
Table 1. Expression of P2 receptors by osteoblasts and osteoclasts
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Both UTP and ATP, at concentrations as low as 1-10 jiM cause strong inhibition 
of mineralised bone nodule formation by cultured rat osteoblasts, whereas adenosine 
and ADP were without effect (Hoebertz et al, 2002). These potent actions of ATP and 
UTP point to the involvement of either P2 Y2 or P2 Y4  receptors. Further evidence for 
P2 Y2 -mediated inhibition comes from the observation that adenosine 5'-0-(3- 
thiotriphosphate (ATPyS), a potent P2 Y2 agonist, also inhibits bone formation in vitro 
(Jones et al, 1997). Additionally, P2 Y2 receptors have been shown to mediate the 
propagation of intercellular Ca2+ waves (Jorgensen et al, 2000) and oscillatory fluid 
flow-induced Ca2+ mobilization (You et al, 2002) in osteoblast-like cell lines. 
Recently, the P2 Y2 receptor has also been implicated in the ATP/UTP mediated 
stimulation of Erg-1 (Pines et al, 2003) and Runx2 (Costessi et al, 2005), via the 
protein kinase C (PKC) and extracellular related kinase (ERK) pathways.
At present, a role for the P2 X2 , P2 Y4 or P2Y6 receptors in osteoblast development 
and function remains to be defined.
Activation of P2 receptors on osteoblasts also influences the production of other 
local factors important in bone cell function. For example, in osteoblast-like cells, 
ATP was shown to increase the expression of IL- 6  mRNA (Ihara et al, 2005) and 
stimulate the release of arachidonic acid (Wanatanbe-Tomita et al, 1997). Moreover, 
several groups have reported ATP release from osteoblast-like cells; this will be 
discussed further in Chapter 4.
Extracellular nucleotides and osteoclast function
Osteoclasts also express multiple P2 receptors (see Table 1). Involvement of P2 
receptors in the control of osteoclast function was first suggested by Bowler et al 
(1995), after ATP was found to stimulate resorption by cells derived from an 
osteoclastoma. Initially, this effect was thought to be mediated via the P2 Y2 receptor, 
however, in a follow-up study UTP failed to stimulate bone resorption (Bowler et al,
1998), suggesting this was not the case. Subsequently, ATP was found to stimulate the 
formation and activity of rodent osteoclasts; the resorptive activity being further 
increased when osteoclasts were first activated by culture in acidified medium 
(Morrison et al, 1998). These pro-resorptive effects were suggested to involve the 
P2 X2 receptor since it is the only P2 receptor sensitive to protons. Moreover, a recent
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study found low micromolar concentrations of ATP, ADP and 2-MeSADP to be potent 
stimulators of both the formation and resorptive activity of rodent osteoclasts, and 
resorption in bone organ cultures (Hoebertz et al, 2001). These findings, together with 
cytochemical evidence, suggest the involvement of the P2Yi receptor in mediating the 
osteolytic effects of ATP and ADP (Hoebertz et al, 2000; Hoebertz et al, 2001; 
Hoebertz et al, 2003). Thus, activation of both the P2X2 and the P2Yi receptors can 
potentially influence osteoclast activity. Conversely, a study on human osteoclasts 
suggested that ATP functions indirectly, via the upregulation of RANKL on 
osteoblasts, to stimulate resorption (Buckley et al, 2002).
The role of the P2 X7 receptor in osteoclast activity has received considerable 
attention in recent years and in vitro evidence suggests this receptor could be involved 
in a number of different processes. Experiments using cells derived from human 
peripheral blood demonstrated P2 X7  receptor antagonism inhibited osteoclast 
formation (Gartland et al, 2003a) suggesting as in macrophages (Chiozzi et al, 1997), a 
potential role in cell fusion. Conversely, P2 X7 -deficient mice possessed functional 
osteoclasts in vivo and using knockout precursor cells osteoclasts could be generated in 
vitro, indicating the P2 X7  receptor is not required for cell fusion (Ke et al, 2003). 
Additionally, the P2 X7  receptor may also play a role in intercellular communication 
between bone cells (Jorgensen et al, 2002).
Activation of both the P2 X7  receptor by Bz-ATP (300 pM) (Korcok et al, 2004) 
and the P2Y6 receptor by UDP (10 fiM) (Korcok et al, 2005) induced translocation and 
activation of NFkB in osteoclasts and their precursors. Moreover, the activation of 
P2Y6 receptor prevented the apoptosis induced by TNFa, indicating a role for this 
receptor in osteoclast survival (Korcok et al, 2005).
At present, how the P2Xi, P2 X4 , P2Y2, P2Y4  and P2Yn receptors signal to 
modulate osteoclast activity remains unclear.
Purinergic signalling and cartilage
Cartilage is a fundamental component of the skeletal system being necessary for bone 
formation via endochondral ossification and essential for the smooth movement of 
joints. The expression of purinergic receptors in cartilage was first suggested
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following the observation that ATP, ADP and to a lesser extent UTP stimulated PGE2 
production from cultured human chondrocytes (Caswell et al, 1991). Recent 
characterisation, demonstrated expression of P2 X2 , P2 X5 , P2Yi and P2 Y2 receptors 
along with the PI receptors, A2A and A2B in chondrocytes (Koolpe et al, 1999; 
Hoebertz et al, 2000).
Extracellular nucleotides act to stimulate cartilage resorption, an effect enhanced 
by IL-lp and IL-la, and intercellular communication through the extracellular matrix 
(Leong et al, 1994; D'Andrea & Vittur, 1996). Chondrocytes release ATP, which, by 
acting in an autocrine/paracrine manner, can induce PGE2 release (Graff et al, 2 0 0 0 ). 
Nucleotide-induced PGE2  release is further enhanced by pro-inflammatory cytokines 
including II-ip, II-la  and TNF-a; this suggests nucleotides may function 
synergistically with these factors and potentially contribute indirectly towards the 
pathophysiology of arthritis (Caswell et al, 1992; Koolpe et al, 1999). Conversely, 
other data indicates a constructive role for extracellular nucleotides as they can 
stimulate proteoglycan synthesis, inhibit their breakdown and induce cartilage repair 
(Kumahashi et al, 2004).
Although an area of active research, the effects of extracellular nucleotides on 
chondrocyte function and cartilage were not the focus of this thesis and will not be 
discussed further.
GENERAL AIM OF THESIS
The aim of this thesis was to investigate further the involvement of purinergic 
receptors and extracellular nucleotides in bone cell function under normal and stress 
situations.
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CHAPTER 2
FUNCTIONAL EXPRESSION OF PURINERGIC 
RECEPTORS BY OSTEOBLASTS
INTRODUCTION
Growing evidence suggests extracellular nucleotides, signalling through P2 receptors, 
might play a significant role in bone biology modulating both osteoblast and osteoclast 
function (Hoebertz et al, 2003). The P2 receptors are grouped into the P2X ligand- 
gated ion channels and P2Y G-protein linked receptors (Abbracchio & Bumstock, 
1994). Currently there are seven known P2X subtypes (P2 X 1.7 ) and eight P2Y 
subtypes P2Yi, P2 Y2 , P2 Y4 , P2Y6, P2Yn, P2 Y 1 2 , P2Yn and P2Yi4; each of these 
receptors has been cloned, characterised and displays distinct tissue expression and 
pharmacology (Bumstock & Knight, 2004).
Studies in the early 1990s showed that extracellular nucleotides act on osteoblast­
like cells to induce formation of inositol triphosphate (IP3 ) and to elevate intracellular 
calcium (Ca2+) transiently; pharmacological profiles were suggestive of the expression 
of P2Yi- and P2 Y2-like receptors [reviewed by Hoebertz et al, 2003], Subsequent 
studies on primary human osteoblasts indicated heterogeneity of P2 receptor 
expression, since all cells exhibited intracellular Ca2+ responses to ATP and UTP 
(suggestive of P2 Y2 and/or P2Y4  receptors) but only a sub-population responded to 
ADP (which is selective for the P2Yi, P2 Yi2  and P2Yn receptors) (Dixon et al, 1997). 
This was taken to indicate that expression of P2 receptors changes during the 
osteoblast life cycle, depending on the differentiation state. A summary of the P2 
receptor subtypes expressed on osteoblasts is provided in Table 1.
Several of the P2 receptor subtypes expressed on bone cells have assigned 
functional effects (see Chapter 1 for more detailed information). For example, in vitro 
data has implicated the P2 X5 receptor in osteoblast proliferation as 10-100 jiM  ATP, 
but not UTP, stimulate DNA synthesis in osteoblast-like MG-63 (Nakamura et al,
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2000) and MC3T3-E1 cells (Shimegi, 1996). The involvement of the P2X2 receptor in 
the modulation of osteoblast activity remains unclear, whereas P2 X7  receptors may 
mediate apoptosis in response to high agonist concentrations (Gartland et al, 2001).
Earlier in vitro evidence indicated that relatively low concentrations of 
extracellular nucleotides exert P2 receptor-mediated effects that would shift the bone 
remodelling balance strongly in the negative direction (Hoebertz et al, 2003). Low 
micromolar concentrations of ATP and ADP, signalling through the P2Yi receptor, 
stimulate the formation and resorptive activity of rodent osteoclasts, and resorption in 
bone organ cultures (Morrison et al, 1998; Hoebertz et al, 2001). In contrast, both 
UTP and ATP cause strong inhibition of mineralised bone nodule formation by 
cultured rat osteoblasts (Hoebertz et al, 2002). These potent actions of ATP and UTP 
point to the involvement of either P2Y2 or P2 Y4  receptors. Additionally, P2Y2 
receptors have been shown to mediate the propagation of intercellular Ca2+ waves 
(Jorgensen et al, 2000) and can stimulate the activity of transcription factors including 
Erg-1 (Pines et al, 2003) and Runx2 (Costessi et al, 2005). Nucleotide signalling in 
bone via P2Yi and P2Y2 receptors can also modulate local remodelling responses to 
key osteotropic agents such as PTH (Buckley et al, 2001; Bowler et al, 2001).
Despite abundant evidence indicating P2 receptor expression on osteoblasts, how 
levels change with osteoblast proliferation and differentiation remained poorly 
investigated. In other cell types including haematopoietic cells, purinergic receptor 
expression is differentiation dependent (Martin et al, 1997). The aim of the work 
presented in this chapter was document changes in P2 receptor expression (P2X2 , 5, 7 
and P2Yi, 2 , 4, 6 ) in normal populations of bone-nodule-forming rat osteoblasts as 
differentiation and maturation proceed. Changes in mRNA and protein levels were 
investigated using reverse transcriptase PCR (RT-PCR) and immunofluorescence, 
respectively. Nucleotide-agonist induced changes in intracellular Ca2+ were studied 
using the high-throughput fluorescence imaging plate reader (FLIPR).
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MATERIALS AND METHODS
Cell culture
Primary rat osteoblast cells were obtained by sequential enzyme digestion of excised 
calvarial bones from 2-day-old neonatal Sprague-Daley rats using a 3-step process (1% 
trypsin in PBS for 10 minutes; 0.2% collagenase type II in Hanks balanced salt 
solution (HBSS) for 30 minutes; 0.2% collagenase type II in HBSS for 60 minutes). 
The first two digests were discarded and the cells resuspended in Dulbecco’s Modified 
Essential Medium (Gibco, Paisley, UK) supplemented with 10% Foetal calf serum, 2 
mM L-glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin and 0.25 pg/ml 
amphotericin (complete mixture abbreviated to DMEM). Cells were cultured for 2-4 
days in a humidified atmosphere of 5% CC>2 -9 5 % air at 37°C in 75cm2 flasks until 
confluent. Upon confluence cells were seeded into 6 , 24 or 96-well trays (105 and 5 x 
104  cells/well, respectively) in DMEM supplemented with (3-glycerophosphate (2 
mM), ascorbic acid (50 pg/ml) and dexamethasone (10 nM). Osteoblasts were 
cultured for 4-21 days with half medium changes every 2-3 days. Throughout the 
culture, medium pH, pC0 2  and p0 2  were monitored using a blood gas analyser (ABL- 
700, Radiometer, Copenhagen).
To investigate the ability of ATP and UTP to prevent bone formation and the P2 
receptor subtypes involved, fresh nucleotides and/or receptor antagonists were added 
to the medium every 2-3 days. As concentrations of ATP/UTP of 1-100 pM (Chapter 
3; Hoebertz et al, 2002) significantly inhibit bone nodule formation, an intermediate 
concentration of 10 pM was employed for all the experiments performed here. The 
purinergic receptor antagonists suramin and reactive blue 2 were tested at 0.1-100 pM.
Measurement o f  intracellular Ca2*
Osteoblastic cells were seeded into poly-D lysine-coated black walled, clear-bottomed 
96-well trays (BD Biosciences, Oxford UK) at a density of 5 x 104  cells/well and 
cultured for 4, 8  or 10 days with half medium changes every other day. Cells were 
twice washed with PBS and loaded for 30 minutes with the cell-permeant Fluo-4 AM 
(2 pM) in PBS containing 2.5% pluronic acid in 100 pi dimethyl sulphoxide (DMSO). 
After removal of the fluorophore loading solution, cell layers were washed twice more
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and 150 pi of PBS added per well. The cell plates were loaded into a fluorescence 
imaging plate reader (FLIPR, Molecular Devices, Wokingham, UK) together with a 
separate 96-well tray containing nucleotide agonists, an ionomycin positive control (1 
pM) and a PBS negative control. The agonists were distributed in a randomised 
pattern to minimise any cell plating effects due to well position. The FLIPR was 
programmed to transfer the agonists simultaneously to all 96-wells, 30 seconds after 
commencement of recording; fluorescence was excited at 488 nm and emission 
measured at 510-560 nm. Duration of recording was typically 3 minutes; at the end of 
experiments, cell layers were fixed with 2.5% glutaraldehyde for 5 minutes and stained 
with 1% alizarin red (w/v) to demonstrate the presence of bone nodules. Due to 
technical constraints (acidification of medium, monolayer peeling) it was not possible 
to culture osteoblasts in the 96-well trays for periods exceeding 10 days.
Cell proliferation assay
Osteoblast proliferation was measured using the MTT assay. The assay exploits the 
ability of mitochondrial dehydrogenases, in metabolically active cells, to reduce the 
yellow tetrazolium 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide 
(MTT) generating a purple formazan product. Rat calvarial osteoblasts were cultured 
in standard 96-well trays as described above. MTT reagent stock solution (5 mg/ml in 
PBS) was added to each cell layer (final concentration 0.5 mg/ml) and plates incubated 
in the dark at 37°C for five hours; culture medium was then carefully removed and 
formazan crystals solubilised by the addition of concentrated DMSO. Absorbance was 
read in a plate reader at 550 and 650 nm (ELX800, Bio-Tek International, Fisher 
Scientific UK, Loughborough): a standard curve for determination of cell numbers was 
constructed using cells seeded at 1 0 2  to 1 0 6 /well.
Total RNA extraction and complementary DNA strand synthesis
Osteoblasts were cultured in 6 -well trays for 6-18 days in supplemented DMEM; every 
2-3 days total RNA was extracted from two wells using TRIZOL® reagent 
(Invitrogen, Paisley, UK) according to the manufacturers instructions. Before first 
strand complementary DNA (cDNA) synthesis, extracted RNA was DNase treated 
with RNase free DNase I (35 U/ml) for 30 minutes at 37°C. The reaction was 
terminated by heat inactivation at 65°C for 10 minutes. Total RNA was quantified
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spectrophometrically by measuring absorbance at 260 nM. For each sample 0.5 pg of 
DNase treated total RNA was used as a template for first strand cDNA synthesis in a 
20 pi reaction also containing 0.5 pg Oligo dT, 3 mM MgCh, 0.5 mM dNTPs, 20 U 
recombinant RNasin® ribonuclease inhibitor, ImProm-II™ 5x reaction buffer and 200 
U ImProm-II Reverse Transcriptase™. The reaction mix was annealed for 5 minutes 
at 25°C, followed by extension at 42°C for 60 minutes and inactivation at 70°C for 15 
minutes. CDNA was stored at -20°C until amplification by RT-PCR.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Rat osteoblast derived cDNA was amplified by RT-PCR in 25 pi reactions containing 
~ 0.5 pg cDNA, 0.2 mM dNTP (10 mM stock), 1.5 mM MgCb, 0.2 pM of both sense 
and antisense primer, 1 U Taq DNA polymerase in thermophilic DNA polymerase lOx 
Buffer. PCR was performed according to manufacturers’ instructions, with cycles of 
denaturation at 95°C for 30 seconds, annealing for 30 seconds (see Table 2 for 
annealing temperatures), extension at 72°C for 45 seconds and reaction termination by 
72°C for 5 minutes. For analysis, PCR products were loaded onto a 1% agarose gel 
containing 0.3 pg/ml ethidium bromide. Gels were run at 80 mA for 30 minutes and 
the DNA position visualised by exposure to UV light. Product size was determined by 
comparison to a DNA ladder run concurrently. To account for differences in original 
cell number and cDNA quality all samples were normalised with P actin prior to 
further reactions. The expression of P2 X2 , P2Xs, P2 X7 , P2Yi, P2 Y2 , P2 Y4  and P2Y6 
receptors was investigated in osteoblasts cultured for 6 , 8 , 11, 13 and 15 days. 
Expression of the bone matrix protein, osteocalcin (OCN), was employed as a marker 
of differentiation. All reactions were carried out in triplicate using cDNAs derived 
from three different osteoblast cultures. Primer sequences and annealing temperatures 
are shown in Table 2. The identity of PCR products generated by these primers has 
previously been confirmed by sequencing (Bailey et al, 2000; Bailey et al, 2001; 
Shibuya et al, 1999)
Immunofluorescence
Rat osteoblastic cells were seeded onto sterile 1 cm discs, cut from Melinex clear 
polyester films (Du Pont, Dumfries UK), in 24-well trays at 5 x 104  cells/disc and
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cultured in supplemented DMEM for 4-18 days. Every three days discs were removed 
(n = 5) and fixed with 4% paraformaldehyde in 0.1 M phosphate buffer for 20 minutes 
at room temperature, washed 3 x 5  minutes with PBS and stored at 4°C in PBS- 
methiolate (0.05%) until staining. Each disc was incubated with a blocking solution 
of 10% normal horse serum (NHS) in PBS-methiolate containing 0.1% Triton x 100 
for 1 hour. Primary antibodies raised in rabbit were diluted in 10% NHS in PBS- 
methiolate at a ratio of 1:200 (P2X receptors) or 1:100 (P2Y receptors). Discs were 
incubated overnight in the primary antibody solution with gentle agitation; negative 
controls were incubated overnight in 10% NHS in PBS-methiolate, containing no 
primary antibody. Following removal of the primary antibody solution, cells were 
subjected to three further 5 minute washes with PBS before incubation for 1 hour with 
the donkey anti-rabbit Cy3-labelled secondary antibody solution (1:400) and a DAPI 
counter stain (1:3500), diluted in PBS with 1% NHS and 0.05% methiolate. After 
three further 5 minute PBS washes discs were mounted onto microscope slides using 
Citifluor AF2 solution and either stored at 4°C or viewed under a fluorescence 
microscope (Cy3 absorbance and emission at 550 nm and 570 nm, respectively). All 
images were acquired using identical camera settings to allow comparison of staining 
intensity.
Quantification o f bone nodule formation
Osteoblast cultures were examined daily using an Olympus IMT-2 inverted 
microscope with phase contrast optics (Olympus Optical Company Ltd, London, UK) 
and after 7 and 10 days plates were stopped to indicate the progression of nodule 
formation. After 15-24 days the experiment was terminated and cell layers were 
washed with PBS, fixed with 2.5% glutaraldehyde for 5 minutes, washed again with 
PBS and following three further washes with 70% ethanol, plates were left to air dry. 
Mineralised bone nodules were visualised by staining with alizarin red (1% solution 
w/v in water) for 5 minutes, rinsed with 50% ethanol to remove excess stain, then air- 
dried. The plates were imaged at 800 dpi using a high-resolution flat-bed scanner 
(Epson Perfection Photo 3200). Using ‘Adobe Photoshop’ (version 5, Adobe Systems 
Inc.) images of individual wells were first changed to greyscale before conversion to 
binary images using Scion Image software (Scion Corporation; 
http://www. scioncorp.comV These images were then subjected to automated analysis,
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using constant ‘threshold’ and ‘minimum particle’ levels, to determine the number and 
plan surface area of mineralised bone nodules.
All images of osteoblast monolayers were taken using a Leica digital camera, 
mounted on an Olympus IMT-2 inverted microscope with phase contrast optics.
Reagents
All chemicals were purchased from Sigma-Aldrich (Dorset, UK) unless otherwise 
mentioned. Fluo-4 AM was obtained from Molecular Probes Inc (Invitrogen, Paisley 
UK). Reverse Transcriptase, Taq DNA polymerase and other molecular biology 
reagents were purchased from Promega UK (Southampton, UK) and all primers from 
MWG Biotech (Ebersburg, Germany). P2Y primary antibodies were obtained from 
Alomone (Jerusalem, Israel), P2X antibodies from Roche Bioscience (Palo Alto, CA, 
USA), donkey anti-rabbit Cy3 labelled secondary antibodies from Jackson 
Immunoresearch (Philadelphia, USA) and Citifluor AF2 solution from Citifluor 
(London, UK).
Statistical analysis
Statistical comparisons were made by one-way analysis of variance (ANOVA) and 
adjusted using the Bonferroni method. Representative data are presented as means ± 
SEM for five to ten replicates. Results are representative for experiments that were 
each repeated at least three times.
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Name Sequence (5’-3’)
Annealing 
temperature °C
Product 
size (bp)
P2X2 S -  gaa tea gag tgc aac ccc aa 
AS -  tea cag gcc ate tac ttg ag
58.5 357
P2X5 S -  gcc gaa age ttc acc tcc ata a 
AS -  tat cac ate aaa geg gat gcc cgt agg
58.5 418
P2Xr S -  gtg cca ttc tga cca ggg ttg tat aaa 
AS -  cca cct ctg taa agt tct etc cga tt
58.5 354
P2Yi S -  acg tea gat gag tac ctg eg 
AS -  ccc tgt cgt tga aat cac ac
57.4 289
P2YZ S -  ctg gtc ege ttt gcc cga gat g 
AS -  tat cct gag tcc ctg cca aat gag a
58.5 311
P2Y4 S -  tgt tcc acc tgg cat tgt cag 
AS -  aaa gat tgg gca cga ggc a
58.5 294
P2Y6 S -  tgc ttg ggt ggt atg tgg agt c 
AS -  tgg aaa ggc agg aag ctg ata ac
60.0 331
p actin S -  gtt ege cat gga tga cga t 
AS -  tct ggg tea tct ttt cac gg
53.0 332
OCN S -  gca gac acc atg agg acc ct 
AS -  gca get gtg ccg tcc ata c
59.8 418
Table 2. Primer sequences and annealing temperatures used in Chapter 2 RT-PCR 
reactions
P2X primers taken from sequences published by Shibuya et al, 1999, P2Yi, P2Y2, P2Y4 
primers taken from Bailey et al, 2000 and P2Y6 primers taken from Bailey et al, 2001. 
Previous sequencing of PCR products ensured amplification of the correct gene, p actin and 
osteocalcin (OCN) primers were designed in our laboratory.
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RESULTS
Nucleotide-induced increases in intracellular Ca2+ in primary rat osteoblasts
Concentrations of ATP, UTP and ADP over the range 0.002 pM to 1000 pM were 
tested in osteoblasts cultured for 8  days. All three agonists triggered increases in 
intracellular Ca2+, measured using the intracellular fluorophore, Fluo-4 AM; responses 
typically peaked 10 seconds after addition, and decayed back to baseline within 2-3 
minutes. Cellular responses were illustrated by expressing baseline fluorescence prior 
to agonist addition as 1 0 0 % and all subsequent readings as a percentage of this value 
(Figure 2.1 A). Immediately after agonist addition, a small artefactual decrease in 
fluorescence was normally observed.
Of the nucleotide agonists tested, ATP was the most potent; eliciting increased
>> 1
intracellular Ca from concentrations of 0.2 pM, with peak responses occurring at ~ 
20 pM (Figure 2.IB). A decrease in response occurred with concentrations 
exceeding 100 pM. UTP was somewhat less potent than ATP with a maximal 
response between 20-100 pM, although this varied between cultures. Comparatively 
speaking ADP was clearly the least potent of the three with concentrations of 2-200 
pM eliciting significantly smaller responses.
At day 8  of culture, other P2 agonists, including (in decreasing order of potency) 
ATPyS, UDP, 2-MeSATP, Bz-ATP and a,p-meATP also increased intracellular Ca2+ 
in osteoblasts; however, with the exception of ATPyS none were as potent as ATP. 
UDP is an agonist at P2 Y4  and P2Y6 receptors, Bz-ATP acts at P2 X7  and a,p-meATP 
can activate P2 X5 and P2 X3 receptors, indicating these receptor subtypes may be 
present on rat osteoblasts. In contrast, no intracellular response was observed to the 
PI agonist’s adenosine and AMP (Figure 2.IC).
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Figure 2.1. Purinergic agonists stimulate increased intracellular Ca?* in rat osteoblasts.
(A) Cellular responses to agonist stimulation were very transient, returning to basal within ~30 
seconds. The arrow represents agonist addition at t = 0 and the slight drop in fluorescence 
observed is a common artefact seen with this technique. (B) ATP, UTP and ADP all caused 
an increase in intracellular Ca2+ (n = 10). Responses are expressed as percentage increase in 
fluorescence following agonist addition. (C) Other P2 agonists elicited an increase in 
intracellular Ca2+ (n = 10), but with the exception of ATPyS, none were as potent as ATP. 
Adenosine and AMP, which are inactive at P2 receptors, had no effect on intracellular Ca2+ (*** 
= p<0.001, ** = p<0.01). Each FLIPR experiment was performed at least three times.
Bisphosphonates do not induce increased intracellular Ca2+ in osteoblasts
The bisphosphonates are a class of drugs clinically used to treat conditions 
characterised by bone loss, such as osteoporosis. Through direct actions on 
osteoclasts, they inhibit bone resorption, although the exact mechanisms involved 
depend on the class of bisphosphonate. First generation bisphosphonates do not 
contain any nitrogen atoms and function via cellular uptake, followed by enzymatic 
conversion to a non-hydrolysable ATP analogue, accumulation of which is toxic to the 
cell. Second or third generation bisphosphonates usually contain nitrogen in at least 
one of their side chains. They disrupt cholesterol synthesis by inhibiting famesyl 
diphosphate synthase, the enzyme that converts mevalonate to cholesterol (Green, 
2004). Several bisphosphonates share structural similarities with nucleotides and so 
the first and third generation bisphosphonates, Clodronate and Zolendronate were 
tested (1-500 pM) for effects on intracellular Ca2+ in osteoblasts, using the FLIPR. 
Even at the highest concentration, neither drug elicited an increase in intracellular Ca2+ 
in primary rat osteoblasts (F igure  2.2).
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Figure 2.2. Bisphosphonates do not increase intraceilular Ca2* in rat osteoblasts.
The bisphosphonates Zolendronate and Clodronate (1-500 pM) did not cause an increase in 
intracellular Ca2+ in rat osteoblasts (n = 5).
70
Intracellular Ca*+ responses o f osteoblasts to nucleotides: dependence on time in 
culture
Primary rat osteoblasts cultured for 4, 8 or 10 days were challenged with ATP, UTP 
and ADP over the concentration range 2-200 pM. Intracellular Ca2+ responses 
increased strikingly with time in culture; all concentrations of ATP induced 
significantly higher responses at 10 days compared to 4 days (up to 6-fold), whilst at 8 
days compared to 4 days, > 20 pM ATP caused significantly increased responses (up 
to 3-fold) (Figure 2.3A). Following a similar trend, 2-200 pM UTP also induced 
significantly enhanced responses at both day 8 and day 10 compared to day 4 (Figure 
2.3B). ADP induced less pronounced alterations in response with only 100-200 pM 
causing significantly increased Ca 2+ release at 8 and 10 days (Figure 2.3C).
To determine whether increased cell number accounted for these results, cell 
proliferation assays were performed in parallel with the FLIPR experiments (Figure 
2.3D). Between 4 and 10 days, cell number only increased by 2.4-fold whilst 
intracellular Ca2+ responses increased up to 6-fold, 3.6-fold and ~ 2-fold following 
treatment with ATP, UTP and ADP respectively. These data indicate cell proliferation 
is a major cause of the enhanced responses to ADP, but cannot entirely explain the 
increased cellular responses to ATP and UTP.
Experimentation on osteoblasts cultured for greater than 10 days was not possible 
due to a marked reduction in medium pH (pH 7.10 instead of 7.40), caused by the 
small volume of fluid bathing the cells, and monolayer peeling. Both of these factors 
detrimentally affect osteoblast activity and functional responses, leading to inaccurate 
readings from the FLIPR
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Figure 2.3. Osteoblast responses to ATP, UTP and ADP change with time in culture.
(A) 2-200 ATP caused increased intracellular responses at day 10 compared to day 4 (up 
to 6-fold). Stimulation with 20-200 pM ATP induced larger intracellular responses at day 8 of 
culture compared to day 4 (up to 3-fold) (n = 10). (B) UTP at 2-200 pM caused significantly 
higher increases in intracellular Ca2* at both 8 and 10 days compared to 4 days (up to 3.6-fold) 
(n = 10). (C) Treatment with 100-200 pM ADP induced significantly increased intracellular 
responses at 8 and 10 days, compared to 4 days (n = 10). (D) Cell number increased 2.4 fold 
between 4 and 10 days of culture (n = 10) (*=p<0.05, **=p<0.01, ***=p<0.001). All FLIPR time 
course experiments were performed in triplicate.
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Expression o f P2 receptor mRNA in osteoblasts
Primary rat osteoblasts were cultured for up to 15 days in 6-well plates, and total 
cellular RNA was extracted at day 6, 8, 11, 13 and 15 to enable the levels of selected 
mRNAs to be determined by PCR amplification. For each of the seven P2 receptors 
investigated, mRNA was detected and representative results are shown in Figure 2.4. 
In all experiments, osteoblast monolayers formed mineralised nodules indicating the 
presence of mature functional osteoblasts
RNA levels in individual samples were normalised using the housekeeping gene P 
actin. OCN mRNA expression, used as a marker of osteoblast differentiation, was 
barely detectable at 6 days but increased to high levels at 11-15 days indicating the 
presence of mature bone forming osteoblasts. The individual P2 receptors showed 
considerable variation in mRNA levels throughout the culture period confirming the 
idea of differentiation dependent receptor expression (Figure 2.4). Expression of 
P2X2 and P2Xs receptor mRNAs peaked at 8 days but then declined to undetectable or 
near-undetectable levels by 15 days. In contrast, P2 X7  receptor mRNA was detected at 
all time points between 6 and 15 days. Expression of P2Yi receptor mRNA remained 
relatively constant level until 15 days, when levels appeared to decline. In contrast, 
P2 Y2 receptor mRNA showed a striking, progressive upregulation with time in culture 
suggesting this receptor plays an important role in mature osteoblasts. P2 Y4  and P2Y6 
receptor mRNAs were most highly expressed between 8 and 13 days of culture.
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F ig u re  2 .4. Expression of P2 receptor mRNA in primary rat osteoblasts.
Total RNA was extracted after 6, 8, 11, 13 and 15 days of culture. Samples were normalised 
with mRNA for (3 actin, and osteocalcin (OCN) mRNA was assessed as a marker of osteoblast 
differentiation. Marked differences in the expression of some P2 receptor mRNAs were 
evident over time. P2X2 and P2X5 receptor mRNAs were expressed in early cultures, whereas 
expression of mRNA for the UTP-selective P2Y2 receptor increased strongly in later cultures. 
Expression of P2X7 and P2Yi receptor mRNA remained relatively constant until 15 days when 
levels decreased. P2Y4 and P2Y6 receptor mRNAs tended to be greatest between days 8 and 
13. Each PCR reaction was carried out in triplicate using cDNA from three separate 
experiments. The product sizes (in base pairs) for each gene amplified are: P2X2 (357), P2X5 
(418), P2X7 (354), P2Y, (289), P2Y2 (311), P2Y4 (294), P2Y6 (331), p actin (332) and OCN 
(418).
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Detection o f P2 receptor subtypes in osteoblasts by immunofluorescence
Specific primary antibodies directed against individual P2 receptors and a Cy3 labelled 
secondary antibody enabled the determination of receptor protein by fluorescence 
microscopy. The development and specificity of the P2X polyclonal antibodies has 
been reported previously (Oglesby et al, 1999; Xiang et al, 1998). The P2Y antibodies 
are commercially available and are directed against specific epitopes located in the 3rd 
intracellular loop between TM5 and TM6 (P2Yi, P2 Y2 ) or in the C-terminus (P2 Y4 , 
P2Y6); they have been employed previously by Ryten et al (2004a) and Cheung et al 
(2003).
In all cases, cell size appears to decrease with culture progression; this reflects the 
compaction of osteoblasts at the later time points. In all cases, no immunostaining was 
observed in the negative controls (no primary antibody). Protein and mRNA 
expression generally followed similar trends, however in some cases protein 
expression was detected when mRNA was absent. Marked changes in immunostaining 
for P2 receptors with time in culture were observed; representative images of are 
shown in Figure 2.5 and 2.6, for P2X and P2Y receptors, respectively. Staining for 
individual receptors was not always uniform across cell layers, reflecting variations in 
differentiation and proliferation.
In agreement with the RT-PCR results, both P2X2 (Figure 2.5A & 2.5B) and P2X5 
(Figure 2.5C & 2.5D) receptor staining was strongest at earlier time points (4-8 days), 
and was increasingly confined to sub-populations of cells as cultures progressed. This 
restricted expression was particularly noticeable in the cells stained for P2X5 receptors 
and may well reflect uneven differentiation across the cell monolayer resulting in 
regions of less differentiated still proliferating osteoblasts. For both P2 X2  and P2X5 
receptors, mRNA and protein expression demonstrated slight variance, with receptor 
protein being detected at later time points when mRNA was absent. P2 X7  receptor 
protein expression appeared widely distributed throughout the monolayer and 
remained at a relatively constant, albeit low level throughout the culture period 
(Figure 2.5E & 2.5F). Similar to the other P2X receptors, P2 X7 receptor protein 
expression appeared to persist for longer than the mRNA expression.
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In accordance with the RT-PCR data, P2Yi receptor protein expression remained 
relatively widespread and constant throughout the culture period (Figure 2.6A & 
2.6B) RT-PCR demonstrated a large increase in P2 Y2 receptor mRNA expression 
between 6 and 15 days of culture and immunofluorescence confirmed protein 
expression also increased strongly with time (Figure 2.6C & 2.6D). Both P2 Y4  and 
P2Y6 receptors had only previously been identified on human osteoblast-like cell lines 
(Maier et al, 1997), however these data provide clear evidence for the widespread 
expression of receptor protein on rat osteoblasts. Expression of both P2Y4 (Figure 
2.6E & 2.6F) and P2Y6 (Figure 2.7G & 2.6H) receptors tended to be greatest at 
intermediate time points.
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EP2X7
F ig u re  2.5. Expression of P2X receptors in rat osteoblasts
Changes in P2X receptor expression over time in culture were studied by immunofluorescence 
using specific primary polyclonal antibodies, Cy3-labelled anti-rabbit secondary antibody (red) 
and DAPI nuclear stain (blue). Photomicroscopy values were the same for each image. Each 
picture is a representative of the staining that occurred in three separate experiments. Image 
(A) illustrates the strong P2X2 receptor expression at 8 days of culture, whilst (B) 
demonstrates the lack of P2X2 receptor expression at 14 days. Image (C) represents the high 
level of P2X5 receptor expression at early stages of culture; in contrast, (D) illustrates the very 
low level of expression in mature osteoblasts. Images (E) and (F) illustrate the constant, low 
level of P2X7 receptor expression seen in these cultures. In all images the scale bar = 10 pm.
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F ig u re  2.6. Expression of P2Y receptors in rat osteoblasts
Changes in P2Y receptor expression over time in culture were studied by immunofluorescence 
using specific primary polyclonal antibodies, Cy3-labelled anti-rabbit secondary antibody (red) 
and DAPI nuclear stain (blue). Photomicroscopy values were the same for each image. Each 
picture is a representative of the staining that occurred in three separate experiments. Images 
(A) and (B) represent the relatively constant P2Yi receptor expression in rat osteoblasts. 
P2Y2 receptor expression increased dramatically from (C) day 4 to (D) day 14. Image (E) 
shows P2Y4 receptor expression at day 8 and image (F) how it increased at 11 days. Image
(G) illustrates the peak expression of P2Y6 receptors at intermediate time points, whilst image
(H) illustrates the lower expression at day 14. In all images scale bar = 10 pm.
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Reactive blue 2 does not prevent UTP-mediated inhibition o f bone nodule formation
ATP and UTP both potently activate rat P2 Y2 and P2 Y4  receptors. The widespread 
expression of the P2 Y4 receptor observed here questions the findings of Hoebertz et al 
(2001), which implicated the P2 Y2  receptor subtype in the inhibition of bone formation 
by nucleotides. The purinergic receptor antagonist, reactive blue 2, inhibits P2 Y4  
receptors but is inactive at P2Y2 receptors; in an attempt to clarify the P2 receptor 
subtype mediating the inhibition of bone formation, this agent was tested in vitro at a 
range of concentrations (0.1-100 pM). UTP-treated osteoblasts demonstrated an 
approximate 85% decrease in bone formation and at 0.1-10 pM, reactive blue 2 failed 
to prevent this inhibitory effect (Figure 2.7A). Reactive blue 2 alone at 0.1-10 pM did 
not adversely affect osteoblast function (Figure 2.7B). Osteoblasts cultured with 100 
pM reactive blue 2 (with or without UTP) failed to form bone nodules, suggesting that 
at high concentrations this agent is toxic. .
Suramin inhibits bone nodule formation in rat osteoblasts
Currently there are no antagonists specific for the P2Y2 receptor subtype. Suramin is a 
non-specific inhibitor acting at multiple P2 receptor subtypes including the P2 Y2 
receptor, however it is inactive at the P2 Y4  receptor. Osteoblasts were treated with 
0.1-100 pM suramin (with or without 10 pM ATP/UTP) and cultured for up to 21 
days. Consistently, treatment with suramin impaired proliferation and completely 
prevented bone nodule formation, indicating that prolonged exposure to this agent was 
toxic to osteoblasts. Thus, this inhibitor could not be employed to further clarify the 
P2 receptor subtype involved in mediating the anti-osteogenic effects of nucleotides on 
osteoblast function.
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Figure 2.7. Reactive blue 2 does not prevent the inhibitory actions of UTP
(A) Treatment with UTP (10 \iM) inhibited bone nodule formation by rat osteoblasts by up to 
85%; reactive blue 2 at 0.1-10 pM did not prevent the anti-osteogenic effect of UTP in vitro (n 
= 6). (B) Application of reactive blue 2 (0.1-10 pM) alone did not effect bone nodule formation 
by rat osteoblasts in vitro (n = 6). These results are representative of experiments performed at 
least three times.
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Late-acting inhibition o f bone nodule formation by nucleotides
The images in Figure 2.8 are low power scans of osteoblast monolayers cultured for 
17 days without (Figure 2.8A) and with (Figure 2.8B) 10 (iM ATP. These pictures 
were acquired using a high-resolution scanner (Epson Perfection Photo 3200) and 
illustrate how long-term culture in the presence of extracellular nucleotides exerts a 
striking inhibitory effect on mineralised nodule formation in vitro.
Rat calvarial osteoblasts were cultured for 17 days and from about day 10 onwards, 
mineralised bone nodules with characteristic ‘trabecular’ morphology began to form. 
ATP or UTP (10 pM) was added to osteoblast cultures from day 1, 7, 10 or 14 and for 
1-7 and 1-10 days. Incubation with ATP or UTP from day 1, 7 or 10 caused a striking 
18-fold reduction in mineralised nodule formation (Figure 2.9A & 2.9B). In contrast, 
nucleotide addition for the first 7 days of culture had no effect on mineralised nodule 
formation at day 17, however, application for the first 10 days elicited a small ~ 20% 
decrease (Figure 2.9C & 2.9D). When ATP was present from 14-17 days only, 
further bone nodule formation by osteoblasts was prevented (although bone already 
formed was unaffected) (Figure 2.9E).
The observation that P2 receptor expression changes with osteoblast 
differentiation, combined with these functional observations led to a more detailed 
investigation regarding the inhibitory effects of nucleotides on bone formation (see 
Chapter 3).
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F ig u re  2.8. Culture with 10 /jM  ATP inhibits bone nodule formation by rat osteoblasts.
These are low power images of osteoblast monolayers cultured for 17 days (A) without or (B) 
with 10 pM ATP. Unlike the control cultures, ATP-treated cultures displayed an almost 
complete inhibition of bone nodule formation in vitro (n = 6). In both images the scale bar = 
0.5 cm.
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Figure 2.9. Late-acting inhibition of bone 
nodule formation by ATP or UTP
(A & B) Addition of ATP or UTP from day 7 or 
10 inhibited nodule formation to the same 
extent (up to 18-fold) as from day 1. (C & D) 
Nucleotide addition for 1-7 days did not impair 
nodule formation, whilst addition for 1-10 days 
caused a slight decrease (~ 20%). (E) ATP 
addition to mature bone forming osteoblasts 
inhibited further nodule formation, however, 
preformed bone was unaffected (***=p<0.001, 
**=p<0.01, *=p<0.05). All experiments were 
performed in triplicate (/? = 6).
83
DISCUSSION
Purinergic signalling appears to have a major role controlling cellular function in a 
wide array of tissues and cells (Bumstock & Knight, 2004). The work shown here 
demonstrates that functional responses of normal osteoblasts to the nucleotides ATP 
and UTP increase during differentiation with time in culture; these changes were 
notably accompanied by an increase in the expression of the P2Y receptors particularly 
the UTP-sensitive P2 Y2 receptor and the P2 Y4  and P2Y6 receptors.
The fluorescence imaging plate reader (FLIPR) system enabled efficient, high 
throughput, quantitative screening of intracellular Ca2+ responses of cell populations to 
agonists. Previous studies have used the FLIPR to demonstrate the presence of 
functional P2 receptors in epithelial cells (Coutinho-Silva et al, 2005); however, this 
study investigated the acute actions of ATP and other nucleotides on primary 
osteoblasts maintained in long-term cultures. Several nucleotide agonists elicited rapid 
increases in intracellular Ca2+; the most potent of these being ATP, the “universal 
agonist” at P2 receptor subtypes, followed by UTP, which is selective for P2 Y2  and 
P2 Y4  receptors. Peak intracellular Ca2+ responses to ATP and UTP occurred in the 
range 2-200 pM, consistent with the blockade of bone nodule formation caused by the 
nucleotides at the same concentrations (Chapter 3; Hoebertz et al, 2002). Smaller 
intracellular Ca2+ responses were also evoked by several other nucleotide agonists, 
consistent with the expression of functional P2 X2 , P2Y4, P2Y6, P2Yi, P2X5 and P2 X7  
receptors on primary osteoblasts [for reviews of P2 receptor pharmacology, see 
Hoebertz et al, 2003; Bumstock & Knight, 2004]. ATPyS and 2-MeATP are also more 
universal purinergic receptor agonists; therefore, the increased intracellular Ca2+ levels 
observed probably involve the activation of several different P2 receptors, although 
from these data alone it is impossible to define which. Adenosine, AMP and the 
bisphosphonates, Zolendronate and Clodronate, were without effect, suggesting that 
these agents do not interact with cell surface receptors to cause increased intracellular 
Ca2+. This study did not determine activation of Ca2+-independent signalling pathways 
(such as cAMP) and would necessitate further investigation.
Several cell types including thymocytes (Koshiba et al, 1997), myeloid cells 
(Adrian et al, 2000) and leukocytes (Clifford et al, 1997) express purinergic receptors
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in a differentiation dependant manner; a trend suggested but not investigated in 
osteoblasts (Dixon et al, 1997). In the present study, sharp augmentations (up to 6 - 
fold) in the intracellular Ca2+ responses of osteoblasts to ATP and UTP occurred as 
cultures progressed towards bone nodule formation; these increases could not be 
accounted for by the modest increases (~ 2-fold) in cell number observed. These 
findings suggested changes in the expression of P2 receptors accompanied osteoblast 
differentiation. Subsequent RT-PCR and immunocytochemical analysis revealed a 
strong differentiation dependence of P2 receptor expression in long-term osteoblast 
cultures, characterised by a shift from early P2X expression to P2Y expression at later 
stages. Most notable was the striking increase in levels of the P2Y2  subtype during the 
second week of culture, coinciding with the onset of bone nodule formation. In some 
cases receptor protein expression appeared to persist somewhat longer than that of the 
respective mRNA; this could be due to heterogeneity between cultures, because the 
protein signal is sustained after degradation of the mRNA and/or because the mRNA 
level was too low for the RT-PCR to detect. Given that both RT-PCR and 
immunofluorescence are only qualitative, further work could involve quantitative 
techniques (such as western blotting or real time PCR) to confirm the findings 
presented here.
P2X2 receptor expression appeared strongest in proliferating osteoblasts. 
Expression of P2X2 receptor mRNA and protein decreased markedly with time in 
culture, with no receptor mRNA and only low levels of P2X2 receptor protein being 
detected beyond 11 days. The physiological role, if any, of P2X2 receptors in bone cell 
function requires further elucidation, although it has been implicated in mediating the 
activation of osteoclastic resorption by acid and ATP (Morrison et al, 1998). Given 
that this receptor displays the distinct property of potentiation at low pH (6 .9-7.0), a 
role in the control of osteoblast function and differentiation during localised acidosis is 
possible. Activation of other P2 receptors negatively effects bone cell function by 
stimulating osteoclast formation and activity (Hoebertz et al, 2001) and inhibiting bone 
formation by osteoblasts (Hoebertz et al, 2002). P2X2 receptor knockout mice display 
age related increases in bone mass suggesting this purinoreceptor might also exert 
negative effects on bone cell function (Chapter 5).
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The P2 X5 receptor is associated with proliferation in many cell types. Moreover, 
ATP-induced activation of P2Xs receptors stimulates the proliferation of osteoblast­
like cells in a Ca2+ independent, MAP-kinase dependent manner (Nakamura et al, 
2000). In accordance with a proliferative role, P2 X5 receptor mRNA and protein 
expression was maximal during early stages of culture, a period characterised by 
pronounced proliferation and low OCN expression. With increasing culture time and 
decreasing proliferation, P2 X5 receptor expression decreased to near undetectable, 
whereas mRNA for OCN increased massively. Low-level, localised P2 X5 receptor 
staining was observed in the mature cultures (11-14 days), this likely reflects the 
uneven rates of cellular proliferation and differentiation across the osteoblast 
monolayer.
The P2 X7  receptor is widely expressed on immune cells including macrophages, 
lymphocytes and osteoclasts from several species (Modderman et al, 1994; Hoebertz et 
al, 2000; Gartland et al, 2003b). These data provide confirmatory evidence for the 
constant expression of the P2 X7  receptor in primary rat osteoblasts, albeit at relatively 
low levels (Gartland et al, 2001). The function of this receptor in bone remains 
enigmatic. At high concentrations of extracellular ATP, the P2 X7  receptor mediates 
the formation of cytolytic pores (Murgia et al, 1992; Di Virgilio, 1995). Activation of 
osteoclast P2 X7  receptors has been reported to facilitate intercellular calcium 
signalling between osteoblasts and osteoclasts (Jorgensen et al, 2002), whilst blockade 
of this receptor inhibits osteoclast formation (Gartland et al, 2003a; Korcok et al, 
2004). Deletion of P2 X7 receptors in mice leads to deficient periosteal bone formation 
together with excessive trabecular bone resorption (Ke et al, 2003). Despite the clear 
link between the P2 X7  receptor and ATP-mediated cell death, the low prevalence of 
apoptosis in osteoblasts suggests that this is an unlikely to be the sole function for 
P2 X7  receptors in bone cell metabolism (Jilka, 1998; Bumstock, 2002). As stimulation 
of P2 X7  receptors mediates the release of cytokines from non-skeletal cells, including 
IL-lp from macrophages (Ferrari et al, 1997; Solini et al, 1999), an alternative 
possibility is that pores induced by transient activation of P2 X7  receptors could play a 
role in the controlled release of certain cytoplasmic components from osteoblasts. 
Further work is required to determine exactly how the P2 X7  receptor modulates 
osteoblast activity and so influences skeletal remodelling.
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In agreement with earlier findings, this study found strong evidence for the 
expression of the P2Yi receptor on osteoblasts, together with significant intracellular 
Ca2+ responses to ADP (the ligand selective for this receptor as well as for the P2 Yi2 
and P2Yo receptors), particularly at higher concentrations (Maier et al, 1997; Bowler 
et al, 1999; Hoebertz et al, 2000; Hoebertz et al, 2003). However, ADP does not
• 74-inhibit bone formation in vitro, suggesting that stimulation of intracellular Ca does 
not automatically lead to decreased bone formation. Data from this study 
demonstrated relatively constant, widespread expression of P2Yi receptors on 
osteoblasts. Earlier work implicated this receptor in the potentiation of PTH receptor 
mediated Ca2+ signalling (Buckley et al, 2001; Bowler et al, 2001); this observation 
combined with the constant expression demonstrated here, suggests a general role for 
the P2Yi receptor in modulating the actions of locally released nucleotides on 
osteoblast function.
The P2Y6 receptor had only previously been identified on transformed human 
osteoblast-like cells (Maier et al, 1997). These data clearly show that the P2Y6 
receptor is expressed by normal rat osteoblasts, and that UDP, the agonist selective for 
this receptor evokes significant intracellular Ca2 responses in osteoblasts. Receptor 
expression appeared to gradually increase, with high levels between 8-13 days, before 
decreasing slightly at later stages. Currently little is known of the role the P2Y6 
receptor might play, if any, in osteoblast metabolism. A recent report has implicated 
P2 Y6 receptors in osteoclast survival, whether the receptor has a similar function in 
osteoblasts is unknown (Korcok et al, 2005).
In vitro, ATP and UTP significantly inhibit bone nodule formation by rat 
osteoblasts, whilst ADP and UDP are inactive (Chapter 3); this ligand specificity 
discounts any participation of the P2Yi and P2Y6 receptors but suggests the 
involvement of either P2 Y2 or P2Y4  receptor subtypes. As earlier in situ hybridisation 
found no evidence for P2Y4  receptor mRNA expression on rat osteoblasts the P2 Y2 
receptor was hypothesized to mediate these functional effects (Hoebertz et al, 2000; 
Hoebertz et al, 2002). In this study, RT-PCR and immunofluorescence analysis 
revealed a striking increase in the levels of P2 Y2 receptor mRNA and protein 
expression during the second week of culture, coinciding with the onset of nodule 
formation. Throughout the culture period, cells exhibited widespread P2Y2 receptor
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staining; at 11 and 14 days, the staining appeared notably more intense, suggesting that 
individual cells expressed increased amounts of receptor protein.
Previously, the P2 Y4  receptor had only been identified in transformed osteoblast­
like cell lines (Maier et al, 1997) and not in normal osteoblasts (Hoebertz et al, 2000). 
This study demonstrates clear expression of P2 Y4  receptor mRNA and protein in rat 
osteoblasts. Several reasons potentially explain why the investigation by Hoebertz and 
colleagues (2000) failed to identify this receptor on rat osteoblasts. Firstly, the 
previous study only examined cells cultured for 2-4 days; given the low levels of P2Y4  
receptor protein observed here at 4 days, expression of the receptor may have been 
undetectable before this point. Secondly, inherent differences in the sensitivities of the 
techniques employed may have contributed to the failure to identify P2 Y4  receptor 
expression. In rat osteoblasts, expression of the P2 Y4  receptor appeared differentiation 
dependent with the highest levels occurring at intermediate time points (~ 1 1  days), 
although in mature cultures, mRNA expression declined whilst protein persisted, albeit 
at a low level.
ATP and UTP equipotently activate both the rat P2Y2 and P2Y4 receptors, whilst 
UTP is more potent than ATP at human P2 Y4  receptors. The finding that rat 
osteoblasts express the P2 Y4  receptor raises the question of whether this receptor 
mediates the inhibitory effects of nucleotides on bone formation. In other cell types 
such as airway epithelial cells, the predominant P2Y2 receptor has been shown to mask 
the effects of P2 Y4  and P2Y6 receptors and this my have occurred here (Lazarowski et 
al, 1997). In an attempt to address this issue, the P2 receptor antagonists reactive blue 
2 and suramin were tested for potential effects. Reactive blue 2 consistently failed to 
have any effect on the inhibition of bone nodule formation caused by UTP suggesting 
no involvement of the P2 Y4  receptor. Unfortunately, inhibitor studies using 0.1-100 
juM suramin provided no further clarification because at > 1 j iM  this agent was toxic to 
osteoblasts. An effect most likely due to the non-specific nature of suramin, as in 
addition to its role as a P2 receptor antagonist, suramin inhibits cell surface binding of 
many growth factors and is a potent anti-proliferative agent. Thus, these data suggest 
that the P2Y2 receptor is the chief mediator of the anti-osteogenic action of 
extracellular nucleotides, however, until a more specific P2Y2 receptor antagonist
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becomes available the involvement of P2 Y4  receptors cannot be ruled out. The role of 
the P2Y4  receptor in bone remodelling now requires further investigation.
The large increases in intracellular Ca2+ responses to UTP and ATP in late stage 
osteoblast cultures, together with increased P2 Y2 receptor expression suggest these 
nucleotides may act to effectively switch off bone formation in mature cells. To test 
this hypothesis, osteoblasts were cultured with ATP or UTP for different periods of 
time and the effects on nodule formation quantified. Incubation with ATP and UTP 
from either 7 or 10 days to the culture end inhibited mineralised nodule formation to 
the same extent as culture from day 1. Conversely, treatment with nucleotide from 1-7 
days failed to inhibit nodule formation whereas treatment from 1 - 1 0  days caused a 
slight decrease. During the first 7 days of culture, P2 Y2 expression is low and these 
data show exposure of osteoblasts to nucleotides during this period does not influence 
their ability to form mineralised nodules in the future. Moreover, treatment with ATP 
at day 14 of culture effectively switched off osteoblasts and prevented further bone 
formation, with all nodules present being formed before nucleotide addition.
Taken together these results suggest that the P2Y receptors, particularly the P2 Y2 
subtype, expressed in differentiated, functional osteoblasts, could play an important 
role in the skeleton by acting as an “off-switch” for bone formation. In view of the 
diversity of P2 receptors expressed by bone cells, it is possible that some redundancy 
of function may exist, with some inhibitory effects mediated additionally, for example 
by the P2Y4  or P2Y6 receptor subtypes. The notion that ATP, the “universal agonist” 
at P2 receptors, could play a physiological role in regulating osteoblast function is 
supported by the recent observation that it is released from primary osteoblast cultures 
in amounts that could equate with local concentrations in the high nanomolar in vivo 
(Chapter 4). Detailed analysis of the skeletal phenotypes of knockout mice deficient in 
single or multiple P2Y receptors is now required to further elucidate the roles of 
extracellular nucleotides and their receptors in bone cell function (Cressman et al, 
1999; Robaye etal, 2003).
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CHAPTER 3
EXTRACELLULAR NUCLEOTIDES INHIBIT 
BONE FORMATION BY PREVENTING 
MINERALISATION
INTRODUCTION
Bone formation or osteogenesis involves two distinct stages firstly, synthesis and 
deposition of the organic matrix and, secondly, mineralisation. The organic matrix 
consists of ~ 90% type I collagen, and 10-15% bone matrix proteins such as 
osteocalcin (OCN), osteonectin, osteopontin, matrix gla protein (MGP) and bone 
sialoprotein (BSP). Collagen is essential for osteogenesis and defects in its production, 
such as in osteogenesis imperfecta, a group of conditions arising from mutations in the 
genes encoding type I collagen, result in the formation of brittle bones. Mature 
osteoblasts contain an extensive endoplasmic reticulum and Golgi apparatus enabling 
them to synthesize, modify and export via exocytosis the proteins needed for bone 
formation. Once deposited, the collagen fibres act as a structural template for 
mineralisation.
Osteoblasts mineralise osteoid by secreting matrix vesicles from specialised 
regions of the plasma membrane (Anderson et al, 1975). The polarised release of 
matrix vesicles into selected areas of the developing bone determines the non-random 
distribution of calcification (Anderson, 1995). Matrix vesicles vary in diameter from 
1 - 1 0 0  nm and are highly enriched in phosphatases, annexins, matrix 
metalloproteinases (MMPs), phosphatidylserine, Ca2+ and orthophosphate (Pi) (Kirsch, 
2005; Balcerzak, 2003). Accumulation of mineral ions within the matrix vesicle 
characterises the initial phase of mineralisation and is mediated by various ion 
channels and transporters; for example annexins II, V and VI, which are highly 
expressed in matrix vesicles, are thought to mediate Ca2+ uptake (Kirsch & Pfaffle, 
1992; Kirsch et al, 2000). Annexin V also binds the type II and V collagen associated
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with the outer leaflet of the matrix vesicle membrane, an interaction which anchors the 
vesicle to the extracellular matrix (Kirsch & Pfaffle, 1992). The initial nucleation or 
deposition of needle-like hydroxyapatite crystals (Caio(P0 4 )(OH2 )) takes place on the 
inner surface of the matrix vesicle membrane and is regulated by phosphatases and 
annexins that control the concentration of inorganic ions. Continued addition of 
mineral ions causes the crystals to grow and upon reaching a certain length, they 
rupture the matrix vesicle membrane. Once released into the extracellular fluid, these 
hydroxyapatite crystals serve as a template for the formation of future crystals. 
Subsequent mineralisation is dependent on the external concentration of Ca2 and Pi
I
(Anderson, 2003). Bone matrix proteins can bind Ca and hydroxyapatite with high 
affinity and appear to regulate mineralisation, although the mechanisms involved 
remain unclear (Boskey, 2003; Murshed et al, 2004). The release of matrix vesicles 
from the osteoblast membrane is regulated by factors such as vitamin D3 (Bonewald et 
al, 1992). A Ca2+, Pi or vitamin D3 deficiency can cause osteomalacia, a condition 
characterised by impaired mineralisation and soft bones with an increased tendency to 
fracture.
Hydroxyapatite crystal formation and propagation depends on a constant supply of 
Pi. Inorganic pyrophosphate (PPi) potently antagonises the ability of Pi to crystallise 
with Ca2+ to form hydroxyapatite, whilst additionally suppressing crystal propagation 
(Fleisch & Neuman, 1961; Fleisch & Bisaz, 1962; Meyer, 1984). Thus, local PPi 
exclusion or degradation appears necessary for mineralisation to proceed and either an 
excess or deficit of PPi will profoundly affect crystal formation. Phosphatases, 
including alkaline phosphatase (ALP), plasma cell membrane glycoprotein-1 (also 
known as PC-1), ATPase and inorganic pyrophosphatase, hydrolyse organic 
phosphate-containing substrates to produce both Pi and PPi. Examples of the reactions 
mediated by these enzymes are as follows:
ATPase /ALP  
ATP + H20  <-* ADP + Pi + H+
Pyrophosphatase 
PPi <r> Pi + Pi
PC-1
ATP + H20  AMP + PPi + H+
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Recent work suggests that ALP and PC-1 are particularly important in the control 
of Pi and PPi levels both in vitro and in vivo (Johnson et al, 2000; Hessle et al, 2002). 
Of the four ALP isoforms (3 tissue-specific, 1 non-specific) mature osteoblasts 
express, the tissue non-specific form which, although covalently bound to the cell 
membrane via a phosphoinositol moiety, can be proteolytically cleaved to produce a 
soluble form. ALP hydrolyses a number of substrates including PPi, P- 
glycerophosphate, ATP and AMP to produce Pi (Hamade et al, 2003). Patients with 
mutations in the gene encoding tissue non-specific ALP first illustrated a direct role for 
this enzyme in mineralisation; these defects cause hypophosphatasia, a condition 
characterised by poorly mineralised cartilage and bones (Henthom & Whyte, 1992). 
Further confirming this role, ALP knockout mice also display hypophosphatasia and 
defects in bone mineralisation that worsen with age (Narisawa et al, 1997; Fedde et al, 
1999; Wennberg et al, 2000).
PC-1 belongs to the ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) 
family of enzymes, members of which hydrolyse the phosphodiesterase bond in purine 
or pyrimidine nucleoside triphosphates, such as ATP, to produce PPi (Goding et al, 
1998). This enzyme is a class II homodimeric transmembrane protein and plays a 
direct role in the inhibition of mineralisation via facilitating PPi accumulation 
(Johnson et al, 1999). Mice with a naturally occurring PC-1 truncation mutation, 
termed “tiptoe walking”, display hypermineralisation especially around the 
intervertebral discs (Okawa et al, 1998); artificially generated homozygous PC-1 
knockouts display an essentially identical phenotype to these natural mutants (Hessle 
etal, 2 0 0 2 ).
The actions of ALP and PC-1 appear antagonistic, an idea supported by study of 
knockout mouse models. ALP-null mice display a hypophosphatasia and impaired 
mineralisation because of increased PPi and reduced Pi levels (Narisawa et al, 1997; 
Fedde et al, 1999). In contrast, PC-1 knockouts exhibit a hypermineralisation because 
of decreased extracellular PPi levels (Okawa et al, 1998; Hessle et al, 2002). 
However, if both ALP and PC-1 are inactivated a normal skeleton develops (Johnson 
et al, 2000; Hessle et al, 2002). Several factors, including vitamin D3 (van Leeuwen et 
al, 2001), PTH, FGF, TGF{3 (Oyajobi et al, 1994a; Oyajobi et al, 1994b; Mansukhani
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et al, 2000) and acidosis (Brandao-Burch et al, 2005), modulate the expression and/or 
activity of ALP and PC-1, and therefore indirectly regulate the rate of mineralisation.
The extracellular nucleotides are important regulators of osteoblast function. In 
this chapter, the anti-osteogenic effects of extracellular nucleotides were studied in 
more detail. A number of techniques were employed (RT-PCR, histological staining, 
colorimetric assays) to determine whether nucleotides inhibit the deposition of the 
organic matrix and/or mineralisation, with particular attention given to the role of ALP 
and bone matrix proteins.
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MATERIALS AND METHODS
Cell culture
Osteoblasts were isolated and cultured as described in Chapter 2. To determine the 
ability of nucleotides to influence bone nodule formation and ALP activity, osteoblasts 
were cultured in standard 24-well trays for up to 21 days; fresh nucleotides were added 
every 1-2 days, medium was exchanged every 2-3 days. For total RNA extraction, 
osteoblasts were cultured (with or without 10 pM nucleotide) in standard 6-well trays 
for up to 21 days; every 3-4 days total RNA (n = 2) was extracted as described in 
Chapter 2. Medium pH, pCC>2 and pC>2 were monitored throughout using a blood gas 
analyser, as described previously.
Quantification o f bone nodule formation
Osteoblasts were cultured with 1-100 pM ATP, UTP, ADP or UDP (n = 6) and bone 
nodule formation quantified as described in Chapter 2.
Determination o f alkaline phosphatase (ALP) activity
The alkaline phosphatase (ALP) activity of cell lysates was determined 
colorimetrically using commercially available kits. Cells were cultured in standard 24- 
well trays (with or without 10 pM ATP, UTP, ADP or UDP) and after 4, 7, 10 and 14 
days selected cell layers were washed and cells harvested using a scraper (n = 6), 
followed by sonication at 4°C and centrifugation at 500 x g. The supernatant was 
collected and stored at 4°C until assaying in a 96-well tray. The ALP activity and 
Lowry protein contents of the supernatants were measured colorimetrically (Elx800 
plate reader, Bio-tek International) at pH 9.8 using kits (Biotron Diagnostics, CA, USA 
and Sigma-Aldrich Dorset, UK, respectively) according to the manufacturers 
instructions. ALP activity was normalised for protein and expressed as 10'3 
units/min/pg.
Masson’s trichrome stain for collagen
Osteoblasts were cultured in 6-well trays for up to 17 days, with or without the 
addition of 10 pM ATP or UTP (n = 6); at 11 and 14 days cell layers were washed in
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PBS and fixed with Bourn’s fixative (Sigma-Aldrich Dorset, UK) overnight at room 
temperature. After fixation, the monolayer was washed in running water (until yellow 
colour disappeared) and stained in Weigert’s haematoxylin (iron) solution (Sigma- 
Aldrich Dorset, UK) for 10 minutes. The cells were thoroughly washed in tap water 
and stained with 0.5% acid fiichsin, 0.5% glacial acetic acid for 5 minutes, rinsed in 
distilled water and treated with 1% phosphomolybdic acid solution for 5 minutes. The 
solution was then drained from the wells by tapping the plate upside down onto a 
tissue and cells stained for 5 minutes in 2% methyl blue, 2.5% glacial acetic acid, 
rinsed in distilled water and treated with 1% glacial acetic acid for 2 minutes. At the 
end of the procedure, the nuclei were stained black, the cytoplasm was red and the 
collagen purple/blue. Plates were visualised under an Olympus IMT-2 inverted 
microscope and images taken using a Leica digital camera.
RNA extraction, DNase treatment, cDNA generation and RT-PCR
These reactions were performed as described in Chapter 2. Specific primers were used 
to probe the expression of ALP, OCN, matrix gla protein (MGP), osteopontin (OPN), 
type I collagen (COL1) and PC-1 in cultures treated with ATP, UTP, ADP or UDP. 
Primer sequences and annealing temperatures are shown in T able 3.
Reagents
Unless mentioned, all chemicals were purchased from Sigma-Aldrich (Dorset, UK) 
and all molecular biology reagents from Promega UK (Southampton, UK). Primers 
were purchased from MWG Biotech (Ebersburg, Germany).
Statistical analysis
Analysis of data was carried out as described in Chapter 2.
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Name Sequence (5’-3’)
Annealing 
temperature (°C)
Product size 
(bp)
p actin
S -  gtt cgc cat gga tga cga t 
AS -  tct ggg tea tct ttc acg g
53.0 332
OCN
S -  gca gac acc atg agg acc ct 
AS -  gca get tgt gcc gtc cat ac 59.8 418
ALP
S -  etc att tgt gcc aga gaa 
AS -  gtt gta cgt ctt gga gac
50.0 238
MGP
S -  ccc tgt cgt atg aat etc 
AS -  gac tcc gta aca aag cga
50.0 297
OPN
S -  egg tga aag tgg ctg agt 
AS -  gac teg gga tac tgt tea 50.0 333
COL1
S -  geg aag aag aca tcc ctg 
AS -  ctg tcc agg gat gcc ate 50.0 377
PC-1
S- gtc agt atg cgt get aac 
AS -  tgg cac act gaa ctg tag
51.0 309
Table 3. Primer sequences and annealing temperatures for Chapter 3 RT-PCR 
reactions.
Gene specific primers were designed in our laboratory; identity of PCR products was 
confirmed by sequencing.
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Figure 3.2. Treatment with 10 fM  UTP blocks matrix m ineralisation b y  rat o steob la sts
(A) This image shows the bone nodules formed by rat osteoblasts cultured in standard 6-well 
trays for 21 days. (B) This phase contrast light microscopy image illustrates the typical 
trabecular morphology of alizarin red stained bone nodules formed by normal rat osteoblasts in 
vitro. (C) This image demonstrates the striking inhibition of bone formation that occurs in 
vitro following treatment with 10 pM UTP for 21 days. (D) Normal deposition of the organic 
matrix occurs in UTP-treated cultures (as highlighted by the arrow) however, the absence of 
alizarin red stained nodules indicates that mineralisation has been inhibited. Scale bars: A & 
C = 0.5 cm, B & D = 50 pm.
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Figure 3.3. Culture with 10 /jM ATP or UTP significantly  inhibits ALP activity
Rat osteoblasts were treated with ATP, UTP, ADP or UDP (10 .^M) and ALP activity quantified 
after 4, 7, 11 and 14 days of culture. At all time points, UTP inhibited ALP activity by 45-65%. 
ATP significantly inhibited ALP activity by up to 53% but only from 10 days of culture. ADP 
and UDP do not block bone nodule formation in vitro and in this assay did not affect ALP 
activity at any stage throughout the culture period (*** = p<0.001, ** = p<0.01). These results 
are typical of those seen in repeated ALP assays (n = 6).
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Lack o f effect o f ATP and UTP on collagen formation
Synthesis and deposition of type I collagen is an essential part of osteogenesis and 
occurs prior to mineralisation. To determine whether extracellular nucleotides impair 
collagen deposition, histological staining was employed to examine the collagen fibres 
in control and nucleotide-treated cultures. The images in Figure 3.4 are representative 
of osteoblast monolayers treated with 10 pM ATP or UTP for 14 days. The osteoblast 
cytoplasm is stained dark red and the collagen fibres purple/blue. In both the control 
and nucleotide-treated cultures, the collagen fibres were orientated in an organised 
manner, although they were slightly less apparent in the controls because, following 
mineralisation, they have been incorporated into bone nodules. Moreover, the quantity 
of collagen in the ATP and UTP-treated cultures did not appear different from 
controls.
ATP and UTP downregulate ALP, COL1, PC-1 and OCN mRNA in osteoblasts but 
do not affect MGP and OPN expression; lack o f effect o f ADP and UDP
RT-PCR was employed to study ALP, COL1, OCN, OPN, MGP and PC-1 mRNA 
expression in osteoblasts treated with ATP, UTP, ADP or UDP (10 pM) at 4, 7 and 14 
days of culture; the results are shown in Figure 3.5A & 3.5B. The dramatic increase 
in OCN and ALP expression illustrates the progression of osteoblast differentiation in 
control cultures. Treatment with ATP or UTP did not influence OPN and MGP 
mRNA expression at any stage (Figure 3.5A). OCN expression was not detected at 
day 4 and at 7 days there were no differences between the control and nucleotide 
treated cells. Conversely, after 14 days of culture OCN mRNA expression appeared 
lower in both the ATP and UTP-treated osteoblasts. Furthermore, unlike the controls, 
OCN expression did not increase from day 7 to day 14 in nucleotide-treated cells. In 
agreement with the colorimetric assay, ALP mRNA expression was downregulated in 
both the ATP and UTP-treated osteoblasts at all time points. Although the effects 
were less pronounced, COL1 expression was also slightly decreased in ATP and UTP- 
treated cells at days 7 and 14. Somewhat surprisingly, PC-1 mRNA levels were also 
decreased in both ATP and UTP-treated cells at 4, 7 and 14 days of culture
Throughout the culture period, expression of ALP, COL1, OCN, OPN, MGP and 
PC-1 mRNA was unaffected by treatment with ADP or UDP (Figure 3.5B).
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UTP
Figure 3.4. Collagen formation appears unaffected  b y  treatm ent with 10/jM  ATP or UTP
These images, taken using light microscopy, illustrate the collagen formation in control and 
nucleotide-treated cultures and are representative of the staining observed in three different 
experiments {n = 6). The collagen fibres (purple/blue) were deposited in an organized fashion 
in all samples, with no perceptible differences in the volume of collagen. Because of 
mineralisation, the collagen fibres were less clear in the control images. In all images the 
scale bar = 10 pm
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C = Control
A = 10 pM ATP treated 
U = 1 0 p M  UTP treated
J3 actin
MGP
COL1
C = Control
A = 10 pM ADP treated 
U= 10 pM UDP treated
Figure 3.5. Treatment with 10 /iM ATP or UTP inhibits the expression  o f  ALP, PC-1 and  
OCN mRNA in rat osteoblasts; lack o f  ef fect  o f  ADP or UDP.
Osteoblasts were cultured with ATP, UTP, ADP or UDP (10 pM) and ALP, OCN, OPN, MGP, 
COL1 and PC-1 mRNA expression studied after 4, 7 and 14 days of culture. In controls, the 
progression of osteoblast differentiation was illustrated by the increased OCN and ALP 
expression at 7 and 14 days. (A) Application of ATP or UTP did not affect OPN or MGP at 
any time point. OCN expression was unaffected at 4 and 7 days, but was downregulated in 
nucleotide treated cultures at 14 days. ALP, PC-1 and to a lesser degree COL-1 mRNA 
expression appeared consistently downregulated in the ATP and UTP-treated osteoblasts. (B) 
ADP and UDP did not affect the expression of any of the factors studied at any time point. 
Each PCR reaction was carried out in triplicate using cDNA from three separate experiments. 
The product sizes (in base pairs) for each gene amplified are: p actin (332), ALP (238), OCN 
(418), OPN (333), MGP (297), COL1 (377) and PC-1 (309).
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DISCUSSION
The investigation by Hoebertz et al (2002) described how low micromolar 
concentrations of ATP and UTP, inhibited bone formation by rat osteoblasts in vitro, a 
finding confirmed during the course of this research. Nevertheless, the mechanisms 
mediating this inhibition and the downstream signalling pathways activated following 
receptor stimulation have remained unclear. The work presented here has started to 
elucidate exactly how extracellular nucleotides act to prevent bone formation.
Osteoblasts were cultured with 1-100 |nM nucleotide (ATP, UTP, ADP or UDP) 
before staining for mineralised nodules (alizarin red). In agreement with earlier 
findings, low micromolar concentrations of ATP and UTP significantly inhibited bone 
nodule formation, whereas ADP was inactive (Hoebertz et al, 2002). As shown in 
Chapter 2, mature rat osteoblasts express high levels of the P2Y6 receptor; thus, the 
effect of UDP on bone formation was also investigated. At all concentrations tested, 
UDP failed to influence nodule formation suggesting no involvement of the P2Y6 
receptor in this process. Closer examination of stained osteoblast monolayers 
demonstrated that, despite a significant inhibition of mineralised nodule formation, 
both collagen formation and organic matrix deposition were relatively unaffected by 
treatment with ATP or UTP. Thus, the notion that nucleotides primarily block 
mineralisation was investigated further.
Mature osteoblasts express high levels of tissue non-specific ALP, an enzyme that 
hydrolyses phosphate-containing substrates to produce Pi necessary for mineralisation. 
ALP expression and activity is regulated by many local and systemic factors including 
localised acidosis (pH 6.90), another potent inhibitor of mineralisation in vitro 
(Brandao-Burch et al, 2005). Given the central role of ALP in mineralisation, the 
ability of extracellular nucleotides to influence its expression and activity was 
investigated colorimetrically and using RT-PCR. To ensure that medium acidification 
did not contribute to any of the effects observed, all experiments were controlled for 
pH (maintained at pH 7.40 throughout). Consistently, the P2Yi agonist, ADP, and the 
P2Y6 agonist, UDP failed to influence ALP activity; conversely, ATP and UTP 
inhibited ALP activity by up to 65%. This ligand specificity correlates with observed 
effects on mineralised nodule formation. ATP and UTP are equipotent at rat P2Y4
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receptors, whereas at P2Y2 receptors UTP is a more potent agonist. Evidence suggests 
that the P2Y2 receptor subtype mediates the anti-osteogenic effects of nucleotides (see 
Chapter 2, Hoebertz et al, 2002) and in agreement, UTP consistently exerted a greater 
inhibitory effect on ALP activity. However, the lack of specific antagonists for the 
P2Y2 and P2Y4 receptors make it impossible to discount any involvement of the P2Y4 
receptor. RT-PCR analysis demonstrated a striking decrease in ALP mRNA levels in 
osteoblasts treated with ATP or UTP, whereas application of ADP or UDP was 
without effect. Taken together, these findings suggest that stimulation of the P2Y2 
receptor and possibly the P2Y4 receptor, leads to decreased ALP expression and 
activity, with the resulting decrease in Pi directly reducing the level of mineralisation.
The observation that ALP knockout mice still deposit bone mineral indicates that 
in vivo Pi can be generated from several sources (Johnson et al, 2000; Wennberg et al, 
2000). In 10 fiM ATP and UTP-treated cultures, up to a 90% reduction in mineralised 
nodule formation was observed; however, ALP activity was only inhibited by up to 
65% and mRNA for the enzyme was still expressed, albeit at a low level. This 
suggests extracellular nucleotides also influence the expression and/or activity of other 
factors involved in mineralisation. PC-1 acts to suppress hydroxyapeptite crystal 
formation and propagation by producing and regulating steady state levels of the 
inhibitory PPi. Thus, PC-1 is thought to act in opposition to ALP to regulate 
mineralisation (Johnson et al, 1999; Hessle et al, 2002). However, treatment with 
ATP or UTP decreased PC-1 mRNA expression in osteoblasts, whilst application of 
ADP or UDP was without effect; further work will be required to determine the 
reasons underlying this surprising observation.
Despite being the most abundant non collagenous protein in bone, the role of OCN 
in osteogenesis remains unclear, although evidence from in vivo (Ducy et al, 1996; 
Boskey et al, 1998) and in vitro (Hunter et al, 1996) studies suggest a role regulating 
mineralisation and matrix maturation. In this study, ATP and UTP decreased OCN 
mRNA expression in mature osteoblasts, whereas ADP and UDP were ineffective. 
This ligand specificity suggests, like ALP, the P2Y2 or P2Y4 receptor subtypes are 
mediating this inhibition, although how this decreased expression contributes towards 
the mineralisation block is unclear at present. OCN is a commonly used as marker of 
the mature osteoblast phenotype thus decreased mRNA expression could represent
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impaired osteoblast differentiation in nucleotide-treated cultures. Both OPN and MGP 
act to inhibit mineralisation and consistently mRNA expression was unaffected by 
nucleotide treatment, indicating no involvement of these bone matrix proteins in the 
anti-osteogenic effects of extracellular nucleotides. Although no differences were 
observed in the histological staining, COL1 mRNA expression was slightly decreased 
in nucleotide treated cultures; these data suggest ATP/UTP may, in addition to 
inhibiting mineralisation, influence collagen formation in rat osteoblasts. Further work 
is now required to quantitatively measure collagen production, either by proline 
incorporation or by colorimetric assay, to determine the effects of extracellular 
nucleotides on organic matrix synthesis.
In contrast to the findings presented here, early investigations found ATP and other 
nucleoside triphosphates, at concentrations > 0.2 mM, significantly increased Ca2+ 
deposition in bovine and rat matrix vesicle systems, an effect attributed to the actions 
of a specific ATPase rather than ALP (Hsu & Anderson, 1977; Hsu & Anderson, 
1996). As nucleotides themselves can be hydrolysed to Pi, it is possible that short 
exposures to high ATP levels directly promote mineralisation by providing excess Pi 
for hydroxyapeptite crystal formation. However, as this effect requires high 
micromolar or millimolar concentrations of ATP (which are unlikely to occur in vivo 
under normal conditions), this stimulatory action on mineralisation may not be 
physiologically relevant. Furthermore, ATP concentrations > ImM induce smaller 
functional Ca2+ responses (Chapter 2) and may cause osteoblast apoptosis (Gartland et 
al, 2001). Thus, if such high levels do occur in vivo they are likely to be detrimental 
to bone cell function.
Information regarding the signalling cascades initiated following P2Y receptor 
activation is still limited. It is widely accepted that activation of P2Yi, P2Y2, P2 Y4  
and P2Y6 receptors leads to a rapid increase in intracellular Ca2+, an effect observed 
here in primary rat osteoblasts (Chapter 2). Although ADP and UDP increase 
intracellular Ca2+, they do not block bone formation or influence the expression of any 
of the factors studied here. Thus, it appears that increased intracellular Ca2+ is not the 
sole mediator of impaired mineralisation by ATP and UTP and factors further 
downstream confer the signalling specificity of individual P2 receptors. This study did 
not determine the effectors mediating the inhibition of ALP, OCN and PC-1 mRNA
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expression. The promoters of both ALP and OCN genes contain consensus-binding 
sequences for a number of transcription factors including Runx2 (Ducy et al, 1996), 
Dlx5 (Kim et al, 2004) and c-fos (Ohta et al, 1992), thus there are several potential 
candidates for transcriptional regulation. Runx2 is commonly associated with 
stimulating the transcription of osteoblast marker genes and therefore inhibiting the 
expression and/or activation of this factor may well contribute to the decreased ALP 
and OCN expression observed here. However, a recent report (Costessi et al, 2005) 
found that ATP and UTP, signalling via P2Y2 receptors and the extracellular signal- 
related (ERK) cascade, enhanced the DNA binding activity of Runx2. Expression of 
common osteoblastic markers such as ALP and OCN was not investigated, although 
the authors reported increased expression of galectin-3, a protein implicated in cell 
proliferation. Moreover, this study employed a higher concentration of nucleotides 
(100 pM) and immortalised human osteoblast-like initial transfectant (HOBIT) cells. 
HOBIT cells do not express either P2 Y4  or P2Y6 receptors, which, as shown here are 
highly expressed on primary rat osteoblasts (Chapter 2) and therefore these cells are 
inherently different. A previous study by the same authors also found that, 100 pM 
ATP, signalling via P2Y receptors and the transcription factor early growth response 
factor 1 (Egrl), acted to transiently increase COL1 expression (Pines et al, 2003). This 
finding is contradictory to those observed here and therefore it seems that HOBIT cells 
may behave in a different way to primary rat osteoblasts, thus it would be of interest to 
see if Runx2 expression and/or activity is affected by nucleotide stimulation in our in 
vitro system. ATP and ADP can stimulate, albeit weakly, the expression of c-fos in 
osteoblast-like cells (Bowler et al, 1999). As this effect is likely mediated by the P2Yi 
receptor, activation of which did not influence OCN or ALP expression, c-fos seems 
an unlikely candidate for mediating the effects observed here. Although purinergic 
signalling has not been implicated in the induction of Dlx5 or its antagonistic factor 
Msx2, their ability to regulate osteoblastic gene expression makes them potential 
candidates for the effects observed here.
Taken together these data indicate that inhibition of ALP expression and activity 
mediates, at least in part, the mineralisation block observed in nucleotide-treated 
cultures. Moreover, RT-PCR analysis suggests that other factors such as PC-1 and 
OCN may also be involved, however, the nature of their participation remains unclear. 
Many other factors can also regulate mineralisation including annexins and MMPs.
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Further work is now required to determine whether extracellular nucleotides influence 
the expression and/or activity of these factors.
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CHAPTER 4
THE EFFECT OF ENVIRONMENTAL STRESSES 
ON OSTEOBLAST FUNCTION AND ATP 
RELEASE
INTRODUCTION
In vivo bone cells are exposed to numerous environmental stresses, including acidosis, 
hypoxia, hypothermia, hyperthermia and mechanical stimulation, all of which can 
influence their function and survival. Several groups have investigated the individual 
effects of these stimuli on cultured bone cells in vitro; however, in a physiological 
situation these events rarely occur in isolation. For example, the vascular disruption 
occurring in a localised tissue injury will cause a hypoxic microenvironment, the 
accompanying increase in anaerobic metabolism and the inflammatory response will 
result in a localised acidosis and hyperthermia, respectively.
In normal human tissues, the oxygen tension (p(>2 ) is between 5-12% and although 
relatively little accurate data exists regarding the pH of interstitial fluid, it is almost 
certainly lower than the pH 7.40 of arterial blood. Experimental limitations mean there 
are few studies into the pC>2 within the human skeleton; however, it has been reported 
that the oxygen tension in the bone marrow of healthy volunteers is 6.5% (Harrison et 
al, 2002) and in the synovial fluid of normal joints is 6-7% (Lund-Olesen, 1970). In 
diseased tissues, such as osteoarthritic joints, the p( > 2  can fall to 1% or lower (Lewis et 
al, 1999).
Localised hypoxia occurs when blood supply is reduced or disrupted, and is 
associated with fracture, tissue damage, inflammation and tumours. Because of the 
vascular disruption, one of the most fundamental processes in wound healing is 
angiogenesis, a process that ensures the delivery of oxygen (O2) and nutrients to the 
regenerating tissue. A number of cytokines are angiogenic, the most important being
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vascular endothelial growth factor (VEGF). VEGF acts to stimulate the formation of 
new vessels whilst critically regulating the budding and growth of new capillaries from 
existing vascular structures. Osteoblasts constitutively produce VEGF, expression of 
which is markedly upregulated during hypoxia, possibly representing a basic 
chemostatic response to low oxygen (Steinbrech et al, 1999; Steinbrech et al, 2000; 
Akeno et al, 2001). In vitro exposure to hypoxia for up to 96 hours also increases the 
osteoblastic expression of other genes involved in fracture repair, including TGF-P, 
IGF-2 and collagen (I and III) (Steinbrech et al, 2000; Warren et al, 2001); conversely, 
expression of the osteoblast differentiation factor Runx2 is markedly decreased (Park 
et al, 2002). These findings suggest transient hypoxia after injury acts as a stimulus 
for extracellular matrix synthesis and fracture repair but more prolonged hypoxia will 
be detrimental to bone matrix formation.
Hypoxia also regulates osteoclast formation and activity. Using cells derived from 
mouse marrow, work performed in our laboratory demonstrated that culture in 2% O2 
caused a significant 3.5-fold and 9.5-fold increase in osteoclast formation and 
resorption, respectively (please see paper in Appendix II by Arnett et al 2003).
Core body temperature in humans varies between 36.4-37.1°C, depending on 
location, for example a healthy knee joint has a reported temperature of 36.45-36.58°C 
(Kenny et al, 2002). Normally, body temperature is carefully maintained as even 
small deviations can affect cellular metabolism by influencing reaction kinetics, 
protein and nucleic acid stability and lipid bilayer properties. Nevertheless, changes in 
body temperature occur during many pathological situations. Inflammation and 
infection increase both local and systemic temperatures and these events at sites close 
to or within bone surfaces have long been associated with bone loss. Hyperthyroidism 
is characterised by an increased metabolic rate and heat production (or thermogenesis) 
as well as accelerated bone remodelling, increased bone loss and fracture risk 
(Lakatos, 2003). In contrast, hypothyroidism is associated with decreased body 
temperature, delayed bone formation and short stature. Ageing is associated with 
attenuated vasoconstrictor responses to cold stress and decreased thermogenesis; this 
inhibits heat retention and can lead to a lower core body temperature (Kenney et al, 
2003). At present, whether these changes in ambient temperature directly affect the 
skeleton in vivo remains to be determined.
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Previous work has demonstrated that prolonged heat or cold can have a striking 
effect on bone cell function; an extreme example of this occurs in frostbite when ice 
crystal formation in the extracellular fluid and direct vascular endothelial injury cause 
marked cellular damage leading to bone necrosis, particularly in the hand and foot 
(Leonard et al, 2001). In vitro work indicated osteoblast-like cells are thermosensitive, 
as culture at 40°C decreases DNA synthesis and proliferation (Flour et al, 1992; Shui 
& Scutt, 2001). Even transient exposure (10 minutes) to severe hyperthermia (48°C) 
causes disruption of the osteoblast cytoskeleton and increased apoptosis and necrosis. 
Moreover, Hsp70 levels were increased dramatically at 45°C and 48°C, indicating the 
activation of protection mechanisms; however, at 48°C given the increased osteoblast 
apoptosis these mechanisms appear to be ineffective (Li et al, 1999). Hypothermia is 
also detrimental to bone cell function as osteoblasts cultured at 33°C for 96 hours 
exhibited decreased DNA synthesis and mineralisation (Shui & Scutt, 2001). Recent 
work in our own lab, using mononuclear cells derived from human peripheral blood, 
has shown that culture at 40°C causes a 4-fold decrease in osteoclast formation and 10- 
fold decrease in resorption per osteoclast. Contrastingly, 34°C caused a 2-fold 
increase in osteoclast formation but was accompanied by a 30% decrease in resorption 
(Utting et al, 2005).
ATP is a ubiquitous intracellular energy molecule, found within the cytoplasm at 
concentrations between 2-5 mM (Hoebertz et al, 2003). Consequently, following 
membrane damage or necrosis, all cells can potentially release ATP into the 
extracellular environment and influence local purinergic signalling. Numerous 
excitatory and non-excitatory cells including neurons (White, 1984), platelets (Beigi et 
al, 1999), epithelial and endothelial cells (Bodin & Burnstock, 2001a; Knight et al, 
2002), fibroblasts (Gerasimovskaya et al, 2002), astrocytes (Coco et al, 2003), 
chondrocytes (Graff et al, 2000), and erythrocytes (Sprague et al, 1998) release ATP in 
a controlled manner. In many cell types, ATP release is enhanced by stressful stimuli 
including hypoxia (Bergfeld & Forrester, 1992; Bodin & Burnstock, 1995; 
Gerasimovskaya et al, 2002), osmotic shock, fluid shear stress (Bodin & Burnstock, 
2001a; Genetos et al, 2005) and mechanical stimulation (Romanello et al, 2001)
The exact mechanisms mediating constitutive ATP release remain unclear but 
differences between cell types are emerging. Current theories involve: (1) ATP
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binding cassette (ABC) transporters, (2) vesicular exocytosis, and (3) gap junctions 
and hemichannels. Extensive investigation of the transmembranous ABC proteins has 
yielded several potential candidates for mediating ATP release, including the cystic 
fibrosis transmembrane conductance regulator (CFTR) and the sulfonylurea receptor 
(SUR). Functionally, these proteins regulate ion channel activity; for example, CFTR 
is an ATP-dependant, cAMP-activated Cf channel, which also regulates K+ channels. 
The CFTR protein has been implicated in ATP release from several cell types 
including erythrocytes (Sprague et al, 1998; Braunstein et al, 2001). Controlled 
vesicular exocytosis is implicated in ATP release from epithelial and endothelial cells 
(Bodin & Burnstock, 1998; Knight et al, 2002). Finally, connexin hemichannels and 
gap junctions, which allow the movement of molecules less than 1 Kda, reportedly act 
as conductive pathway to mediate ATP release from astrocytes (Cotrina et al, 1998; 
Coco et al, 2003). For a detailed review on ATP release mechanisms, see Lazarowski 
etal, 2003.
Constitutive ATP release has been reported from various modified osteoblast-like 
cell lines including: SaOS-2 cells (Buckley et al, 2003), human osteoblast-like initial 
transfectant (HOBIT) cells (Romanello et al, 2001; Romanello et al, 2005) and 
MC3T3-E1 cells (Genetos et al, 2005). Furthermore, both mechanical stimulation and 
fluid shear stress are reported to enhance this basal ATP release (Romanello et al, 
2001; Genetos et al, 2005).
ATP release from primary osteoblasts has not previously been investigated; 
therefore, to obtain results that maximise physiological relevance, the research 
presented here utilised normal, bone forming osteoblasts derived from neonatal rat 
calvaria. The work in this chapter falls into three main areas: (1) the properties and 
mechanisms of constitutive ATP release from osteoblasts, (2) the effect of transient 
exposure to low oxygen, hypothermia or hyperthermia on ATP release, and (3) the 
effects of continuous culture under these conditions on osteoblast function and ATP 
release.
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MATERIALS AND METHODS
Cell culture
Primary rat osteoblastic cells were isolated as described previously and cultured for up 
to 24 days in standard 6-well trays. To determine the effect o f long-term culture at low 
O2 plates were transferred to gas-tight fuse (“hypoxia”) boxes 24 hours after subculture 
and gassed daily for 90 seconds with the appropriate O2 (2% or 20% O2, 5% CO2; 
balance N 2) concentration. Cylinders containing custom mixtures o f O2 , CO2 and N 2 
were purchased from BOC (London, UK). To examine the effects o f temperature 
change on osteoblast function, plates were transferred to humidified incubators running 
at 34°C or 40°C (5% CC>2-95% air) 24 hours post-seeding. Medium pH, pC>2 and pCC>2 
were monitored throughout, using a blood gas analyser as described previously.
Quantification of ATP release
To measure ATP release, culture medium was removed, cell layers were washed with 
PBS, serum free DMEM added (1 ml/well) and plates incubated at 5%CC>2-95% air, 
37°C for 30-60 minutes prior to sample collection (n = 12). To investigate release 
mechanisms, several agents (monensin, brefeldin A, w-ethylmaleimide (NEM) and 
gadolinium (Gd3+) at 1-1000 pM) were added to the serum free DMEM and the effects 
measured. Previous reports implicated increased intracellular Ca2+ in ATP release, so 
the calcium ionophore ionomycin was also tested (0.1-10 pM) for potential effects. In 
all cases, samples were frozen immediately after collection for later ATP 
quantification.
To examine the affects o f long-term hypoxia on ATP release, plates containing 
osteoblasts were positioned into gas-tight “hypoxia” boxes 24 hours after seeding and 
gassed daily for 90 seconds with 20% or 2% O2 . Cell layers were prepared for ATP 
determination as described above before regassing to ensure the correct O2 
concentration. To determine the effect o f transient hypoxia on ATP release test plates 
minus lids were sealed in hypoxia chambers and exposed to 20% or 2% O2 for 
between 30 seconds and 11.5 minutes. A similar method was employed to study the 
effects o f transient and continuous hypothermia and hyperthermia on ATP release. 
Finally, in all cases osteoblast monolayers were fixed and stained as described
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previously to demonstrate the presence of mature osteoblasts and mineralised bone 
nodules.
Luciferin-luciferase assay
ATP release is measured luminetrically using the luciferin-luciferase assay, which 
exploits the ability of firefly luciferase to catalyse its substrate D-luciferin to 
oxyluciferin and light, in the presence of ATP. The equation for this reaction is shown 
below:
ATP + D-luciferin -> AMP + PPi + oxyluciferin + C02 + light
ATP standards (10 pM to 1 pM) and test samples (50 pi) were pipetted into a white 
(nonphosphorescent) 96-well plate (Nunc, Fisher Scientific, UK) and sited in the 
luminometer (Lucy 1, Anthos Labtec, Salzburg, Austria). The luciferin-luciferase 
reagent (100 pi) was automatically injected into each well and measured for 10 
seconds at ~ 560 nm. All standards, blanks and the lyophilised ATP reagent 
containing D-luciferin and luciferase were dissolved in serum free DMEM. A 
calibration curve was constructed using the ATP standards and used to calculate ATP 
levels in test samples.
Assessment o f plasma membrane integrity
Cell viability at 3, 7 and 14 days of culture was investigated using the Promega 
CytoTox 96® non-radioactive cytotoxicity assay. This assay quantitatively measures 
lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released on cell lysis. 
LDH oxidises lactate into pyruvate, generating NADH, which is then used to convert a 
tetrazolium salt into a red formazan product. The amount of colour formed is 
proportional to the number of lysed cells.
Culture medium was removed, serum free DMEM added (1 ml/well) and plates 
incubated for 1 hour at 37°C before sample collection (n = 12); all test samples were 
kept at 4°C until assaying. To establish total cellular LDH levels, cell layers, bathed in 
serum-free DMEM, were harvested using a scraper followed by sonication at 4°C and 
centrifugation at 500 x g. The LDH content of the supernatants and cell lysates were
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measured colorimetrically (490 nm) (Elx800 plate reader, Bio-tek International, Fisher 
Scientific UK, Loughborough) as per manufacturer’s instructions. By expressing 
released LDH as a percentage of the total cellular LDH cell viability could be 
calculated.
Proliferation, alkaline phosphatase (ALP) and hone nodule formation assays
Osteoblast proliferation, ALP and bone nodule formation were quantified using the 
methods described previously. To rule out direct effects of temperature or oxygen 
tension on reaction kinetics, all assays were carried out at 37°C or atmospheric O2 . To 
study the effects of continuous culture at low O2 , hypothermia or hyperthermia on 
osteoblast function, cells were cultured for 15-24 days, depending on the onset of 
mineralisation, which varied between cultures.
Reagents
All tissue culture reagents were purchased from Gibco (Paisley, UK). Unless 
mentioned all chemicals were purchased from Sigma-Aldrich (Dorset, UK) and 
dissolved in distilled water with the exception of monensin and Brefeldin A, which 
were dissolved in ethanol and methanol, respectively. The CytoTox 96® Non­
radioactive cytotoxicity assay was obtained from Promega UK (Southampton, UK) 
and ATP monitoring reagent from Biothema (Handen, Sweden)
Statistical analysis
All data was analysed as described in Chapter 2.
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RESULTS
Replacement o f medium stimulates ATP release
The foetal calf serum (FCS) in normal growth medium contains factors inhibitory to 
the luciferin-luciferase assay; consequently, it was necessary to bathe cells in serum- 
free DMEM for the duration of the experiment. As the absence of serum is inherently 
stressful to osteoblasts, time in this medium was kept to a minimum. Shear stress is a 
known stimulator of ATP release; therefore, it is highly likely the mechanical 
disturbances arising during medium exchange exert a similar effect. Medium change 
was found to have a dramatic effect on ATP release; within 30 seconds ATP levels had 
increased approximately 3-fold (Figure 4.1 A). The ATP levels remained significantly 
elevated for up to 5 minutes post medium exchange returning to basal levels within 20 
minutes. Following this observation, in all subsequent ATP release experiments, 
plates were left for 30-60 minutes prior to sample collection, to enable complete 
degradation of any ATP released because of mechanical perturbations.
Constitutive ATP release increases with osteoblast differentiation
Using primary bone forming rat osteoblasts, ATP release and cell proliferation were 
measured throughout the culture period, allowing expression of data as ATP release 
per osteoblast. Compared to 4 days, ATP release per osteoblast was significantly 
increased by up to 7-fold at 8, 11 and 15 days of culture, with the maximum level of 
release occurring at 11 days (Figure 4.IB). A quantitative ALP assay illustrated the 
progression of osteoblast differentiation in these cultures and between 4-18 days 
enzyme activity increased up to 12-fold (Figure 4.IB). Measurement of osteoblast 
viability consistently showed no significant changes in the level of cell lysis 
throughout the culture period.
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Figure 4.1. Constitutive ATP release from primary rat osteoblasts increases with 
differentiation and is stimulated by medium exchange
(A) Medium exchange (t = 0) induced a rapid 3-fold increase in ATP release from osteoblasts; 
levels returned to basal within 20 minutes (n = 12). (B) ATP release per osteoblast increased 
up to 7-fold at 8, 11 and 15 days of culture compared to day 4 (n = 12). This indicates that 
osteoblast differentiation may influence ATP release, an idea confirmed by the concurrent 
increase in ALP activity (*** = p<0.001, ** = p<0.01, * = p<0.05). These data are representative 
of the results obtained from three separate experiments.
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Constitutive ATP release from osteoblasts involves vesicular exocytosis
Previous reports indicate basal ATP release from osteoblast-like cells occurs, at least in 
part, by vesicular mechanisms (Genetos et al, 2005; Romanello et al, 2005); to 
establish whether this is the case in primary rat osteoblasts the exocytosis inhibitors 
monensin, NEM and brefeldin A (1-1000 pM) were tested. When compared to 
untreated controls, addition of 1, 10 or 100 pM monensin to culture medium 
significantly decreased the level of ATP detected by between 40-50%. At 
concentrations of 100 pM and 1000 pM NEM also reduced ATP release by 90% and 
99%, respectively. Although 1 pM and 10 pM NEM elicited a small (~ 15%) decrease 
in ATP release these values were not statistically significant. Brefeldin A caused an 
18-30% decrease in ATP release; however, at all concentrations these inhibitory 
effects were non-significant (Figure 4.2A).
In other cell types, increased intracellular Ca2+ is thought to mediate the release of 
ATP from intracellular stores (Knight et al, 2002). The trivalent lanthanide 
gadolinium (Gd3+) inhibits several stretch-activated ion channels including the 
mechanosensitive selective cation channel (MSCC); this channel, which is expressed 
on osteoblasts, facilitates rapid Ca2+ entry into the cell and is implicated in increased 
intracellular Ca2+ in response to shear stress. Cells were treated with a range of Gd3+ 
concentrations (1-100 pM), but even at the highest levels, this agent had no effect on 
constitutive ATP release (Figure 4.2B).
The Ca 2+ ionophore, ionomycin, acts to increase intracellular Ca2+ by decreasing 
plasma membrane integrity. When tested, all concentrations (0.1-10 pM) of 
ionomycin caused enhanced ATP release with l-10pM causing a significant up to ~ 2- 
fold increase (Figure 4.2).
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Figure 4.2. ATP release from osteoblasts is mediated by vesicular exocytosis.
(A) Vesicular exocytosis inhibitors 1-100 pM Monensin and 100 pM NEM significantly blocked 
ATP release from osteoblasts by 50% and 90% respectively, whereas brefeldin A was without 
significant effect (n = 12). (B) The MSCC channel blocker Gd3+ did not affect constitutive ATP 
release from osteoblasts {n =12). (C) The Ca2+ ionophore ionomycin increased ATP release 
by up to ~ 2-fold (n = 12) (*** = p<0.001, ** = p<0.01, * = p<0.05). All inhibitor studies were 
performed a minimum of three times.
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Continuous hypoxia inhibits osteoblast proliferation and function, and reduces cell 
viability
The effect o f continuous culture in low oxygen (2% O2) on osteoblast proliferation and 
viability was quantified at regular intervals over a 14-day period. In control cultures 
(20% O2), cell number increased progressively between day 4 and day 14; in contrast, 
in 2% O2 osteoblast proliferation appeared to arrest around day 11 with culture beyond 
this point associated with a slight reduction in cell number (Figure 4.3A). Osteoblast 
numbers were consistently lower in 2% O2, increasing by only ~ 20% over the 14 day 
culture period; concurrently cell number increased by approximately 100% in control 
cultures. At 11-14 days osteoblast numbers were significantly reduced by up to 52% 
in 2% O2 compared to 20% O2 . Using the LDH cytotoxicity assay, the medium of  
hypoxic cultures was found to contain higher levels o f cellular LDH (up to 3-fold) 
compared to controls, indicating continuous culture at low oxygen decreases osteoblast 
viability (Figure 4.3B). Limitations o f this particular assay mean it is not possible to 
determine whether the decreased viability in 2% O2 occurs because o f increased 
necrosis, apoptosis or a combination o f the two. LDH levels in the 20% O2 controls 
exhibited no significant variation, indicating osteoblast viability remains relatively 
unchanged throughout the culture period.
Following culture for 21 days, osteoblast cell layers were fixed, stained with 
alizarin red and mineralised bone nodule formation was quantified. Repeated 
experiments demonstrated a marked inhibition (up to 90% decrease) o f bone nodule 
formation in the 2% cultures, compared to 20% controls (Figure 4.3C). Osteoblasts 
cultured under normoxia displayed abundant nodule formation with structures 
exhibiting the typical trabecular morphology seen in vitro (Figure 4.4A & 4.4C). In 
contrast, the 2% O2 cultures exhibited significantly fewer nodules, and those that were 
formed appeared small and rounded (Figure 4.4B & 4.4D).
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Figure 4.3. Long-term hypoxia inhibits osteobiast proliferation, viability and function
(A) Continuous culture in 2% 0 2 impairs osteoblast proliferation leading to a 50% decrease 
in cell number at 11 and 14 days (n = 6). (B) Levels of cellular LDH in the culture medium 
were increased up to 3-fold in 2% 0 2 compared to 20% controls, indicating a reduced 
osteoblast viability following prolonged exposure to hypoxia (n = 6. (C) Long-term culture in 
2% 0 2 caused up to 90% inhibition of mineralised bone nodule formation (n = 6) (*** = 
p<0.001, ** = p<0.01). All experiments into the effect of hypoxia on osteoblast function were 
performed at least three times.
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Figure 4.4. Hypoxia inhibits bone nodule formation by  rat o steob lasts
(A & B) Representative scanned images of osteoblast monolayers following prolonged culture 
in 20% (A) and 2% (B) 0 2 in a standard 6-well tray. Osteoblasts cultured in 2% 0 2 form 
significantly fewer bone nodules than the 20% controls. (C) This image represents the typical 
trabecular morphology of bone nodules formed in vitro by osteoblasts cultured in 20% 0 2. (D) 
In contrast, the bone nodules formed in hypoxic cultures are fewer, smaller and rounded in 
appearance. Images C & D were taken using phase contrast light microscopy with a digital 
camera attachment. Scale bars in images A & B = 0.5 cm, in images C & D = 50 pm.
 — .
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Transient exposure to hypoxia stimulates ATP release from osteoblasts without 
affecting cell viability
Hypoxia is a known stimulator of ATP release from numerous cell types, including 
endothelial cells (Bodin et al, 1995), fibroblasts (Gerasimovskaya et al, 2002) and 
erythrocytes (Bergfeld et al, 1992). Primary rat osteoblasts, cultured until the 
initiation of bone nodule formation (10-14 days), were exposed to 20% or 2% O2 for 
30 seconds to 11.5 minutes. Exposure to 2% O2 for up to 90 seconds caused a rapid 
significant increase in ATP release; after 30 seconds and 90 seconds, ATP levels were 
~ 2.5-fold and 2-fold higher, respectively (Figure 4.5A). Exposure to hypoxia for 
periods in excess 2 minutes resulted in smaller but insignificant increases in ATP 
release. Repeated experiments demonstrated the length of elevated ATP release varied 
between cultures, however, generally it did not exceed 3 minutes. For all control 
samples gassed with 20% O2 , the level of ATP release did not vary greatly; indicating 
the movement of gas over the culture medium was not stimulating the increased 
release. Levels of cellular LDH in the culture medium were measured to determine 
whether transient hypoxia caused increased cell lysis, therefore accounting for the 
increased ATP levels detected. Repeatedly, transient hypoxia did not influence the 
amount of LDH in the medium (Figure 4.5B).
Hypoxia induced ATP release involves vesicular exocytosis
To establish whether hypoxia-induced ATP release occurred via a vesicular 
mechanism, cells were incubated in serum free DMEM containing either NEM or 
monensin (100 pM) before transient exposure to 20% or 2% O2 . In untreated cells, 2% 
O2 induced a significant 2-fold increase in ATP secretion compared to 20% O2 
controls. Treatment with monensin and NEM decreased ATP release from control 
samples by 40% and 65%, respectively (Figure 4.6). Hypoxia-induced ATP release 
was also inhibited by these agents, being decreased by 62% and 80% following 
application of monensin and NEM, respectively (Figure 4.6).
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Figure 4.5. Transient hypoxia stimulates ATP release from (}steoblasts without affecting 
cell viability
(A) Transient exposure to 2% 0 2 for 30-90 seconds caused a rapid increase in ATP release 
from osteoblasts (2.5-fold) (n = 12). (B) Medium LDH levels were unchanged in 2% 0 2 
cultures compared to controls suggesting hypoxia induced ATP release was not caused by 
increased cell lysis (n = 12) (*** = p<0.001, * = p<0.05). These data are representative of the 
results from three separate experiments.
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Figure 4.6. Hypoxia-induced ATP reiease occurs via vesicular exocytosis
Exposure to 2% 0 2 for 30 seconds caused a 2-fold increase in ATP release from osteoblasts 
(# = p<0.05). Addition of monensin and NEM to the culture medium (100 fxM) significantly 
inhibited both hypoxia-induced and constitutive ATP release (n = 12) from primary rat 
osteoblasts by up to 80% (*** = p<0.001, ** = p<0.01, * = p<0.05). All experiments were 
performed in triplicate.
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Continuous hypoxia decreases total ATP release from osteoblasts during the early 
stages o f culture
Since long-term culture in low oxygen dramatically impairs osteoblast proliferation 
and function, basal ATP release was quantified after 8 and 15 days from cells cultured 
in 20% or 2% O2 . At day 8 of culture, total ATP levels were significantly lower at 2% 
O2  (67% decrease) but by day 15 although lower at 2% O2 (30% decrease) the level of 
total ATP release was not significantly different (Figure 4.7A). Consistent with 
earlier observations, osteoblast proliferation was impaired in the 2% O2 cultures and 
therefore ATP secretion was normalised for cell number. ATP release per osteoblast, 
although lower was not significantly different at 2% O2 compared to 20% controls 
(Figure 4.7B).
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Figure 4.7. Chronic hypoxia does not influence the level of ATP release per osteoblast.
(A) Total ATP release from osteoblasts cultured for 8 days in 2% 0 2 (n = 12) was decreased 
by -  67%, but following 15 days of culture although reduced (30%) the level of total ATP 
release did not vary significantly. (B) When normalised for cell number the level of ATP 
release per osteoblast in 2% 0 2 did not vary significantly from 20% controls (** = p<0.01). 
These data are representative of at least three separate experiments.
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Continuous culture in hypothermic or hyperthermic conditions inhibits osteoblast 
function
Osteoblasts were cultured for up to 18 days to determine the effects of hypothermia 
(34°C) and hyperthermia (40°C) on cell proliferation (measured every 3 days). In 
34°C cultures, a significant reduction in osteoblast number was observed at most time 
points; cell number being decreased by up to 33% (Figure 4.8A). Chronic exposure to 
40°C also reduced osteoblast proliferation by up to 25% (Figure 4.8B). At both 34°C 
and 40°C, a greater inhibitory affect was observed at the early stages of culture (4-7 
days). Osteoblast proliferation, at all three temperatures, followed a typical ‘S’ shaped 
curve, with a log phase of steady growth followed by a stationary phase, characterised 
by virtually no proliferation. However, in the 34°C and 40°C cultures, this growth 
curve was shifted to the right, reflecting the slower rate of cell proliferation in 
hypothermia or hyperthermia.
At the end of the experiments, osteoblast monolayers were fixed, stained with 
alizarin red and mineralised nodule formation quantified. Continuous exposure to both 
34°C and 40°C caused a striking inhibition of osteoblast activity, with a 95% and 75% 
reduction in bone nodule formation observed, respectively (Figure 4.8C). Prolonged 
hypothermia reproducibly, exerted a greater inhibitory effect on osteoblast function 
than hyperthermia. The images in Figure 4.9 were acquired using a high-resolution 
scanner (Epson Perfection Photo, 3200) and by light microscopy with digital camera 
attachment. They are representative of the mineralised bone nodules formed in 34°C, 
37°C and 40°C following 21 days in culture. At both 34°C and 40°C, there are 
significantly fewer bone nodules and those formed do not display the typical curved 
morphology observed at 37°C. The nodules formed in hypothermic or hyperthermic 
temperatures are similar to those observed in hypoxic cultures (Figure 4.4), being 
small and rounded in appearance.
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Figure 4.8. Prolonged exposure to hypothermia or hyperthermia inhibits osteoblast 
proliferation and function
(A) Long-term culture (up to 18 days) at 34°C inhibited osteoblast proliferation by up to 33% 
(n = 6). (B) Continuous culture in hyperthermic temperatures (40°C) reduced osteoblast 
number by up to 25% (n = 6). (C) Prolonged exposure to 34°C or 40°C significantly impaired 
osteoblast function, inhibiting bone nodule formation by 95% and 75%, respectively (n = 6) (*** 
= p<0.001, ** = p<0.01, * = p<0.05). All experiments into the effect of temperature on 
osteoblast proliferation and function were performed in triplicate.
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Figure 4.9. Prolonged hypothermia or hyperthermia inhibits bone nodule formation by  
rat o steob la sts
Representative images of bone nodules formed by primary rat osteoblasts cultured at 34°C, 
37°C or 40°C for 21 days. The low power images on the left were acquired using a high- 
resolution scanner. Osteoblasts cultured at 37°C form bone nodules displaying the typical 
trabecular morphology shown in the higher power image on the right (taken using phase 
contrast light microscopy). Bone formation was significantly reduced at both 34°C and 40°C, 
and those nodules that were formed appear considerably smaller and rounded in appearance. 
Scale bars: low power images = 0.5 cm, high power images = 50 pm.
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Transient hyperthermia stimulates ATP release from osteoblasts without affecting 
cell viability
Figure 4.5 shows how transient hypoxia stimulates ATP release from osteoblasts; in 
vivo localised hypoxia is likely to occur in association with inflammation, 
consequently the effects of temperature on ATP release were also investigated. At the 
onset of bone formation (10-14 days of culture at 37°C), osteoblasts were exposed to 
34°C or 40°C for 1-120 minutes and the level of ATP release compared to 37°C 
controls. Consistently, decreasing the temperature to 34°C had no effect on ATP 
release from osteoblasts (Figure 4.10A). In contrast, increasing the ambient 
temperature to 40°C for 30, 60 or 120 minutes caused a significant 2-fold increase in 
the level of ATP release (Figure 4.10B and 4.10C). Exposure to 40°C for periods 
shorter than 30 minutes did not have any stimulatory effects on ATP release. 
Assessment of cell viability using the LDH cytotoxicity assay demonstrated that 
exposure to hyperthermia for up to 120 minutes did not affect the level of cellular LDH 
detected in the medium (Figure 4.10C). Therefore, transient increases in temperature 
do not induce membrane damage and instead, the enhanced ATP release is likely to 
occur via controlled mechanisms.
Long-term culture at 34 °C or 40 °C decreases constitutive A TP release
After 7 and 14 days of continuous culture in 34°C, 37°C or 40°C, medium samples 
were collected to determine the effect of prolonged hypothermia and hyperthermia on 
constitutive ATP release from osteoblasts. Culture at 34°C or 40°C significantly 
impaired ATP secretion from osteoblasts, levels being decreased by 35-40% in 34°C 
and 60-70% in 40°C (Figure 4.11). Prolonged hyperthermia reproducibly inhibited 
constitutive ATP release per osteoblast to a greater extent than hypothermia. Taken 
together these data show that long-term culture at 34°C or 40°C has a marked negative 
effect on constitutive ATP release from osteoblasts.
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Figure 4.10. Transient hyperthermia stimuiates ATP release from osteoblasts without 
affecting cell viability
(A) Incubation at 34°C for 20-60 minutes had no effect on ATP release (n = 12). (B) Exposure 
to 40°C for 30-60 minutes increased ATP release from osteoblasts up to 2-fold (n = 12). (C) 
Transient hyperthermia (t = 120 minutes) enhanced ATP release approximately 2.5-fold 
without affecting cell viability (n = 12) (*** = p<0.001, ** = p<0.01). These data are 
representative of those observed in three separate experiments.
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Figure 4.11. 
osteoblasts.
Chronic hypothermia or hyperthermia inhibits ATP release from
After 7 and 14 days of culture, medium samples were collected for ATP quantification via the 
luciferin-luciferase assay (n = 12). Results were normalised for cell number and compared to 
37°C controls; continuous culture at 34°C or 40°C significantly reduced the amount of ATP 
released per osteoblast by up to 40% and 70% respectively (*** = p<0.001, ** = p<0.01). All 
experiments were performed in triplicate.
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DISCUSSION
This study aimed to investigate constitutive ATP release from osteoblasts and how it is 
affected by the stresses hypoxia, hypothermia and hyperthermia (both chronic and 
acute). Earlier work examined the consequences of relatively short hypoxic exposures 
on osteoblast function (up to 96 hours) and found they exerted a striking effect on 
proliferation, differentiation and gene expression (Steinbrech et al, 1999; Steinbrech et 
al, 2000; Park et al, 2002). Likewise, short-term culture (96 hours) at 33°C and 40°C 
significantly impaired proliferation in osteoblast-like cells (Flour et al, 1992; Shui & 
Scutt, 2001). However, the effects of chronic exposure to low oxygen, hypothermia or 
hyperthermia on osteoblast function and ATP release remained poorly investigated.
In this study, prolonged hypoxia exerted a marked effect on proliferation with up to 
a 52% reduction in cell number observed. Chronic hypothermia or hyperthermia were 
also inhibitory decreasing osteoblast number by up to 33%. In control (37°C or 20% 
O2 ) cultures, osteoblast proliferation followed the usual in vitro growth kinetics with a 
log period of steady growth followed by a stationary phase, characterised by low 
proliferation. Culture at 34°C or 40°C shifted the growth curve to the right, indicating 
that prolonged hypothermia or hyperthermia retard osteoblast proliferation. In 
contrast, osteoblasts cultured for up to 14 days in 2% O2 exhibited only minimal 
changes in cell numbers, suggesting that long-term oxygen deprivation arrests 
proliferation. Moreover, prolonged hypoxia significantly affected osteoblast viability, 
particularly at the later stages of culture, although whether this was caused by 
increased necrosis, apoptosis and/or decreased membrane integrity remains to be 
determined. Conversely, the effect of long-term hypothermia or hyperthermia on 
osteoblast viability provided inconsistent results.
Quantification of mineralised nodule formation demonstrated the effect of hypoxia, 
hypothermia and hyperthermia on osteoblast function in vitro. Prolonged exposure to 
2% O2 reproducibly inhibited mineralised matrix formation by up to 90%. Bone 
formation is dependent on the correct synthesis and deposition of collagen; recent data 
from our group demonstrated impaired collagen formation at 2% O2 (Utting et al, 
submitted). Several post-translational modifications are required for the formation of 
mature collagen including the hydroxylation of proline residues by prolyl-4-
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hydroylase, a reaction that enables the formation of stabilising intrastrand hydrogen 
bonds. Inhibition of this reaction prevents the formation of a stable triple helix and 
produces collagen that is more susceptible to proteolytic degradation and denatures at 
lower temperatures (Fessler & Fessler, 1974). Prolyl-4-hydroxylase, is oxygen 
dependent; therefore, impaired proline hydroxylation in hypoxia may explain the 
impaired collagen and bone nodule formation observed here in vitro.
Continuous culture at 34°C and 40°C inhibited mineralised bone nodule formation 
by 95% and 75%, respectively. Ambient temperature may also effect collagen 
formation as early studies demonstrated that the thermal stability of procollagen is 
proportional to the hydroxyproline content, with low temperatures (20°C-30°C) being 
associated with a marked reduction in proline hydroxylation reactions (Jimenez et al, 
1974). Moreover, reports suggest fully hydroxylated procollagen denatures at 37.9°C 
(Rosenbloom et al, 1973), preventing the formation of stable, mature collagen at 
higher temperatures. These observations suggest that the impaired nodule formation 
observed here in vitro at 34°C and 40°C may occur because of disrupted collagen 
production. In agreement, unlike the noticeable mineralisation block seen in the 
nucleotide-treated cultures (Chapter 3), unmineralised matrix was not apparent in the 
osteoblast monolayers cultured at 34°C or 40°C.
This investigation has provided the first evidence for constitutive ATP release from 
primary rat osteoblasts. Earlier reports demonstrated ATP release from modified 
osteoblast-like MC3T3-E1 (Genetos et al, 2005) and SaOs-2 cells (Buckley et al, 
2003) in the nanomolar range, however, this study only detected release in the 
picomolar range. The transformed MCT3T3-E1 cell line is derived from murine 
neonatal calvaria and expresses many characteristics of the mature osteoblast 
phenotype including bone formation in vitro. In contrast, SaOS-2 cells are derived 
from human osteosarcomas and, despite producing mineralised matrix in vitro, lack 
some characteristics of the mature osteoblast phenotype. The inherent differences 
between primary cells and these immortalised osteoblast-like cell lines, combined with 
the different species of origin may explain the lower levels of ATP release detected 
here. Constitutive ATP release from rat osteoblasts changed with time, increasing up 
to 7-fold in the second week of culture; this was accompanied by increased ALP 
activity, confirming the progression of osteoblast maturation. Over the same period
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cell viability was unchanged indicating that increased cell lysis is unlikely to 
contribute towards the elevated levels. Combined these data suggest that cellular 
differentiation influences the basal level of ATP release and potentially local 
purinergic signalling.
At present, the exact processes mediating controlled ATP release remain unclear 
but there are several different hypotheses. The transmembranous ABC proteins, 
including CFTR and SUR, bind and hydrolyse ATP to provide energy for the active 
translocation of substrates including inorganic ions and amino acids. Currently, there 
is evidence for the involvement of ABC proteins, particularly CFTR, in both basal and 
stimulated ATP release from erythrocytes and fibroblasts (Pasyk & Foskett, 1997; 
Sprague et al, 1998; Braunstein et al, 2001). However, the exact mechanisms involved 
require further definition and may involve the modulation of a separate ATP 
permeable channel. The involvement of these channels in ATP efflux was not studied 
here but current evidence indicates that ABC proteins do not mediate ATP release 
from osteoblast-like cells (Romanello et al, 2001).
In other cell types, including astrocytes (Cotrina et al, 1998), gap junctions and 
hemichannels have been implicated in ATP secretion, however, current evidence 
suggests they are unlikely to mediate ATP release from osteoblasts. HOBIT cells 
engineered to over-express a major component of the gap junction, connexin 43, 
displayed no differences in either basal or stimulated ATP release compared to 
controls (Romanello et al, 2001). Additionally, gap junction inhibition failed to effect 
fluid shear stress induced ATP release from osteoblasts (Genetos et al, 2005).
Purinergic neurotransmission is mediated by the controlled release of ATP-filled 
synaptic vesicles, making vesicular exocytosis a major ATP release mechanism in 
neuronal cells (Bodin & Bumstock, 2001b). Certain non-neuronal cells, including 
epithelial and endothelial cells (Bodin & Bumstock, 2001a; Knight et al, 2002) and 
mechanically stimulated osteoblast-like cells (Genetos et al, 2005; Romanello et al, 
2005) have also been shown to release ATP via vesicular mechanisms. The inhibitors 
monensin, brefeldin A and NEM disrupt different components of the vesicular 
exocytosis pathway and thus are widely utilised in the study of ATP release 
mechanisms. Monensin inhibits vesicular formation at the golgi apparatus and whilst 
concentrations of 100 pM inhibit ATP secretion in other systems (Knight et al, 2002),
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in this study, concentrations of > 1 pM blocked ATP release from osteoblasts. By 
interfering with vesicle-associated NSF proteins, NEM inhibits vesicular fusion with 
the plasma membrane and it inhibits ATP secretion at concentrations between 1-10 pM 
in some systems but 100 pM in others (Bodin & Bumstock, 2001a; Genetos et al, 
2005). In this investigation, 100-1000 pM NEM almost completely blocked ATP 
release, whereas lower concentrations were ineffective. Brefeldin A disrupts vesicular 
trafficking by blocking protein transport from the endoplasmic reticulum to the Golgi 
apparatus. Although inhibitory at 10 pM in other cell types, brefeldin A did not 
significantly affect ATP release from osteoblasts.
Gadolinium (Gd3+) is a potent blocker of mechanosensitive ion channels, including 
the MSCC channel present on osteoblasts; these channels, following activation by 
membrane stretch and mechanical perturbations, facilitate Ca2+ influx and have been 
implicated in ATP release from cells including hepatocytes (Roman et al, 1999). A 
previous study reported concentrations of 10 pM Gd3+ as sufficient to block cation 
channels (Caldwell et al, 1998). Here, 1-100 pM Gd3+ failed to affect constitutive 
ATP release, suggesting that mechanosensitive ion channels, including MSCC, do not 
mediate the increase in intracellular Ca2+ required for ATP secretion under normal 
conditions. This is in agreement with a report by Genetos et al (2005), which found 
Gd3+ failed to affect basal or shear stress stimulated ATP release from osteoblast-like 
cells. The Ca2+ ionophore, ionomycin, significantly increased constitutive ATP release 
from rat osteoblasts agreeing with earlier findings implicating increased intracellular 
Ca2+, either by influx from the extracellular environment or release from internal 
stores, in mediating ATP release (Knight et al, 2002). The inhibitory actions of 
monensin and NEM suggest an involvement of vesicular exocytosis in constitutive 
ATP release from primary rat osteoblasts. However, in view of the high 
concentrations of NEM required to inhibit ATP release, it is possible the effects 
observed were non-specific. Moreover, the inability of monensin and NEM to 
completely block ATP release and the lack of activity of Brefeldin A, suggest another 
pathway may be involved. Taken together this investigation illustrates further the 
complex mechanisms involved in controlled ATP release from cells.
Many cell types, including endothelial cells (Bodin & Bumstock, 1995), fibroblasts 
(Gerasimovskaya et al, 2002) and erythrocytes (Bergfeld & Forrester, 1992; Bozzo et
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al, 1999) release ATP in response to hypoxia, a response which has been linked to 
ATP-induced vasodilatation of the vascular endothelium (Marshall, 2000). Transient 
exposure to 2% O2 caused a rapid increase in ATP release from osteoblasts (up to 2.3- 
fold) that was sustained for up to 180 seconds. Lactate dehydrogenase (LDH) levels in 
the culture medium were consistently unaffected by transient hypoxia. Taken together, 
these data indicate sudden exposure to low oxygen prompts the release of ATP by 
controlled mechanisms rather than by increased cell lysis or membrane damage. Since 
basal ATP release appears to involve vesicular exocytosis, inhibitor studies were 
performed to determine the processes mediating the increased secretion following 
transient exposure to low O2 . Both monensin and NEM inhibited hypoxia-induced 
ATP release by up to 80%, indicating that vesicular exocytosis is involved in the 
increased ATP secretion from osteoblasts following a stressful stimulus. In agreement, 
osteoblast-like cells exposed to fluid shear displayed increased ATP release with the 
peak secretion occurring after 1 minute, a response that was also inhibited by 
monensin and NEM (Genetos et al, 2005). Transient hypoxia (50 seconds) also 
stimulates ATP release from erythrocytes, however, this efflux was inhibited by the 
channel blockers, dipyridamole and 4,4'-diisothiocyanatostilbene-2,2'disulphonic acid 
(DIDS), illustrating the different mechanisms employed by cells to secrete ATP 
(Bergfeld & Forrester, 1992).
Following acute exposure to hypoxia one of the first cellular responses is a sharp 
increase in intracellular Ca2+, the duration of which depends on the intensity of the 
hypoxic event (Toescu, 2004). Since increased intracellular Ca2+ is a prerequisite for 
ATP secretion, this response may well be the stimulus for the hypoxia-induced release 
observed here. The increase in Ca2+ levels, is primarily mediated via influx from the 
external environment, and may involve three different families of ion channels: (1) 
voltage sensitive calcium channels (VSCCs); (2) ligand operated ion channels such as 
glutamatergic receptor channels; (3) transient receptor potential (TRP) channels 
(Toescu, 2004). A number of these ion channels are expressed on osteoblasts 
including L-VSCC (Genetos et al, 2005), both ionotrophic glutamatergic receptors 
(AMPA and NMD A) (Itzstein et al, 2001; Hinoi et al, 2002;) and TRPV6 (Weber et 
al, 2001). Consequently, there are several potential candidates for mediating the 
increased intracellular Ca2+ and subsequent ATP secretion from osteoblasts following 
exposure to acute hypoxia.
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No published data exist at present on the effect of acute hypothermia or 
hyperthermia on ATP release from cells. In this study, whilst transient cold shock (1 
minute to 2 hours) did not affect the level of ATP release, exposure to 40°C for 30-120 
minutes caused a sustained elevation in ATP release from primary rat osteoblasts. A 
study of patients with mandibular fractures demonstrated a ~ 2.5°C increase in 
temperature within the fracture callus (Kourie et al, 2000), consequently the heat- 
shock induced ATP release measured here may well occur in vivo. Ion channels 
belonging to the TRP superfamily sense and respond to local temperature changes and 
are widely expressed in the nervous system. These thermosensitive channels, 
including TRPV1, TRPV2 and TRPV3, are stimulated by a range of temperatures 
(Patapoutian et al, 2003; Bender et al, 2005) and once activated cause a significant 
increase in cation conductance and intracellular Ca2+ (Xu et al, 2002). Of these, 
TRPV3 is potentially the best candidate by which increased local temperature could 
result in elevated ATP release because its response range is 37-39°C. However, with 
the exception of the non-thermosensitive TRPV6 (Weber et al, 2001) there are no 
published data on the expression of TRPV channels on osteoblasts; but, this does 
present an interesting area for further study.
Prolonged hypoxia, hypothermia and hyperthermia exerted a striking inhibitory 
effect on ATP release from osteoblasts. Hypoxic cultures displayed up to a 65% 
decrease in total ATP release. Since culture at 2% O2 impairs proliferation, this 
reduction is probably due to fewer cells being present. Conversely, when normalised 
for cell number ATP release per osteoblast was not significantly different. Chronic 
hypoxia causes cells to switch from mitochondrial-based metabolism (the citric acid 
cycle and the electron transport chain) to anaerobic glycolysis. Since the glycolytic 
pathway only produces two ATP molecules per glucose molecule hydrolysed, 
prolonged exposure to low oxygen strongly reduces ATP synthesis. Consequently, 
under these conditions cells would be expected to preserve their energy stores, thus the 
observation that cellular ATP release remains unchanged in 2% O2 seems surprising. 
Assessment of LDH levels demonstrated a marked reduction in osteoblast viability in 
2% O2 , especially during the later stages of culture. Therefore, it is possible that 
increased cell lysis and/or membrane damage may have contributed to the hypoxia- 
induced ATP release. Additionally, chronic hypoxia is reported to reduce ecto- 
nucleotidase activity, and thus, decrease the rate of extracellular ATP hydrolysis
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(Gerasimovskaya et al, 2002). The increased cell lysis combined with decreased 
hydrolysis could potentially explain why ATP release per osteoblast appeared 
unaffected by chronic exposure to hypoxia.
Prolonged hypothermia and hyperthermia reduced constitutive ATP release per 
osteoblast by ~ 40% and ~ 70% respectively. Since temperature influences enzyme 
tertiary structure, activation energies and consequently reaction kinetics, the effect of 
temperature changes on the enzymes responsible for ATP synthesis and hydrolysis 
might help to explain the observed results. Moreover, temperature regulates the 
properties of biological membranes, with subsequent influences on vesicle formation 
and the function of integral membrane proteins (Hazel, 1995).
The data presented in this chapter indicate how environmental stresses modulate 
osteoblast function and ATP release. Chronic hypoxia was shown to be inhibitory to 
both osteoblast proliferation and activity. The basic effects of hypoxia on osteoblasts 
are examined in more detail in a recent manuscript (Utting, Robins, Behar, Brandao- 
Burch, Orriss & Arnett, submitted). Furthermore, other data from our laboratory has 
shown osteoclast formation and activity is dramatically increased at low oxygen 
(Arnett, Gibbons, Utting, Orriss, Hoebertz, Rosendaal & Meghji, 2003). Combined 
these findings suggest that a prolonged hypoxic environment in vivo, would negatively 
effect bone remodelling, shifting the balance in favour of net bone loss. These 
findings can potentially explain the bone loss occurring in many pathological 
situations characterised by low oxygen including tumours, ischemia and inflammation.
Prolonged exposure to temperatures only a few degrees above or below 37°C also 
exerted striking effects on osteoblast proliferation and function. Moreover, recent 
work performed in our laboratory demonstrated that ambient temperature also affects 
osteoclast formation and activity in vitro, with osteoclast formation being decreased in 
hyperthermia but increased in hypothermia (Utting et al, 2005). These results suggest 
strongly that local temperature changes occurring because of inflammation, infection, 
ageing or conditions such as hypothyroidism, could contribute to the low bone 
formation, remodelling and increased bone loss observed in these situations.
Transient exposure to hypoxia or hyperthermia caused increased ATP release, 
whereas more prolonged exposures reduced ATP secretion. Enhanced concentrations
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of extracellular nucleotides following these stressful stimuli is likely to directly 
influence local purinergic signalling and therefore may contribute towards the initial 
repair processes. This idea will be discussed further in Chapter 6.
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CHAPTER 5
THE BONE PHENOTYPE OF P2X2, P2X3, P2X2/3 
AND P2Yi RECEPTOR KNOCKOUT MICE
INTRODUCTION
The development of transgenic (“knockout”) mouse models has facilitated the detailed 
study of preselected gene products in vivo. Now widely utilised, these animals have 
provided vital information regarding the physiological roles of many hormones, 
growth factors and proteins. Generation of knockout mice is a complex, multi-step 
process taking many months, the first step being the synthesis of a DNA construct 
designed to introduce a mutation into the mouse genome at the desired locus. 
Following transfection and colony expansion, mouse embryonic stem cells undergo 
southern blot analysis to determine which cells contain the construct DNA integrated 
at the correct location. Suitably modified embryonic stem cells are used to generate 
the knockout animals via injection into mouse blastocysts and implantation in a 
surrogate mother. Selective interbreeding between offspring can eventually generate 
homozygous knockout mice. These animals, known as “constitutive knockouts”, each 
contain the same mutated gene that is expressed throughout development and in all 
cells of the adult. In some cases, disruption of the target genes fails to produce viable 
offspring, often termed embryonically lethal. When this occurs, the above technique is 
modified to enable the production of a “conditional knockout”; these animals contain 
mutations inducible at different stages of development or in selected cell types.
Use of knockout animals in bone research has provided fundamental information 
regarding the transcription factors, cytokines and signalling molecules involved in 
skeletal development and bone remodelling. Disruption of some genes exerts gross 
effects on the skeleton; for example, animals lacking the transcription factor Runx2, 
which is a prerequisite for osteoblast development, demonstrate an almost complete 
lack of ossification (Komori et al, 1997), whilst RANKL knockout mice exhibit severe
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osteopetrosis (Kong et al, 1999). Removal of less essential factors has slighter skeletal 
effects, for example mice lacking FGF-2, which is a potent mitogen for osteoblasts and 
osteoprogenitors, develop a skeleton but exhibit decreased bone mass and a decreased 
rate of bone formation (Montero et al, 2000).
To date, mice deficient in P2Xi, P2X2, P2X3, P2X2/3, P2X7, P2Yi, P2Y2 and P2Y4 
receptors have been created. These animals have provided useful information 
regarding purinergic signalling in vivo, but with the exception of P2X7 receptor 
knockouts (Ke et al, 2003; Gartland et al, 2003c; Jorgensen et al, 2003), there are no 
reports of skeletal alterations in these animals. This study investigates whether P2X2, 
P2X3, P2X2/3 and P2Yi receptor knockout mice display a changed bone phenotype. 
Background information regarding the expression profile and pharmacology of these 
P2 receptors is provided in Chapter 1.
Both P2X2 knockout (P2X2‘ ‘) and P2X3 knockout (P2X3'/ ) mice display normal 
viability with no overt phenotypic differences (Cockayne et al, 2000; Zhong et al, 
2001; Cockayne et al, 2005). However, approximately 90% of P2X2/P2X3 double 
receptor knockouts (P2X2/ / w‘7‘) die between 5 days and weaning. These animals fail 
to thrive because of stunted growth, lymphohematopoietic hypoplasia in the bone 
marrow and thymus and die because of bacterial pneumonia and multiple organ 
dysfunctions. Both P2X2'7' and P2X3' mice exhibit deficits in pain-related behaviour 
and normal sensory processes such as urinary bladder reflexes and gastrointestinal 
peristalsis (Cockayne et al, 2000; Zhong et al, 2001; Cockayne et al, 2005). P2X2‘ 
and P2X2/3rfWV" mice also demonstrate impaired ventilatory responses to hypoxia (Rong 
et al, 2003) and lack responses to agonist stimulation in parasympathetic otic ganglion 
nerves (Ma et al, 2004), suggesting a role for the P2X2 subunit in the sensory effects of 
ATP in the carotid body and nerve transmission in parasympathetic neurones. 
Additionally, P2X2"  mice also exhibit abnormalities in the neuromuscular junction and 
in skeletal muscle function (Ryten et al, 2004).
P2Yi knockout (P2Y f  ) mice are viable, with no gross external abnormalities, and 
display normal development, survival and reproduction (Leon et al, 1999). However, 
these animals are resistant to acute thromboembolism and exhibit increased bleeding. 
Moreover, functional studies of platelets derived from P2Yi'7' mice demonstrated a loss 
of ADP-induced aggregation, suggesting an important role for the P2Yi receptor in
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platelet aggregation and blood clotting (Fabre et al, 1999; Leon et al, 1999; Leon et al, 
2001).
Comparison of several murine strains demonstrated that skeletal maturity is 
reached by approximately 4 months of age, with large changes in both total and 
femoral bone mineral density (BMD) and bone mineral content (BMC) observed 
between 2-4 months; from 6  months upwards, only small changes in BMD and BMC 
occur (Beamer et al, 1996). Investigations into the mechanical properties of mouse 
femoral bones demonstrated peak bone strength is achieved at approximately 2 0  weeks 
of age (Brodt et al, 1999). The skeletons of juvenile animals (2-3 months) exhibit 
rapid growth remodelling and contain abundant osteoclasts; marrow cultures from 
young mice efficiently generate large numbers of osteoclasts in vitro when stimulated 
by M-CSF and RANKL. Comparative studies using several different mouse strains, 
all raised in identical environments, demonstrated marked differences in bone density, 
indicating genetic variation influences bone mass: for example the C57BL/6 inbred 
strain has a lower BMD compared to other strains such as the C3H/HEJ strain (Beamer 
et al, 1996; Chen & Kalu, 1999). Thus, it is important that experimental comparisons 
are made between knockouts and wild type controls derived from the same genetic 
background.
Previous investigations have shown that the P2 X2 receptor and the P2Yi receptor, 
but not the P2 X3 receptor, are expressed on both osteoblasts and osteoclasts (Chapter 
2; Hoebertz et al, 2003). From the experimental data available, it is possible to 
hypothesize the effects of receptor removal on the skeletons of P2 X2 A, P2 X3 *7', 
P2X2/3 ^ /~ and P2Yi'' animals. In vitro evidence has implicated both the P2Yi 
receptor (Hoebertz et al, 2001) and the acid-activated P2 X2 receptor (Morrison et al, 
1998) in the nucleotide-mediated stimulation of osteoclast formation and activity. 
Given this ability to shift the balance of bone remodelling in the favour of resorption, 
removal of either the P2 X2 receptor or the P2Yi receptor may well lead to increased 
bone mass. In contrast, as P2 X3 receptors are not expressed on bone cells, receptor 
removal would not be expected to have any direct skeletal effects. The effect of P2 X2 /3  
receptor removal on the skeleton is harder to predict because although heteromeric 
P2X2/3 receptors are not present on bone cells, P2X2/3^//‘ mice will also lack 
homomeric P2 X2 and P2 X3 receptors. The present study employed the non-invasive
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technique of dual-energy x-ray absorptiometry (or DEXA) scanning to investigate 
whether these proposed effects of P2 X2 , P2 X3 , P2X2/3 or P2Yi receptor removal occur 
in vivo.
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MATERIALS AND METHODS
Principles o f DEXA scanning
Dual-energy x-ray absorptiometry (DEXA) scanning is widely used both clinically and 
experimentally to determine bone density. This study employed the PIXImus DEXA 
scanner (Lunar, GE Healthcare, USA) specifically designed to study the skeleton of 
small rodents (Figure 5.1).
DEXA scanning works on the principle that x-rays reflect from bone in a density 
dependent manner. The PIXImus system exposes the entire animal to a cone shaped 
beam of high energy (80 kV) and low energy (55 kV) x-rays. A CCD (charged couple 
device) camera detects the radiation hitting a luminescent panel below the test subject. 
The varied compositions of bone mineral, fat and lean tissue means they differentially 
absorb or reflect the dual energy x-rays; thus by digitally processing the detected 
radiation, the PIXImus can calculate the relative quantities of bone, fat and lean tissue 
along the x-ray path. During each scan, the dual x-ray exposure is performed four 
times and on completion, the data is collated to produce a ‘summary’ image, the 
density of which is compared to a standard object (mouse phantom) used to calibrate 
the instrument
In this study, the PIXImus system was used to measure the bone mineral content 
(BMC), bone mineral density (BMD), total fat and lean tissue and percentage fat of 
test subjects. The BMC, a parameter directly calculated by the DEXA scanner, is 
measured in grams and represents the total amount of bone mineral present in a 
defined area. BMD is calculated by dividing the BMC by projected bone area and 
represents the amount of bone mineral present in a cm2. However, the BMD, which is 
measured in grams/cm2, is not a true density measurement because it does not take into 
account the volume in which the bone mineral is contained.
Generation of knockout animals
The knockout mice used in this study originated from two separate sources and have 
slightly different genetic backgrounds; the P2X2"/", P2X3 ' and P2X2// fe/'/' mice are 
from a C57BL/6 x 129/Ola lineage, whilst the P2Yf ' mice are derived from a
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C57BL/6 J lineage. These strains, particularly C57BL/6, are widely used in knockout 
generation, have a long lifespan and display no inherent bone defects. The P2X 
knockouts were a kind gift from Dr D Cockayne (Roche Bioscience, USA) and the 
P2Yi'/_ mice from Dr C Gachet (Strasbourg, France). P2X2 mice were generated via 
introduction of a deletion encompassing exons 2-11 in the mouse P2X2 gene, whilst a 
1-kb deletion encompassing exon 1 and the ATG initiation codon produced the P2X3’‘ 
animals. Breeding of P2X2"  with P2X3' '  mice to eventually produce offspring 
carrying a deletion in both P2X2 and P2X3 genes generated the P2X2/ / W‘A knockouts. 
P2Yi'/_ animals were generated via insertion of a poly(A)cassette into exon 1. All P2X 
knockouts scanned were female, whilst the P2Yi ‘ animals were male. All knockouts 
were derived from homozygous breeding pairs, in which each mutant line was 
compared with its own filial generation-matched wild type controls, thus eliminating 
any strain related effects on bone mass. The P2X receptor knockouts were housed in a 
designated animal facility and routinely maintained on a 12 hour light/12 hour dark 
cycle and given ad libitum access to food and water.
Bone mineral measurements
The P2X2"  and P2X3' '  animals (n = 10) were received aged 2 months, and changes in 
bone mass monitored over a 7-month period; however the P2X2/3rfW'/' mice (n = 10) 
were 6 months old on arrival and so were only monitored for a 2-month period. Two 
month old mice are experiencing puberty, rapid growth, rapid bone remodelling and 
are considered juveniles, by 4 months they are classified as young adults and > 6 
months corresponds to full adult maturity.
Following weighing, anaesthesia was induced by exposure to isofluorane for up to 
2 minutes (exact time dependent on subject size); an intraperitoneal injection of 2.5% 
tribomoethanol in 2-methylbutan-2-ol at 0.16 ml/lOg (Sigma-Aldrich, Dorset, UK) 
was administered to fully anaesthetize each mouse for approximately 15-20 minutes. 
Subjects were carefully positioned with their limbs extended and the head excluded, on 
plastic trays designed specifically for the PIXImus system (Figure 5.1); all live 
animals were scanned in triplicate with repositioning between scan. On completion, 
animals were carefully monitored until fully recovered from the anaesthesia. All 
procedures were performed according to Home Office guidelines and regulations 
(Animals for Scientific Procedures Act, 1986).
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Unlike the P2X receptor knockouts, the 2-month-old P2Y f' mice (n = 10) were 
frozen when received for scanning, thus any age-related changes in bone mass could 
not be measured. P2Yi'' mice and their wild type controls were thoroughly defrosted 
before being positioned on plastic trays for scanning as described above. Since initial 
triplicate scans of three P2Yf animals showed no differences in the bone mineral 
measurements it was only necessary to scan each test subject once.
All data was analysed using the PIXImus software (version 1.8, Lunar, GE 
Healthcare, USA) (Figure 5.1) and for P2X receptor knockouts the three scans were 
averaged to give final values for total BMD, BMC, fat and lean tissue. Localised 
analysis was additionally carried out to determine the BMD and BMC of the spine, 
femora and tibiae/fibulae.
Statistical analysis
Data were analysed as described in Chapter 2
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RESULTS
P2X2 ~ and P2X3/~ mice: general observations
The P2X2' ' and P2X3 animals did not exhibit any obvious changes in phenotype; 
however, previous behavioural analysis found P2X2 mice had a tendency to 
hyperactivity (Cockayne et al, 2005) (Figure 5.1A-C). Throughout the study, all 
subjects were healthy, the only exception being at 9 months of age when some P2X3' '  
mice developed an autoimmune skin condition (n = 4). Before developing this 
condition animals experienced hair loss on the back and shoulders, which eventually 
lead to excessive scratching and the development of skin lesions. As the condition was 
untreatable, animals developing lesions were culled. This pathology was not present in 
any of the test subjects throughout the duration of the experiment and only developed 
after completion of the final scans. Many disorders of bone and mineral metabolism, 
such as osteopetrosis, present dental manifestations including impaired tooth eruption. 
Normal tooth eruption is dependent on bone resorption surrounding the developing 
tooth; inadequate resorption can hinder this process leading to unerupted and 
malformed teeth or delayed eruption (Krebsbach & Polverini, 1999). However, in both 
P2X2 and the P2X3 ' mice tooth eruption was unaffected indicating no gross effects 
of receptor deletion on bone resorption.
P2X2/~ andP2Xj/~ mice: total bone mineral measurements
Total BMD and BMC measurements from P2X2‘‘, P2X3' ' and wild types at 2-9 
months of age are summarised in Figure 5.2. In all animals, the largest change in both 
bone mineral parameters took place between 2-4 months of age with only marginal 
changes occurring at 6-9 months. Throughout the test period P2X2 \  but not P2X3 
animals displayed a significantly enhanced total BMD compared to age matched 
controls (Figure 5.2A). The P2X2'A mice exhibited a 9% increase in total BMD at 2 
months of age, decreasing to 6% at 4 months and 5% at 6-9 months, indicating the 
effect of P2X2 receptor removal is most prevalent in juvenile animals. P2X2 animals 
also displayed an age related increase in total BMC. In the 2-month old mice, total 
BMC was increased by 18% at 2 months, decreasing to 9% at 4 months and 10% at 6-9 
months. The P2X3"  animals did not display variations in total BMC at any age 
(Figure 5.2B)
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F ig u re  5.1. P2X2V and P2X3'/' mice and the PIXImus system
Representative images of female (A) wild type, (B) P2X2''' and (C) P2X3''' mice aged 4 months. 
These pictures show that the knockout animals have no gross abnormalities. (D) An image 
showing the PIXImus analysis software used to calculate levels of bone mineral and soft 
tissues. (E) The PIXImus system. (F) This image represents the typical image of a mouse 
produced following a 5 minute DEXA scan. The scale bar in images A-C = 2 cm.
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Figure 5.2. Total BMD and BMC was increased in P2X2'/' mice
Compared to controls, P2X27 mice displayed increased (A) total BMD (up to 9%) and 
increased (B) total BMC (up to 18%). The largest differences between wildtypes and P2X2 A 
occurred in the 2-month-old animals. Total BMD and BMC were unchanged in female P2X3 7' 
animals (n = 10, all animals female) (*** = p<0.001, ** = p<0.01, * = p<0.05).
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P2X2~/~ and P2X3~/ ~ mice: total weighty fa t and lean tissue content
Total body weight was monitored throughout the experimental period and at all ages 
the P2X2 mice were significantly heavier than the wild types (Figure 5.3A). In 
contrast to the total BMD/BMC, these differences in body weight increased slightly 
with age; the animals being ~ 9% heavier at 2 months, increasing to 12% at 4 and 6  
months before reducing to 10% at 9 months. The body weight of P2X3'A mice did not 
vary from age-matched controls.
The PIXImus was also employed to measure soft tissues. Compared to wildtypes, 
P2 X3 ' '  animals demonstrated no differences in lean tissue at any point. Conversely, 
the P2 X2 ' ' knockouts displayed an age related increase in lean tissue (Figure 5.3B); 
with levels being enhanced by 8 %, 10%, 11% and 14% at 2, 4, 6  and 9 months of age, 
respectively.
P2 X2"'" and P2X3 mice displayed no differences in percentage fat at any time 
point, compared to age matched controls (Figure 5.3C). Total fat levels in P2X2-7" 
animals were generally unchanged (Figure 5.3D).
P2X2/~ and P2Xi/~ mice: bone mineral measurements o f the femora and 
tibiae/fibulae
To determine whether the age-related trend observed in the whole body scans was 
reflected in individual bones, the PIXImus was also used to quantify the BMD and 
BMC of the long bones in the hind legs (femora, tibiae and fibulae). Due to limitations 
of resolution, the PIXImus system cannot distinguish between the tibia and fibula, so 
the readings for these bones are combined. In keeping with the whole body results, the 
P2 X3 _/' mice displayed no differences in any of these measurements at any age.
The P2X2"a mice displayed significantly increased tibiae/fibulae BMD at 2 and 4 
months (5-6 % increase) but not 6  and 9 months (Figure 5.4A). A large 24% increase 
in tibiae/fibulae BMC was apparent at 2 months, decreasing to 18%, 10% and 13% at 
4, 6  and 9 months, respectively (Figure 5.4B).
Femoral bone mineral measurements were also increased in the P2X2 " animals, 
although the differences were smaller than the tibiae/fibulae readings. The P2 X2 " 
mice exhibited a significantly higher femoral BMD at 2-6 months but not 9 months of
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age; the values being increased by 7%, 6%, 5% and 4% at 2, 4, 6 and 9 months, 
respectively (Figure 5.4C). Femoral BMC displayed a larger increase than the BMD. 
P2 X2"  animals display a significant 15% increase in femoral BMC at 2 months and 
7% increase at 4 months of age (Figure 5.4D). In 6 and 9-month P2 X2" " mice, the 
femoral BMC was no different from the controls.
P2X2/~ and P2Xi/" mice: bone mineral measurements o f  the spine
In keeping with the other measurements, P2X3"  mice displayed no differences in 
either spinal BMD or BMC. The V IX f1' knockouts did display differences in spinal 
BMD and BMC but they were smaller than those observed in the long bones. Spinal 
BMD was significantly increased by 9% in the 2-month-old P2 X2  A mice, but from 4 
months upwards, no differences between the knockouts and wild types were observed 
(Figure 5.5A). However, the 2-month P2X2 ‘ knockouts displayed a large 27% 
increase in spinal BMC, which decreased to 15% at 4 months. The 6 and 9 month old 
animals showed little or no variation in spinal BMC compared to controls (Figure 
5.5B)
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Figure 5.3. Total weight and lean tissue content was increased in PIX2 ' mice
(A) At all ages, P2X27 but not P2X37 mice displayed an increased weight (up to 12%) 
compared to wildtypes (n = 10, all female). (B) P2X2 7' mice displayed up to a 14% increase in 
the level of lean tissue compared to age matched controls, whereas P2 X3 7' animals showed no 
differences. (C) Percentage fat was unchanged in both P2X2 7 or P2X3 7 knockout animals. 
(D) Throughout the study, total fat was generally unchanged, with the exception of the 4- 
month-old P2 X2_/‘ mice who had slightly increased fat levels (*** = p<0.001, ** = p<0.01, * = 
p<0.05).
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Figure 5.4. The long bones of P2X2 ' mice display age-related increases in BMD and 
BMC
(A) Tibiae/fibulae BMD was significantly enhanced by 5-6% in P2X2'/' mice aged 2 and 4 
months but not 6 and 9 months. (B) Tibiae/fibulae BMC was increased by up to 15% in P2X2' 
'' animals; P2X3'A mice exhibited no differences in tibiae/fibulae BMC and BMD at any age. (C) 
Femoral BMD was increased by 5-7% in 2-6 month old P2X2 7 knockouts. (D) Femoral BMC 
was increased by 7-15% in 2-4 month old P2X2'7' mice; P2X3_/' mice exhibited no differences 
in femoral BMC and BMD at any age (n = 10, all animals female) (***=p<0.001, **=p<0.01, 
*=p<0.05).
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Figure 5.5. Spinal BMD and BMC was increased in young P2Xz' mice
(A) Spinal BMD was significantly increased by 9% in 2-month old P2X2'/~ mice, whereas 4-9 
month old animals displayed no differences. (B) P2X2'/' knockouts displayed a significantly 
increased spinal BMC at 2 and 4 months, being increased by 27% and 15% respectively. 
Spinal BMD and BMC were unchanged in the P2X3 7' animals at all ages (n = 10, all animals 
female) (*** = p<0.001, * = p<0.05).
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P 2X 2/3dbl'A m ice: genera l observations
The double knockouts appeared slightly runty and were somewhat smaller than their 
corresponding age matched controls. Tooth eruption was unimpaired in the P2X.mdbl''' 
mice. Following day-to-day observations it became apparent that the double 
knockouts displayed some behavioural differences; they appeared less active and were 
less inclined to move around the cages than the wild types. The images in Figure 5.6 
are representative of these animals at 6 months and demonstrate the slight size 
difference between ?2Xmdbl'1' mice and their controls.
WT
6 m o n th s
P2X 2/3<",w- 
6  m o n th s
Figure 5.6. P2X2n tu ' m ice were som ew hat sm aller than the age-m atched controls
These images are representative of the female P2X2l3dbN' mice are their corresponding female 
wild types (WT) at 6 months of age. In both images scale bar = 2 cm
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P2X2/3dhl~/~ mice: total bone mineral measurements
As these animals were mature adults when received for study, there is no data available 
on the effect of receptor deletion on the skeleton of younger animals. When compared 
to age matched controls, the P2X2/3C?W'/' mice displayed a significant 6-7% decrease in 
total BMD at both 6 and 8 months; this is contrary to the single P2X2 knockouts, 
which exhibited a 5-9% increase in total BMD (F igure 5.7A). Somewhat surprisingly, 
the P2X2/3^z'/' mice displayed no differences in the total BMC at either 6 or 8 months 
of age (F igure 5.7B). These data suggest P2X2/3 knockouts possess similar levels of 
bone mineral, but a reduced bone density. Because the murine skeleton has reached 
maturity by 6 months, there was little variation in both total BMD and BMC between 
the two scans.
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Figure 5.7. Total BMD was decreased but total BMC was unchanged in P2X2^ db^ ’ 
animals
(A) At 6 and 8 months, P2X2/3CtoW' mice displayed a 6-7% decrease in total BMD compared to 
wild types. (B) There were no differences in the total BMC of the P2X2nbN~ and wild type 
animals. Only minimal changes in BMD and BMC were observed between the scans at 6 and 
8 months (n = 10, all animals female) (** = p<0.01).
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P2X2/3 iblV~ mice: total weight, lean tissue and fa t content
Total body weight of the P2X2/3^/’/" animals was ~ 10% and ~ 16% lower than the 
wildtypes at 6 and 8 months, respectively (Figure 5.8A). Quantification of total lean 
tissue in P2 X2/3rfW'A mice demonstrated an 8% decrease at 6 months and 10% reduction 
at 8 months. For both these values, the observed differences were only statistically 
significant in the 8-month old mice (Figure 5.8B).
P2X2/3^/'/‘ mice displayed reduced levels of total fat (11 %-22%) (Figure 5.8C) and 
percentage fat (22%-38%) (Figure 5.8D) at both 6 and 8 months; however, none of 
these decreases were statistically significant.
P2X2/3dM'/~ mice: bone mineral measurements o f femora and tibiae/fibulae
Quantification of femora and tibiae/fibulae bones from P2X2/3rfW'/' mice and 
corresponding wild types revealed marked changes in the local BMD and BMC. 
P2X2/3^z /' animals exhibited a 9% and 12% reduction in femoral BMD at 6 and 8 
months respectively (Figure 5.9A). P2X2/3</w'/' mice displayed no changes in total 
BMC, however femoral analysis demonstrated a significant ~ 16% decrease in femoral 
BMC at both 6 and 8 months of age (Figure 5.9B). Similar effects were seen in 
tibiae/fibulae BMD and BMC; at 6 and 8 months, P2X2/3^ /’/" animals displayed a 11% 
and 14% reduction in BMD (Figure 5.9C), accompanied by an 11% and 15% decrease 
in BMC (Figure 5.9D)
In both cases, the local decreases in BMD and BMC were greater than the total 
measurements. Comparable to the whole body readings, the local scans showed 
nominal changes between 6 and 8 months in both knockouts and wild types.
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Figure 5.8. Changes in weight, lean tissue and fat content in P2X^3db^ ' mice
(A) Total body weight was significantly reduced at 8 months (16% decrease) but not 6 months 
(10% decrease) in P2X2/3dbN~ animals. (B) Lean tissue content was only decreased in the 8- 
month P2X2/3db,/' mice, being reduced by 10%. Although lower, there were no significant 
differences in (C) percentage fat and (D) total fat between P2X2ndbl~1' animals and 
corresponding wild types at 6 or 8 months (n = 10, all animals female) (* = p<0.05).
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Figure 5.9. The long bones of PTXy*™' mice display decreased BMD and BMC
(A) Femoral BMD was reduced in the P2X2/3dbN' mice at both 6 and 8 months, by 9% and 12% 
respectively. (B) P2X2j3dbl'1' animals displayed a -  16% decrease in femoral BMC at both 
ages. (C) Tibiae/fibulae BMD was reduced by 11-14% in the P2X2/3dbW‘ mice. (D) P2X2/3dbN~ 
knockouts displayed a decreased tibiae/fibulae BMC at both 6 and 8 months being reduced by 
11% and 15%, respectively (n -  10, all animals female) (*** = p<0.001, ** = p<0.01, * = 
p<0.05).
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P2 Xy3 dblr/~ mice: bone mineral measurements o f  the spine
In contrast to the long bone analysis, quantification of the spinal BMD and BMC in 
P2X2/3/w"/" mice demonstrated little effect of receptor removal on this region of the 
skeleton. The spinal BMD of the P2X2/3£/w’/'' animals did not vary from the wild types 
at 6 or 8 months of age (Figure 5.10A); spinal BMC appeared similarly unchanged 
varying by > 2% in test subjects (Figure 5.10B).
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Figure 5.10. Lack of effect of P2Xm receptor removal on spinal BMD and BMC
P2X2/3db/'/' animals displayed no differences in (A) spinal BMD or (B) spinal BMC at either 6 or 
8 months of age, compared to wildtypes (n = 10, all animals female).
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P2Y/~ mice: general observations
The P2Yf/_ receptor deficient mice displayed no gross physical abnormalities and 
tooth eruption was unaffected. The images in Figure 5.11 are representative of these 
animals when received aged 2 months
WT
Figure 5.11. P 2 Y m i c e  do no t display any overt changes in pheno type
Representative images of the male, 2-month old P2Y1'/' mice and their controls scanned in this 
study. In both images scale bar = 2 cm.
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P2Y{/~ mice: total bone mineral measurements
Quantification of the 2-month old P2Yi' ' mice and corresponding wild types revealed 
receptor removal causes a significant, albeit small, change in bone phenotype; 
however, in contrast to the P2X2 /’ animals, the P2Yi'/'mice exhibited decreases in both 
total BMD and BMC. A 5% reduction in total BMD (Figure 5.12A) and a 7% 
decrease in total BMC (Figure 5.12B) was observed; these differences were similar in 
magnitude to those observed in the P2 X2/3^W"/" mice but smaller than those observed in 
the P2 X2 _/' animals.
P2Y/~ mice: total body weight, fa t and lean tissue content
Analysis of total body weight (Figure 5.12C), lean tissue (Figure 5.12D), fat (Figure 
5.12E) and percentage fat (Figure 5.12F) in P2Y f  mice demonstrated no differences 
in any of these parameters.
P2Y{/~ mice: femora, tibiae/fibulae and spinal bone mineral measurements
Analysis of individual bones from wild type and P2Yf/' animals revealed some small 
decreases in the bone mineral values. Quantification of the femoral bones 
demonstrated a non-significant 4% decrease in BMD (Figure 5.13A) but a significant 
14% reduction in the BMC (Figure 5.13B).
The tibiae/fibulae bones of the P2Yi_/* mice displayed a decreased BMD (Figure 
5.13C) and BMC (Figure 5.13D), being in both cases, reduced by 9%. Finally, spinal 
analyses revealed an 8% reduction in BMD (Figure 5.13E) but only a non-significant 
5% reduction in BMC (Figure 5.13F).
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Figure 5.12. P2Y^'mice display decreased total BMD and BMC but unchanged weight, 
lean tissue and fat content
(A) Total BMD was reduced by 5% in the P2Y1"/' animals. (B) P2Y1/ mice displayed a 
significant 7% decrease in total BMC. P2Yi receptor deletion did not influence (C) total weight, 
(D) lean tissue content, (E) fat and (F) percentage fat (n = 10, all animals male) (* = p < 0.05).
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Figure 5.13. Changes in BMC and BMD in the spine, femora and tibiae/fibulae of P2Yi/' 
mice
(A) Femoral BMD was unchanged in P2Y /' mice compared to wild type, whereas (B) femoral 
BMC was decreased by 14%. Both Tibiae/fibulae (C) BMD and (D) BMC were decreased by 
9% in P2Y1'/' animals. (E) P2Y /' mice displayed an 8% decrease in spinal BMD, (F) but 
spinal BMC was no different to controls (n = 10, all animals male) (*** = p < 0.001, ** = p < 
0.01, * = p <  0.05).
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DISCUSSION
Previous study of P2 receptor knockout mice highlighted the important role of P2X2, 
P2 X3 and P2Yi receptor-mediated purinergic signalling in vivo (Leon et al, 1999; 
Cockayne et al, 2000; Vlaskovska et al, 2001; Rong et al, 2003; Cockayne et al, 
2005). The work carried out here provides the first indication that P2X2, P2 X2 /3  and 
P2Yi but not P2 X3 -receptor knockout mice display changes in bone phenotype.
The acid-activated P2X2 receptor is expressed on osteoclasts and proliferating 
osteoblasts (Chapter 2; Hoebertz et al, 2000). In this study, DEXA analysis 
demonstrated a significantly increased total BMD and BMC in the P2X2‘‘ mice. 
Moreover, closer investigation of selected regions indicated similar changes occurred 
at a local level, with the femora, vertebrae and tibiae/fibulae all showing increases in 
BMD and BMC. Of the other parameters measured, both body weight and lean tissue 
levels also appeared increased in the P2X2' ' mice, whereas total and percentage fat 
were generally unaffected. In younger P2X2' ' animals (2-4 months), although weight 
and lean tissue were increased, these changes were smaller than the increases in bone 
mass. Conversely, in older P2X2' animals (6-9 months), there were bigger changes in 
weight and lean tissue than bone mass. Developing mammalian skeletal muscle, but 
not adult muscle fibres express the P2X2 receptor, and earlier work demonstrated 
P2X2-receptor deficient animals display abnormalities in neuromuscular junction 
structure and skeletal muscle function (Ryten et al, 2004b). These muscle defects are 
not observed in P2 X3 knockouts, which in this study displayed no changes in lean 
tissue; therefore, these skeletal muscle abnormalities may have contributed to the 
increased lean tissue seen in the P2X2-receptor deficient mice. It reasonable to 
suppose that these changes in lean tissue may have contributed indirectly, to some 
extent, to the bone phenotype observed in these animals by affecting loading on the 
skeleton.
The increased bone mass, particularly in the younger P2X2“  animals, suggests that 
receptor deletion is also having direct effects on bone cell function and is consistent 
with a role for the P2X2 receptor in the negative regulation of bone remodelling. In 
agreement, previous work implicated the P2X2 receptor and extracellular ATP in 
stimulating the resorptive activity of osteoclasts (Morrison et al, 1998); thus, the
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increase in BMD and BMC observed here could be the result of a small decrease in 
resorption. Since osteoblasts also express the P2X2  receptor, impaired cell function 
may also contribute to the changes in bone phenotype observed in the P2X2 knockouts.
The local and total differences in BMC and BMD between the P2X2" mice and 
wild type controls reduced with age, however, why this occurred remains unclear. 
Bone cells express a number of purinergic receptors (Chapter 2; Hoebertz et al, 2003) 
thus, it is possible that ATP responses are mediated, via increasing compensation, by 
other P2 family members in the older P2X2 animals. Conversely, as the mouse 
skeleton does not reach maturity until about 4 months and the largest effects of 
receptor deletion were observed in the 2 -month old animals, these data could indicate a 
role for the P2X2  receptor in modulating bone cell function in the developing skeleton.
Numerous studies have failed to detect P2 X3 receptor expression on either 
osteoblasts or osteoclasts; thus receptor deletion is unlikely to influence bone cell 
function directly [see review Hoebertz et al, 2003]. DEXA analysis of P2X3'/_ mice 
demonstrated no significant differences, from juveniles through to mature adults, in 
total BMD, total BMC, weight, lean tissue and fat content; additionally, closer 
investigation of the femoral, tibial and vertebral bones indicated no significant changes 
in local BMC or BMD. The absence of a skeletal phenotype in these animals suggests 
P2 X3 receptors do not play a role, either directly or indirectly via other cell types, in 
modulating bone remodelling in vivo.
To date there are no reports identifying the expression of heteromeric P2 X2 /3 
receptors on bone cells (Hoebertz et al, 2003). The P2X2/3Gto/'/‘ animals, in addition to 
lacking P2 X2 /3  receptors, do not possess functional homomeric P2X2 and P2 X3 
receptors. DEXA analysis demonstrated that the P2 X2 /3^ /_/' animals exhibited a 
decreased total BMD whilst total BMC was unchanged. Local analysis showed BMD 
and BMC was decreased in the long bones but unaffected in the spine. P2 X2 /3 receptor 
deletion had a small influence on the other parameters measured as both lean tissue 
and body weight were decreased in 8 -month animals. Fat content was lower in 
P2 X2/3rffe//' mice but not significantly so. Thus, decreased levels of soft tissues may 
help to explain the decreased weight observed in 8 -month P2 X2/3 JW"/" mice.
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Removal of both P2X2 and P2X3 receptor subunits disrupts a number of 
physiological processes and produces animals with an unhealthy constitution and high 
rate of mortality (Cockayne et al, 2000; Vlaskovska et al, 2001; Cockayne et al, 2005). 
Thus, deficits in the nervous system and general illness may act indirectly to influence 
bone remodelling in P2X2/3dbl~A animals. During the course of this study, it was also 
noted that movement and activity appeared considerably reduced in P2 X2/3 *ft/’/‘ mice. 
Since mechanical loading is necessary for the maintenance of bone mass it is possible 
that reduced activity and bone loading may have also contributed towards the altered 
skeletal phenotype of the P2X2/3<*/"/" animals. Therefore, the effects of decreased body 
weight and activity combined with the increased level of illness may outweigh any 
positive effects that removal of P2X2 receptors has on bone mass. This can potentially 
explain why the P2X2/3cfe/'A mice displayed alterations in skeletal phenotype opposite to 
that of the P2X2’ ’ animals.
Several investigations have provided in vitro evidence for the involvement of P2Yi 
receptors in the modulation of bone cell function. In osteoclasts, ATP and ADP can 
signal via the P2Yi receptor to stimulate formation and activity (Hoebertz et al, 2001). 
Whereas in osteoblasts, extracellular nucleotides can act to modulate local responses to 
systemic factors such as PTH (Bowler et al, 2001; Buckley et al, 2001). Surprisingly, 
the 2-month-old P2Yf ' mice displayed small decreases in total and local BMC and 
BMD. No differences were observed in total body weight, lean tissue or fat content. 
However, P2Yf ' mice are known to display defects in platelet aggregation and blood 
clotting (Leon et al, 1999; Leon et al, 2001); thus, other systemic perturbations may 
indirectly influence bone cell function and counteract any positive effects P2Yi 
receptor deletion has on bone mass.
Three separate studies have described skeletal changes in P2X7 knockout animals, 
albeit with conflicting results (Gartland et al, 2003c; Jorgensen et al, 2003; Ke et al, 
2003). Garland et al (2003) reported no differences in total and local BMD, as 
measured by DEXA analysis, but did report increased cortical bone thickness in the 
tibial shaft. Jorgensen and colleagues (2003) reported increased bone mass in female 
but not male P2X7 knockouts, whilst Ke et al (2003) found that skeletal changes 
occurred in both sexes (including decreased cortical bone thickness), with a greater 
effect in male animals. These opposing data may reflect the different genetic
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backgrounds of the mice studied. In the present investigation, all the P2X knockouts 
were female and all P2Yi knockouts were male, so no gender-related effects could be 
determined. Given the sex differences seen in the P2X7-null mice, it would be of 
interest to see if male P2X and female P2Yi knockouts exhibited similar changes in 
BMD and BMC.
The long bones and vertebrae contain differing proportions of cortical and 
trabecular bone. By providing localised measurements for the spine and long bones, 
the data in this present study may give a rough indication of the differential effects of 
P2 receptor deletion on cortical and trabecular bone. Generally, the long bones were 
more affected by receptor deletion, suggesting a greater effect on cortical bone. 
However, more detailed information regarding changes in bone structure on the 
microscopic scale, for example cortical/trabecular area and density, can be obtained 
using techniques such as quantitative micro computed tomography. To determine how 
receptor deletion affects bone resorption, formation or mineralisation would require 
invasive techniques such as bone histomorphometry.
The uses of a PIXImus densitometer are limited by its relatively low resolution and 
because the parameters measured are static, it provides no information regarding 
potential effects on bone remodelling. Conversely, DEXA scanning is very rapid 
(each scan ~ 5 minutes) and can be used on live animals. For these reasons, this 
technique is commonly employed prior to carrying out more invasive and time- 
consuming techniques, to screen knockout animals for the presence of a changed bone 
phenotype. Despite its limitations, DEXA scanning has found quite widespread usage 
with a number of published studies employing PIXImus densitometers. For example, 
van’t Hof et al (2004) demonstrated 10-week old neuronal nitric oxide synthase 
(nNOS) knockouts displayed a 13% increase in total BMD and 26% increase in total 
BMC. These effects are slightly better than the biggest effects observed in this study, 
as P2 X2 "' mice displayed a 9% increase in total BMD and 18% increase in total BMC. 
In addition, work by Idris and colleagues (2005) demonstrated an 18% increase in 
femoral BMD in cannabinoid type 1 (CBi) receptor knockouts. In both of these 
investigations, further study using peripheral quantitative computed tomography 
(pQCT) illustrated similar sized defects in excised bones, indicating that defects 
detected by DEXA scanning are reproducible via other techniques.
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In conclusion, this study provides the first indication of an altered bone phenotype 
in P2 X2 , P2 X2 /3  and P2Yi but not in P2X3-receptor deficient mice. The effects 
described here are moderate in size and may reflect the potential redundancy of this 
primitive signalling system in vivo. Given the findings from earlier chapters (2 & 3), 
which demonstrated widespread expression of the P2Y2, P2Y4 and P2Y6 receptors on 
osteoblasts and the ability of extracellular nucleotides to “switch off’ mineralisation 
analysis of these receptor knockouts is now required.
170
CHAPTER 6
GENERAL DISCUSSION AND FUTURE 
DIRECTIONS
ATP is a ubiquitous molecule with a fundamental role in many intracellular 
biochemical processes. The “purinergic” concept was first introduced by Bumstock in 
1972; it is now widely recognised that signalling by extracellular nucleotides and their 
receptors plays an important role in both neuronal and non-neuronal cells (Bumstock 
& Knight, 2004). Over recent years, the involvement of extracellular nucleotides in 
the regulation of bone cell function has become more apparent [see review by 
Hoebertz et al, 2003], The aim of this thesis was to investigate the effects of 
extracellular nucleotides on bone cell function during normal and stress situations.
This chapter contains a brief summary of the key experimental findings of this 
thesis and suggests potential future work. Additionally, several issues arising from the 
experimental chapters will be discussed in a broader purinergic context with particular 
reference to bone pathophysiology.
Bone cells express multiple P2 receptor subtypes [see review by Hoebertz et al, 
2003], and despite earlier indications that purinergic receptor expression changes with 
osteoblast differentiation (Dixon et al, 1997), this idea remained poorly investigated. 
In the first experimental chapter, I demonstrated for the first time that expression of P2 
receptors on primary rat osteoblasts is strongly dependent on differentiation and time 
in culture by using RT-PCR and immunofluorescence. These changes were 
characterised by a shift from P2X to P2Y receptor expression, with mature osteoblasts 
strongly expressing P2Y2, P2Y4 and P2Y6 receptors. The effect of osteoclast 
differentiation on P2 receptor expression was not studied here having already been 
investigated to some extent; a previous report found that, with the exception of the 
P2Y6 receptor, no changes in P2 receptor mRNA expression occurred during human 
osteoclast formation in vitro (Buckley et al, 2002). Some cell types preferentially
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express particular P2 receptors for example; vascular smooth muscle cells express high 
levels of P2Xi, P2 Y2 and P2Y6 receptors but lower levels of P2X4, P2 X7 , P2Yi and 
P2Y4 receptors (Wang et al, 2002). Since both osteoblasts and osteoclasts express 
several P2 receptors, future work should involve quantitative analysis, by employing 
techniques such as real time PCR and western blotting, of the relative levels of each P2 
receptor subtype on bone cells as they proliferate and differentiate.
Research into purinergic signalling presents some special difficulties; firstly, the 
fundamental role of nucleotides in cellular biochemistry means that, unlike other 
signalling factors, ATP (and other nucleotides) cannot be removed from an in vitro 
system. Secondly, the multiplicity of P2 receptors, the lack of information regarding 
receptor tertiary structure and the overlap of receptor actions has meant that there are 
few specific agonists and antagonists available (Bumstock & Knight, 2004). For these 
reasons, only a small proportion of the P2 receptors expressed on bone cells (P2X5, 
P2 X7 , P2Yi, P2 Y2) have assigned functional effects. In this thesis, the inhibitory 
effects of ATP and UTP on osteoblast function were shown to be late acting, 
effectively “switching off’ mineralised bone formation in mature cells. Although the 
P2 Y2 receptor is the most likely mediator of these anti-osteogenic effects in vitro, 
because there is no selective P2 Y2 receptor antagonist, involvement of the P2Y4 
receptor is possible. However, two approaches could be employed to clarify this issue; 
either by culture of calvarial cells from knockout animals or by using the technique of 
RNA interference (RNAi) it should be possible to study the functional responses of 
osteoblasts lacking the P2Y2 or the P2Y4 receptor in vitro. Moreover, RNAi could also 
be employed to investigate how activation of other P2 receptors (especially where a 
knockout model is currently unavailable such as the P2Y6 receptor) influences both 
osteoblast and osteoclast development and function
In Chapter 3, closer study of nucleotide-treated osteoblast cultures indicated that 
ATP and UTP primarily inhibit mineralisation rather than organic matrix deposition. 
Collagen expression, as assessed by RT-PCR, was slightly decreased by nucleotide 
treatment; however, collagen formation and deposition seemed relatively unaffected. 
Further clarification of the effects of extracellular nucleotides on collagen production 
is now required and could be obtained by electron microscopy or quantitatively by 
measuring proline incorporation. The impaired mineralisation observed here was due,
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at least in part, to decreased alkaline phosphatase (ALP) expression and activity, 
however, other mechanisms are likely to be involved and this presents an interesting 
area of future study. Mineralisation involves the coordinated actions of many enzymes 
(including ALP), ion transporters (annexins) and bone matrix proteins (osteocalcin, 
osteopontin) (Kirsch, 2005; Balcerzak, 2003), which regulate the levels of Ca2+ and Pi 
as well as the calcification inhibitor PPi. One potential target of purinergic signalling 
is the transmembrane protein ANK, which mediates the active transport of PPi across 
the plasma membrane. Truncation of this protein, as seen in ank/cmk null mice, causes 
hypermineralisation (Ho et al, 2000) and suggests a potential role for ANK in the 
regulation of mineralisation. Microarray analysis could be employed to investigate 
changes in osteoblast gene expression following treatment with nucleotide agonists, 
thus indicating which genes are the target of purinergic signalling and, potentially, 
other factors (such as ANK) involved in the nucleotide-mediated inhibition of 
mineralisation. Additionally, microarray could be employed to study the gene 
expression of nucleotide-treated osteoclasts, thereby providing information regarding 
the factors mediating the functional effects of nucleotides (including increased 
resorption) in these cells.
Many cell types, including epithelial and endothelial cells (Bodin & Bumstock, 
2001a; Knight et al, 2002), fibroblasts (Gerasimovskaya et al, 2002), chondrocytes 
(Graff et al, 2000) and osteoblast-like cells (Romanello et al, 2001; Buckley et al, 
2003; Genetos et al, 2005) have been shown to release ATP constitutively. In Chapter 
4, ATP release from osteoblasts, under basal and stimulated conditions, was 
investigated using the luciferin-luciferase assay. For the first time, primary rat 
osteoblasts were shown to constitutively release ATP, probably via vesicular 
exocytosis, in a differentiation-dependent manner. Transient hypoxia or hyperthermia 
increased ATP release from osteoblasts 2-3-fold, whereas hypothermia was without 
effect. Conversely, more prolonged exposures to low oxygen, hyperthermia or 
hypothermia impaired osteoblast proliferation, function and ATP release. The 
mechanisms by which osteoblasts sense the sudden change in oxygen tension or 
temperature, leading to the increased ATP release are unknown at present. Some 
potential candidates for this role include L-VSCC and TRP channels, which have been 
discussed in detail in Chapter 4. Since inflammation and hypoxia are commonly 
associated with a localised acidosis, which is deleterious to the skeleton, the ability of
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decreased pH to influence ATP release from osteoblasts presents an interesting 
extension to the work performed here. Other cells derived from the 
monocyte/macrophage lineage, including macrophages (Beigi St Dubyak, 2000), 
release ATP constitutively; to date, basal release of ATP and UTP from osteoclasts has 
not been reported but presents an area for future study.
Quantification of ATP release in vitro is complicated by a number of issues; firstly, 
the volume of fluid bathing cells is significantly larger in vitro than it is in vivo and, 
secondly, rapid hydrolysis or transphosphorylation reactions by ecto-enzymes can 
influence the local nucleotide concentration (Lazarowski et al, 2003). Consequently, 
ATP levels measured in vitro are likely to underestimate the actual concentration at the 
cell membrane; an idea confirmed by studies using luciferase anchored to the platelet 
plasma membrane, which measured ATP release in the range 10-15 pM (Beigi et al, 
1999). With these factors in mind, ATP release from osteoblasts in vivo could be in 
the high nanomolar or low micromolar range rather than the high picomolar/low 
nanomolar range measured in this investigation. This could result in a local 
concentration sufficient to activate, in an autocrine/paracrine manner, purinergic 
signalling in the bone microenvironment.
Uridine-containing nucleotides potently activate a subset of P2Y receptors, with a 
broad spectrum of cell responses resulting from receptor stimulation. Although UTP 
can be generated from other nucleotides by the activity of extracellular nucleoside 
diphosphate kinase (E-NDPK), cellular release of UTP remains poorly researched 
(Lazarowski et al, 2000). Using the UDP-glucose pyrophosphorylase assay, UTP 
release has been reported from endothelial cells, epithelial cells and platelets 
(Cressman et al, 1999; Lazarowski & Harden, 1999). To date there are no reports of 
UTP release from osteoblasts but given the widespread expression of several uridine- 
sensitive P2Y receptors (Chapter 2) and the ability of UTP to enhance ATP release 
(Bowler et al, 2001) and inhibit mineralisation (Chapter 3), it may present a 
worthwhile area for future research.
The aim of Chapter 5 was to evaluate, by employing bone densitometry to screen 
selected P2 receptor knockout mice, the significance of purinergic receptors on bone 
metabolism in vivo. This investigation demonstrated for the first time that P2 X2 
receptor knockouts displayed an age-related increase in bone mass, whereas P2 X2/3C/W‘/'
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and P2Yi A mice had a decreased bone mass. P2X3 receptor knockout mice exhibited 
no skeletal changes. The most common application of the PIXImus system, as 
employed here, is to screen knockout animals for an altered bone phenotype prior to 
more detailed analysis (see the discussion of Chapter 5 for advantages and 
disadvantages of DEXA scanning). Since P2X2, P2X2 / 3 and P2Yi-receptor deficient 
mice experienced skeletal changes future work could involve bone histomorphometry 
to determine changes in bone structure on a microscopic scale. Additionally, in vitro 
culture of cells derived from knockout animals may help to establish whether receptor 
removal influences osteoblast and/or osteoclast development and/or function. A 
standard model used to amplify the skeletal effects of a particular factor is to study it in 
mice already stressed by ovariectomy. This technique has been employed to illustrate 
the involvement of many molecules in bone metabolism including nitric oxide 
(Wimalawansa et al, 1996) and osteopontin (Yoshitake et al, 1999). Considering the 
protective effect oestrogens exert on the skeleton and the negative effects extracellular 
nucleotides have on bone remodelling, it would be of interest to challenge the P2 
receptor knockouts with ovariectomy to determine whether differential effects on bone 
mass occur.
Expression of multiple P2 receptor subtypes is now considered the norm in most 
tissues including bone [see review by Bumstock & Knight, 2004], It is well known 
that P2X receptor subunits interact to form homomultimers or heteromultimers, with 
differing pharmacological activities (see Chapter 1 for overview); however, at present, 
expression of heteromeric P2X receptors in bone cells has not been reported. Over 
recent years, experimental evidence using immunoprecipitation and ligand-binding 
analysis challenged the view that G-protein coupled receptors (GPCRs) exist and 
function as monomers; instead it is now widely accepted that many GPCRs form 
functional homodimers, heterodimers or oligomeric complexes [see review by 
Milligan, 2004], The first purine receptor reported to form heteromeric complexes was 
the adenosine Ai receptor, which forms functional heteromultimers with dopamine 
receptors (Gines et al, 2000). The ability of the adenosine A 2a  receptor to also form 
heteromeric complexes with dopamine receptors was reported recently (Fuxe et al, 
2005). The ability of P2Y receptors to form homo- or heteromultimeric assemblies is 
less well studied, however, one report by Wang et al (2002) reported the presence of a 
180-kd protein, which could correspond to a P2Yi receptor tetramer, in smooth muscle
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cells. Moreover, it was shown recently that the Ai receptor forms a heteromeric 
complex with P2Yi receptors in rat brain tissue, producing an adenosine receptor with 
P2Y-like-agonist pharmacology (Nakata et al, 2005; Yoshioka et al, 2002). Given that 
bone cells express many GPCRs, including at least four P2Y receptor subtypes, it is 
possible that they form heteromultimers (such as P2Y2 and P2 Y4) that influence bone 
cell function in a different manner to homomeric complexes. Investigation into the 
expression of heteromeric P2Y and P2X receptor complexes on bone cells is now 
required.
To be physiologically relevant regulators of bone remodelling, extracellular 
nucleotides must be delivered into the bone microenvironment in a controlled manner. 
Once released nucleotides are rapidly broken down by an extracellular hydrolysis 
cascade that results in the formation of the respective nucleoside and free phosphate 
(Pi). Molecular and functional characterisation has shown that there are several 
families of ecto-nucleotidases; these include (1) the E-NTPDase (ecto-nucleoside 
triphosphate diphosphohydrolase) family, (2) the E-NPP (ecto-nucleotide 
pyrophosphatase/ phosphodiesterase) family, (3) alkaline phosphatases and, (4) ecto- 
5’-nucleotidase (Zimmerman, 2000). Ecto-nucleotidases are usually membrane bound, 
but can be cleaved to produce soluble isoforms often referred to as exo-nucleotidases. 
Many of these ecto-nucleotidase families have overlapping specificities; for example 
members of the E-NTPDase (also referred to as ecto- ATPase or ecto-apyrase) family 
catalyse reactions including NTP —> NDP + Pi and NDP -» NMP + PPi, whereas 
members of the E-NPP family hydrolyse NTP —» NMP + PPi or NDP -> NMP + Pi. 
Thus, the combined activities of these ecto-enzymes limit the actions of extracellular 
nucleotides to cells within close proximity of the release site.
The expression of ecto-nucleotidases in bone remains poorly investigated; 
therefore little is known about ATP hydrolysis in bone under normal and pathological 
conditions, although in vitro, ATP has a reported half-life of between 50 seconds 
(Bowler et al, 2001) and ~ 5 minutes (Chapter 4). Osteoblasts are known to express 
tissue non-specific alkaline phosphatase and PC-1 (E-NPP 1), both of which are 
important in the regulation of mineralisation (Johnson et al, 2000). PPi is a potent 
inhibitor of mineralisation and can be produced by the hydrolysis of extracellular 
nucleotide triphosphates. Both ATP and UTP inhibit mineralisation at concentrations
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of 1-100 fiM (Chapter 3; Hoebertz et al, 2002), an effect thought to be mediated via 
the P2 Y2 and possibly the P2Y4  receptor. However, an intriguing possibility is that 
hydrolysis of extracellular nucleotides by PC-1 results in excess PPi, which then acts 
directly to inhibit hydroxyapatite crystal formation and mineralisation. Although 
quantitative physiologically relevant data are scarce; using femurs derived from 9-day- 
old chick embryos, Fleisch et al (1965) demonstrated that low micromolar 
concentrations of PPi inhibited calcification. Moreover, a recent investigation reported 
that 30 |iM ATP produces ~ 4 pM PPi in vitro (Zhong et al, 2005). In an attempt to 
clarify whether these inhibitory effects are direct or P2 receptor mediated, studies are 
ongoing to determine the levels of PPi that block mineralisation and the extracellular 
levels of PPi following treatment with nucleotides in our in vitro nodule system.
The rapid hydrolysis of extracellular nucleotides means that, once released, they 
must act relatively quickly on their target cells to induce signalling events and 
functional effects. The duration of cellular responses to nucleotide stimulation is less 
clear, although, as shown in Chapter 2, a single application of ATP to mature rat 
osteoblasts had lasting and significant effects on bone formation. Due to differential 
rates of release, breakdown and diffusion, ATP concentrations will vary in both time 
and space, thus the local environment surrounding one cell is likely to differ to that 
experienced even a few cell diameters away. Furthermore, as osteoblasts express the 
interconversion enzyme E-NDPK (Buckley et al, 2003), relative levels of different 
nucleotide agonists are also likely to vary in the bone local environment. Since the 
effects of extracellular nucleotides on bone cell function and apoptosis are 
concentration and agonist dependent, the rate of release, interconversion and 
breakdown will directly influence purinergic signalling and make any functional 
effects highly localised.
In many cell types, including erythrocytes (Bergfeld & Forrester, 1992), 
endothelial cells (Bodin & Bumstock, 1995), fibroblasts (Gerasimovskaya et al, 2002) 
and osteoblasts (Chapter 4; Genetos et al, 2005), ATP release is enhanced by stressful 
stimuli including hypoxia. Pathological situations such as fracture are commonly 
characterised by both inflammation (including hyperthermia) and hypoxia and thus are 
likely to be associated with an increased extracellular nucleotide concentration. 
Moreover in such situations, ATP levels can be further enhanced by the ability of
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extracellular nucleotides to induce their own release, leakage from damaged cells 
and/or release from other cell types (including immune cells and platelets) in the 
vicinity (Bodin & Bumstock, 1996).
Once released, extracellular nucleotides can potentially act in several ways, either 
by directly modulating bone cell function or indirectly by stimulating the release of 
other local factors important in bone metabolism. For example, ATP secreted in 
response to shear stress mediates enhanced PGE2 release from osteoblast-like cells 
(Genetos et al, 2005) and endothelial cells (Ostrom et al, 2000). The localised acidosis 
associated with inflammation and hypoxia will provide the low pH necessary for 
osteoclast activation; thus, ATP and its degradation product ADP can act through an 
autocrine/paracrine loop to directly stimulate osteoclastic resorption of damaged bone 
(Hoebertz et al, 2001). On mature osteoblasts, ATP can signal to down-regulate ALP 
expression and activity, arresting mineralisation and preventing further bone formation 
(Chapter 2 and 3). Moreover, if the extracellular concentration is high enough ATP 
may function via the P2 X7 receptor to induce osteoblast apoptosis (Gartland et al, 
2001).
The inflammatory response following tissue injury recruits cells such as 
macrophages, dendritic cells and monocytes to the damaged region. Extracellular ATP 
can enhance the release of proinflammatory cytokines, including IL -la/-ip  (Ferrari et 
al, 1997; Perregaux & Gabel, 1998; Ferrari et al, 2000), IL- 6  (Ihara et al, 2005; 
Hanley et al, 2004) and TNF-a (Ferrari et al, 2000), from many of these cells. Once 
released, these cytokines could act directly on bone cells to modulate their function. 
For example, IL-1 can promote mature osteoclast survival and resorption (Jimi et al, 
1998; Xing et al, 2003), whilst also suppressing osteoblast function (Kwan et al, 
2004). Thus, the primary event following a sudden stress situation could be increased 
osteoclastic resorption and removal of any damaged bone (an important process in 
fracture healing). ATP can act synergistically with TNF-a in the activation and 
maturation of dendritic cells (Schnurr et al, 2000); whether the same happens during 
the stimulation of osteoclastogenesis and/or resorption is unknown at present but 
presents an interesting area of future study. Based on the evidence presented here, it is 
possible that extracellular nucleotides play a role in cellular responses after an initial
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exposure to a stress situation; a model for this involvement is summarised in Figure 
6.1
Many pathological situations characterised by chronic hypoxia, hypothermia and/or 
hyperthermia are also associated with increased bone loss and include inflammatory 
conditions such as rheumatoid arthritis (Schett & Smolen, 2005). Long-term exposure 
to hypoxia decreases the expression of common osteoblastic markers such as 
osteocalcin and ALP and is likely to impair osteoblast differentiation (Utting et al, 
submitted), whilst increasing osteoclast formation and activity (Arnett et al, 2003). 
Furthermore, both hyperthermia and hypothermia have marked effects on osteoblast 
(Chapter 4) and osteoclast function (Utting et al, 2005). However, because nucleotide 
release from osteoblasts is generally decreased following longer-term exposures to 
these stressful stimuli, purinergic signalling is less likely to mediate the bone loss 
occurring in these situations.
As shown in this thesis, P2 receptor expression on osteoblasts is dependent on 
cellular differentiation. Given that chronic hypoxia impairs osteoblast differentiation, 
the P2 receptor expression profile of cells exposed to these conditions may well be 
different to normal. Therefore, it would be of interest to study expression of P2 
receptors in bone cells subjected to hypoxia, hypothermia, hyperthermia and acidosis. 
An effective way to screen for changes in gene expression in these situations would be 
to use microarray analysis.
In summary, the work presented in this thesis has helped to elucidate the functions 
of nucleotides on bone cell function. A speculative model for the role and interactions 
of P2 receptors on bone cells, based on the present results, is shown in Figure 6.1.
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Figure 6.1. A speculative role for ATP once released from osteoblasts following 
transient hypoxia or hyperthermia or loading
Purinergic signalling following increased ATP from osteoblasts following transient hypoxia or 
hyperthermia. Potential cellular mechanisms for sensing hypoxia and temperature include 
HIF, L-VSCC channels and TRP channels (see Chapters 1 and 4).
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APPENDIX I
ABBREVIATIONS
2-MeSADP 2-MethylthioADP
2-MeSATP 2-MethylthioATP
aP-meATP a,(3-methylene ATP
ABC proteins ATP binding cassette proteins
AC Adenylate cyclase
ADP Adenosine diphosphate
ALP Alkaline phosphatase
AM Acetomethoxyester
AMP Adenosine monophosphate
ANOVA One way analysis of variance
AP-1 Activating protein 1
ARNT Arylhydrocarbon nuclear transporter
ATP Adenosine triphosphate
ATPyS Adenosine 5'-0-(3-thiotriphosphate)
BMC Bone mineral content
BMD Bone mineral density
BMP Bone morphogenetic protein
BMU Bone multicellular unit
BSP Bone sialoprotein
Bz-ATP 2'3 '-0-(benzoyl-4-benzoyl)-ATP
cAMP 3-5'cyclic adenosine monophosphate
Ca2+ Calcium
CRE Cyclic AMP response element
CBi Cannabinoid type I receptor
Cbfal Core binding factor al
CCD Charged coupled device
cDNA Complementary deoxyribonucleic acid
C/EBPa CCAAT/enhancer binding protein alpha
CFTR Cystic fibrosis conductance regulator
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cr Chloride ions
co2 Carbon dioxide
COLl Type I collagen
Csps Cold shock proteins
DAG Diacylglycerol
DEXA Dual energy x-ray absorptiometry
Dhh Desert hedgehog
DIDS 4,4'-diisothiocyanatostilbene-2,2'disulphonic acid
Dlx5 Distal-less gene 5
Dmem Dulbecco’s Modified Essential Medium
DMSO Dimethyl sulphoxide
DNA Deoxyribonucleic acid
ECM Extracellular matrix
E-NPP Ecto-nucleotide pyrophosphatase/ phosphodiesterase
E-NTPDase Ecto-nucleoside triphosphate diphosphohydrolase
E-NDPK Ecto-nucleoside diphosphokinase
ER Endoplasmic reticulum
Erg-1 Early growth response factor 1
ERK Extracellular signal regulated kinase
FCS Foetal calf serum
FGF Fibroblast growth factor
FGFR Fibroblast growth factor receptor
FLIPR Fluorescence imaging plate reader
Gd3+ Gadolinium
GPCRs G-protein coupled receptors
h+ Protons
HESS Hanks balanced salt solution
HIF Hypoxia inducible factor
HOBIT Human osteoblast-like initial transfectant cells
HREs Hormone response element
HRE Hypoxia response element
HSE Heat shock element
HSFs Heat shock factors
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Hsps Heat shock proteins
IGF Insulin growth factor
Ihh Indian hedgehog
IKK Inhibitor of NFkB
IL-1 Interleukin-1
IL-6 Interleukin-6
IFNy Interferon-y
IP3 Inositol triphosphate
JNK c-Jun N-terminal kinase
K+ Potassium ions
LDH Lactate dehydrogenase
LH Lysyl hydroxylase
MAPK Mitogen activated protein kinase
M-CSF Macrophage colony stimulating factor
MGP Matrix gla protein
MMP Matrix metalloproteinase
mRNA Messenger ribonucleic acid
MRS2179 A^-methyl-2'-deoxyadenosine-35 '-bisphosphate
MRS2220 Cyclic pyridoxine-a4,5-monophosphate-6-azophenyl-2',5'-
disulphonate
MRS-2279 2-chloro-A/6-methyl-(A)-methanocarba-2-deoxyadenosine-3', 5'-
bisphosphate
MSCC Mechanosensitive cation selective channel
Msx2 Muscle segment homologue 2
MTT 3 -(4,5-dimethylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide
N2 Nitrogen
Na+ Sodium ions
NADH Nicotinamide adenine dinucleotide (reduced)
NCP Non collagenous proteins
NEM /?-ethylmaleimide
NFATcl Nuclear factor of activated T cells 1
NFkB Nuclear factoncB
NHS Normal horse serum
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nM Nanomolar
nm Nanometre
NO Nitric oxide
NOS Nitric oxide synthase
0 2 Oxygen
OCN Osteocalcin
ODF Osteoclast differentiation factor
ON Osteonectin
OPG Osteoprotegerin
OPN Osteopontin
OSE Osteoblast-specific cis-acting elements
Osx Osterix
P2X2 7 P2X2 receptor knockout
P2'&mdbl l~ P2X2/P2X3 double receptor knockout
P2X3 7 P2X3 receptor knockout
P2Yi'a P2Y1 receptor knockout
PC-1 Plasma membrane glycoprotein 1
PBS Phosphate buffered saline
PGE2 Prostaglandin E2
Pi Orthophosphate
PIP2 Phosphatidyl inositol 4,5-bisphosphate
PKC Protein kinase C
PO2 Oxygen tension
PPADS Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid
PPARy Peroxisome proliferator-activated receptor gamma
PPi Pyrophosphate
pQCT Peripheral quantitative computed tomography
PTH Parathyroid hormone
PTHrP Parathyroid hormone related peptide
RANKL Receptor activator of nuclear factor kappa B ligand
RGD Integrin binding consensus sequence Arg-Gly-Asp
RNA Ribonucleic acid
RNAi RNA interference
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RT-PCR Reverse transcriptase polymerase chain reaction
Runx2 Runt related transcription factor 2
Shh Sonic hedgehog
SIBLINGS Small integrin binding ligand N-linked glycoproteins
SRE Serum response element
SUR Sulfonylurea receptor
TGF(3 Transforming growth factor beta
TM Transmembranous domain
TNFa Tumour necrosis factor alpha
TNFR Tumour necrosis factor receptor
TNP-ATP 2', 3 '-0-(2.4,6-trinitrophenyl)-ATP
TRANCE TNF-related activation induced cytokine
TRAF TNFR-associated factor
TRACP Tartrate-resistant acid phosphatase
TRP Transient receptor potential
UDP Uridine diphosphate
Pg Microgram
|iM Micromolar
UTP Uridine triphosphate
VEGF Vascular endothelial growth factor
VSCC Voltage sensitive calcium channels
WT Wild type
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